
<html lang="en"     class="pb-page"  data-request-id="08af60a9-07cf-4dc3-937d-f3844f7258cb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-11;article:article:10.1021/acs.jmedchem.5b01571;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells" /></meta><meta name="dc.Creator" content="Vanna  Sanna" /></meta><meta name="dc.Creator" content="Salvatore  Nurra" /></meta><meta name="dc.Creator" content="Nicolino  Pala" /></meta><meta name="dc.Creator" content="Salvatore  Marceddu" /></meta><meta name="dc.Creator" content="Divya  Pathania" /></meta><meta name="dc.Creator" content="Nouri  Neamati" /></meta><meta name="dc.Creator" content="Mario  Sechi" /></meta><meta name="dc.Description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeu..." /></meta><meta name="Description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 26, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01571" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01571" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01571" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01571" /></link>
        
    
    

<title>Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01571" /></meta><meta property="og:title" content="Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0015.jpeg" /></meta><meta property="og:description" content="Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease. Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage. We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells. Previously, we discovered a novel class of compounds (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling. Herein, we prepared novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1. Similarly, we prepared QD-based NPs densely decorated with an isatoic anhydride derivative. Furthermore, we evaluated their impact on ligand binding and antiproliferative activity against PDAC cells. The targeted NPs were more potent than the nontargeted constructs in PDAC cells warranting further development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01571"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01571">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01571&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01571&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01571&amp;href=/doi/10.1021/acs.jmedchem.5b01571" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5209-5220</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01697" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01938" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vanna++Sanna">Vanna Sanna</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>||</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Salvatore++Nurra">Salvatore Nurra</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicolino++Pala">Nicolino Pala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Salvatore++Marceddu">Salvatore Marceddu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Divya++Pathania">Divya Pathania</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nouri++Neamati">Nouri Neamati</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mario++Sechi">Mario Sechi</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>||</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Department of Chemistry and Pharmacy, University of Sassari, 07100 Sassari, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">||</span> <span class="aff-text">Laboratory of Nanomedicine, University of Sassari, c/c Porto Conte Ricerche, 07041 Alghero, Italy</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">Istituto di Scienze delle Produzioni Alimentari (ISPA)-CNR, sez. di Sassari, 07040 Baldinca, Italy</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">â¥</span> <span class="aff-text">Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, California 90089, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">â¡</span> <span class="aff-text">Department of Medicinal Chemistry, College of Pharmacy, Translational Oncology Program, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1 734 647-2732. E-mail: <a href="/cdn-cgi/l/email-protection#98f6fdf9f5f9ecf1d8edf5f1fbf0b6fdfced"><span class="__cf_email__" data-cfemail="bfd1daded2decbd6ffcad2d6dcd791dadbca">[emailÂ protected]</span></a>. Fax: +1 734 647-8430.</div><div class="corresp-info"><strong>*</strong>Phone: +39 079-228-753. E-mail: <a href="/cdn-cgi/l/email-protection#c6aba7b4afa9e8b5a3a5aeaf86b3a8afb5b5e8afb2"><span class="__cf_email__" data-cfemail="e68b87948f89c89583858e8fa693888f9595c88f92">[emailÂ protected]</span></a>. Fax: +39 079-229-559.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01571&amp;href=/doi/10.1021%2Facs.jmedchem.5b01571" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5209â5220</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 3, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 October 2015</li><li><span class="item_label"><b>Published</b> online</span>26 May 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 June 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01571" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01571</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5209%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DVanna%2BSanna%252C%2BSalvatore%2BNurra%252C%2BNicolino%2BPala%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D11%26contentID%3Dacs.jmedchem.5b01571%26title%3DTargeted%2BNanoparticles%2Bfor%2Bthe%2BDelivery%2Bof%2BNovel%2BBioactive%2BMolecules%2Bto%2BPancreatic%2BCancer%2BCells%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5220%26publicationDate%3DJune%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01571"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2241</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01571" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Vanna&quot;,&quot;last_name&quot;:&quot;Sanna&quot;},{&quot;first_name&quot;:&quot;Salvatore&quot;,&quot;last_name&quot;:&quot;Nurra&quot;},{&quot;first_name&quot;:&quot;Nicolino&quot;,&quot;last_name&quot;:&quot;Pala&quot;},{&quot;first_name&quot;:&quot;Salvatore&quot;,&quot;last_name&quot;:&quot;Marceddu&quot;},{&quot;first_name&quot;:&quot;Divya&quot;,&quot;last_name&quot;:&quot;Pathania&quot;},{&quot;first_name&quot;:&quot;Nouri&quot;,&quot;last_name&quot;:&quot;Neamati&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Sechi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;5209-5220&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01571&quot;},&quot;abstract&quot;:&quot;Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease. Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage. We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells. Previously, we discovered a novel class of compounds (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling. Herein, we prepared novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1. Similarly, we prepared QD-based NPs densely decorated with an isatoic anhydride derivative. Furthermore, we evaluated their impact on ligand binding and antipro&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01571&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01571" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01571&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01571" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01571&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01571" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01571&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01571&amp;href=/doi/10.1021/acs.jmedchem.5b01571" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01571" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01571" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01571%26sid%3Dliteratum%253Aachs%26pmid%3D27139920%26genre%3Darticle%26aulast%3DSanna%26date%3D2016%26atitle%3DTargeted%2BNanoparticles%2Bfor%2Bthe%2BDelivery%2Bof%2BNovel%2BBioactive%2BMolecules%2Bto%2BPancreatic%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D11%26spage%3D5209%26epage%3D5220%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292544" title="Targeting">Targeting</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291243" title="Copolymers">Copolymers</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/jmcmar.2016.59.issue-11/20160609/jmcmar.2016.59.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options. Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease. Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage. We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells. Previously, we discovered a novel class of compounds (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling. Herein, we prepared novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1. Similarly, we prepared QD-based NPs densely decorated with an isatoic anhydride derivative. Furthermore, we evaluated their impact on ligand binding and antiproliferative activity against PDAC cells. The targeted NPs were more potent than the nontargeted constructs in PDAC cells warranting further development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23721" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23721" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It has been estimated that in 2015 about 53,000 people will be diagnosed with PDAC, and about 41,800 people will die of this disease in the United States,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> with similar statistics in the European Union.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The high mortality rate of PDAC patients is linked to an aggressive malignant character and extensive metastasis and late onset of clinical symptoms, leading to a late-stage detection and chemoresistance.<a onclick="showRef(event, 'ref1 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref4 ref5">(1, 4, 5)</a> In addition to radiotherapy and surgery, chemotherapy represents a significant therapeutic option, however with only modest benefits.<a onclick="showRef(event, 'ref1 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref5">(1, 5)</a> First-line chemotherapy includes combination of folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The other option includes gemcitabine<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> in combination with albumin-bound paclitaxel (nab-paclitaxel).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Similar to nab-paclitaxel, other strategies consisting of targeting therapeutic payload to cancer cells through conjugation to a tumor-cell-specific ligands can be equally effective in treating PDAC.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a></div><div class="NLM_p">Recently, we identified novel quinazolinedione-based compounds (QDs)<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> that target metabolic reprogramming and oxidative stress, the emerging hallmarks of cancer cells.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14-18)</a> These novel QD compounds alter the cellular bioenergetic characteristic of cancer cells, resulting in cytotoxicity by Akt-directed generation of reactive oxygen species (ROS)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and inhibited growth of tumors in a mouse xenograft model of PDAC.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The lead compound effectively blocked the activation of three critical signaling pathways: Src, FAK, and STAT3.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Due to limited therapeutic options for PDAC, we designed a novel delivery system to increase bioavailability and efficacy of the lead compound, the 6-[(3-acetylphenyl)amino]quinazoline-5,8-dione.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Recently, we developed PEGylated ligand targeted polymeric biocompatible nanoparticles (NPs) recognizing the prostate cancer cells.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Active targeting by NPs âdecoratedâ with specific ligands such as antibodies, aptamers, peptides, and small molecules is envisioned to provide the most effective therapy.<a onclick="showRef(event, 'ref9 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref9 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28">(9, 20-28)</a> Several ligand-targeted nanotherapeutics are either approved or under clinical evaluation.<a onclick="showRef(event, 'ref11 ref25 ref28'); return false;" href="javascript:void(0);" class="ref ref11 ref25 ref28">(11, 25, 28)</a> Membrane receptors with significantly higher expression on cancer versus normal cells are suitable targets for therapeutic intervention.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Functionalization of NPs with ligands targeting the extracellular domain of these receptors can enable selective delivery of therapeutic payload to tumor cells.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28">(23-28)</a></div><div class="NLM_p">For example, Plectin-1 (Plec-1), a high molecular weight protein (â¼500 kDa) that links intermediate filaments to microtubules and microfilaments, has an important function in tumor pathogenesis.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> It has been shown that Plec-1 levels are low in normal pancreatic ductal cells, but its expression is upregulated in PDAC.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Importantly, Plec-1 exhibits distinct cytoplasmic and nuclear localization in normal fibroblasts, whereas an aberrant expression on the cell membrane with cell surface localization is observed in PDAC. Moreover, Plec-1 was suggested as a useful biomarker for PDAC.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Previously, Weissleder et al. developed proof-of-concept targeted magnetofluorescent NPs composed of Plec-1 targeted peptides (PTP) for imaging of PDAC.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The same group reported on the development of magnetofluorescent reporters as a novel nanomaterial for biomedical application.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Moreover, a nonspecific targeting ligand, the isatoic anhydride with its corresponding isatoic nanoconjugate (i.e., 2-aminobenzoic-carboxylic-coated magnetic NPs), showed higher uptake in cancer versus normal cells.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Here, we report on design and preparation of novel biocompatible NPs encapsulating QD242 (<b>1</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> covered by small organic molecules (2ABA, <b>11</b>) or peptides (Cys-PTP, <b>12</b>) as targeting ligands (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) in their polymeric shell surface to selectively bind to Plec-1 or to nonspecifically target PDAC cells. We used pseudodiblock copolymer PLGA-<b>11</b> as well as the parent PLGA-A and pseudotriblock copolymer PLGA-PEG-<b>12</b> and the parent  PLGA-PEG-NH<sub>2</sub> to generate two sets of 200â300 nm size targeted and nontargeted (<b>1</b>)-encapsulated NPs (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). These NPs were characterized for drug-content, drug-release, binding affinity, and cytotoxicity in MIA PaCa-2 cells.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the designed targeted PLGA-<b>11</b>- and PLGA-PEG-<b>12</b>-(<b>1</b>)-loaded NPs. Materials: chemical structure of QD242 (<b>1</b>), the low molecular weight organic molecule targeting ligand 2ABA (<b>11</b>), the cysteine-containing Plec-1 targeting peptide Cys-PTP (<b>12</b>), PLGA, and PLGA-PEG polymers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design of Targeted NPs</h3><div class="NLM_p">We incorporated a representative ROS-inducing compound, 6-{[4-(phenylcarbonyl)phenyl]amino}quinazoline-5,8-dione (<b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> into a polymeric NPs conjugated to 2-amino-<i>N</i>-(3-aminopropyl)benzamide (<b>11</b>) as well as a targeting peptide (<b>12</b>, amino acid sequence: KTLLPTPC, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> Compound <b>1</b> produced IC<sub>50</sub> value of 1.6 Â± 0.2 Î¼M in MIA PaCa-2 cells<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and is well suited as a model drug for nanoformulation. It carries a lipophilic benzoyl substituent instead of an acetyl group on the lead compound (i.e., 6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) on the aminophenyl side chain. We chose poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactide-<i>co</i>-glycolide) carboxylic acid (PLGA-COOH, namely PLGA-A) and a poly(ethylene glycol) derivative, PLGA-PEG-NH<sub>2</sub>, as polymer systems because of their well-established safety profile.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a></div><div class="NLM_p">Initially, we used the 2-aminobenzoic-carboxylate conjugated with the aminopropane linker (<b>11</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) as the nonspecific PDAC targeting ligand, to obtain an intermediate to react with activated PLGA-NHS. The 2-aminobenzoic-carboxylic was derived from isatoic anhydride (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><div class="NLM_p">The PTP peptide (amino acid sequence: KTLLPTP), identified using peptide phage display, targets Plec-1 with a high affinity and specificity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> We decided to use the cysteine-containing PTP (<b>12</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) because it can react with maleimide terminal groups of PEG in the PLGA-PEG-maleimide (i.e., PLGA-PEG-mal). PEGylation confers immune shielding and âstealthâ properties to NPs and is a suitable spacer to maintain an optimal distance between the targeting ligand and the NP surface.</div><div class="NLM_p last">We also efficiently synthesized the targeting ligand <b>11</b> as well as PLGA-<b>11</b>, PLGA-PEG-NH<sub>2</sub>, PLGA-PEG-mal, and PLGA-PEG-<b>12</b> that are required for the NP formulation. To obtain a better control of <b>11</b> and <b>12</b> functionalization, we conjugated these ligands to their respective polymeric systems (i.e., PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) prior to nanoformulation.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of <b>1</b></h3><div class="NLM_p">Compound <b>1</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A) was synthesized using Bracherâs methodology with slight modifications to our previously reported procedure.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Regioselective substitution of quinazoline-5,8-dione (<b>2</b>) with 4-aminobenzophenone (<b>3</b>) in the presence of Ce(III) ions gave <b>1</b> as expected. The key synthone <b>2</b> was synthesized starting from the readily available 2,5-dimethoxybenzaldehyde (<b>4</b>), which was nitrated with concentrated nitric acid in the presence of acetic anhydride under magnetic stirring affording the 3,6-dimethoxy-2-nitrobenzaldehyde (<b>5</b>). The acid-catalyzed cyclization of this regioisomer by exposing it to gaseous HCl led to the formation of the diformamido-derivative <b>6</b>, which was then cyclized to 5,8-dimethoxyquinazoline (<b>7</b>) by treatment with zinc powder and acetic acid. Final oxidation by cerium ammonium nitrate gave the compound <b>2</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B). It is worth noting that the nitration reaction, using nitric acid/acetic anhydride in mild condition, gives higher yield than a previously reported condition<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> using a molar excess of silica gel supported nitric acid (68% vs 50â58%, respectively). Moreover, similar results were observed by the oxidation of <b>7</b> to <b>2</b> with cerium ammonium nitrate in acetonitrile/water solution. These modifications led to a 2-fold improvement in overall yield of the key synthone <b>2</b>. Compound <b>1</b> and the intermediates were fully characterized by NMR, MS, and elemental analyses.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for the Preparation of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (A) (<i>i</i>) CeCl<sub>3</sub>Â·7H<sub>2</sub>O, abs EtOH, O<sub>2</sub>, room temp, 3 h. (B) (<i>i</i>) conc. HNO<sub>3</sub>, (CH<sub>3</sub>CO)<sub>2</sub>O, 0 Â°C, 1.5 h; (<i>ii</i>) H<sub>2</sub>NCHO, HCl<sub>(g)</sub>, from 40 to 80 Â°C, 1 h; (<i>iii</i>) glacial CH<sub>3</sub>COOH, Zn, 0 Â°C for 2 h, room temp for 4 h; (<i>iv</i>) (NH<sub>4</sub>)<sub>2</sub>Ce(NO<sub>3</sub>)<sub>6</sub>, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 Â°C, 20 min.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Synthesis of <b>11</b></h3><div class="NLM_p">The intermediate <i>tert</i>-butyl (3-(2-aminobenzamido)propyl)carbamate (<b>10</b>) was prepared by treating isatoic anhydride (<b>9</b>) with <i>tert</i>-butyl (3-aminopropyl)carbamate (<b>8</b>) in the presence of potassium carbonate and THF at 70 Â°C with 74% yield (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The <i>tert</i>-butyloxycarbonyl (Boc) group of <b>10</b> was removed with 50% trifluoroacetic acid (TFA) in CH<sub>2</sub>Cl<sub>2</sub> solution at room temperature to obtain the desired ligand <b>11</b>, which was characterized by NMR, MS, and elemental analyses.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of Ligand <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) K<sub>2</sub>CO<sub>3</sub>, THF, N<sub>2</sub>, 70 Â°C for 20 h; (<i>ii</i>) TFA:CH<sub>2</sub>Cl<sub>2</sub> (1:1), 0 Â°C for 3 h.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Synthesis of Pseudodiblock Copolymer PLGA-<b>11</b></h3><div class="NLM_p">Block copolymers are effectively used as preconjugated starting materials for the preparation of precisely engineered NPs targeted nanoconjugates for cancer therapy.<a onclick="showRef(event, 'ref24 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref24 ref36 ref37 ref38">(24, 36-38)</a> Conjugation of the terminal amine group of <b>11</b> ligand with the activated electrophilic NHS esters of PLGA carboxylic acids (e.g., PLGA-A) allows the formation of physiologically stable amide bonds. The designed PLGA-<b>11</b> copolymer and diblock copolymers were synthesized in a two-step reaction. Specifically, the amine functional groups of <b>11</b> were reacted with the carboxy-capped PLGA-NHS in DMF in the presence of DIPEA (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, stage 1). The activated amine-reactive NHS-ester of PLGA (PLGA-NHS) was prepared by treating PLGA-A with EDC/NHS in an organic solvent at room temperature (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). As expected, the <sup>1</sup>H NMR analysis revealed aromatic peaks in the range 6.5â8.0 ppm, corresponding to proton pattern of <b>11</b> (S25). The successful conjugation of <b>11</b> to PLGA polymer also was supported by two absorption bands in 190 and 255 nm regions as depicted in the UV chromatogram (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Copolymer PLGA-<b>11</b> (Stage 1) and Nanoformulation (Stage 2)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) NHS, CH<sub>2</sub>Cl<sub>2</sub>, EDC, N<sub>2</sub>, room temp for 12 h; (<i>ii</i>) <b>11</b>, DIPEA, DMF, N<sub>2</sub>, room temp for 24 h.</p></p></figure><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Characterization of PLGA-<b>11</b> polymer. UV spectra comparison of PLGA-NHS (black line), <b>11</b> (red line), and PLGA-<b>11</b> (blue line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Synthesis of Diblock Copolymer of PLGA-PEG-NH<sub>2</sub> and PLGA-PEG-mal</h3><div class="NLM_p">NPs should ideally have a favorable hydrophobic/hydrophilic balance on their surface in order to (a) have a minimal selfâself and self-nonself interaction, (b) escape capture by the reticuloendothelial system (RES) to ensure immune evasion, (c) reduce opsonization, (d) facilitate efficient clearance of materials from the body, and (d) prevent nanoparticle loss to undesired location. PEGylation constitutes a suitable strategy for this purpose, and the preparation of PEGylated NPs is well documented.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39-41)</a> PLGA-PEGs are usually synthesized by conjugation or polymerization of PEG to PLGA via standard carbodiimide/NHS-mediated chemistry.<a onclick="showRef(event, 'ref37 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref37 ref41 ref42">(37, 41, 42)</a></div><div class="NLM_p">The starting polymer PLGA-PEG-NH<sub>2</sub> and the carboxylate-functionalized diblock copolymer PLGA-PEG-mal (<a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, stage 1, respectively) were prepared by conjugating bifunctional PEGs, NH<sub>2</sub>-PEG-NH<sub>2</sub> or NH<sub>2</sub>-PEG-mal, to activated PLGA-A. The structure of copolymers was confirmed by <sup>1</sup>H NMR spectroscopy. Specifically, signals centered at 1.58 ppm for both polymers are attributed to the lactide methyl repeat units (resonance shift a, <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Overlapping multiplets observed in the range 5.10â5.32 and 4.63â4.96 indicate the lactide methine (b, <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) and the glycolide protons (c, <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>), respectively. In addition to the defined signals for PLGA, the presence of the peak at 3.64/3.65 ppm (for NH<sub>2</sub>-PEG-mal and NH<sub>2</sub>-PEG-NH<sub>2</sub>, respectively), corresponding to the PEG methylene protons (d, <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>), confirmed the successful preparation of both polymers.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Copolymer PLGA-PEG-NH<sub>2</sub><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) CHCl<sub>3</sub>, DIPEA, N<sub>2</sub>, room temp for 24 h.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0014.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Copolymer PLGA-PEG-<b>12</b> (Stage 1) and Nanoformulation (Stage 2)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) CHCl<sub>3</sub>, DIPEA, N<sub>2</sub>, room temp for 24 h; (<i>ii</i>) <b>12</b> (KTLLPTPC), ACN:DMF (1:1), N<sub>2</sub>, room temp for 24 h.</p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of Pseudotriblock Copolymer PLGA-PEG-<b>12</b></h3><div class="NLM_p">We obtained a prefunctionalized biopolymer, PLGA-PEG-<b>12</b>, to avoid the postparticle modifications. The peptide <b>12</b> was prepared by fluorenylmethyloxycarbonyl-(Fmoc)-based solid-phase peptide synthesis (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Figures S29âS32</a>). Conjugation of the targeting agent, i.e., <b>12</b>, to carboxylate PEG terminal group was performed using the electrophilic maleimide functionality of PEG activated carboxylic acids. Reaction between the terminal SH group of <b>12</b> with PEG-mal resulted in the formation of physiologically stable SâC bonds. The designed pseudo-triblock copolymer, PLGA-PEG-<b>12</b> copolymer, was synthesized using a two-step reaction (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, stage 1) as described above for the preparation of the diblock copolymer. The <sup>1</sup>H NMR spectrum recorded for PLGA-PEG-<b>12</b> revealed resonance shifts at 1.58, 3.64, 4.64â4.88, and 5.10â5.28 ppm characteristics of PLGA-PEG backbone. Moreover, it also shared a series of partially overlapped multiple peaks (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Figure S27</a>), especially in the aliphatic zone, attributable to the <b>12</b> signal pattern (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Figure S32</a>). Furthermore, the strong absorption bands in 245 nm region observed in the UV chromatogram (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) support the successful conjugation of <b>12</b> to PLGA-PEG copolymer. Further characterization analyses such as molecular weights and refractive and polydispersity indexes were assessed by gel permeation chromatography-size exclusion chromatography (GPC-SEC) (see in <a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of PLGA-PEG-<b>12</b> polymer. UV spectra comparison of PLGA-PEG-mal (green line), <b>12</b> (red line), and PLGA-PEG-<b>12</b> (blue line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Nanoformulation and Characterization of Nontargeted and Targeted NPs</h3><div class="NLM_p">In the present study, we used PLGA-A, PLGA-PEG-NH<sub>2</sub>, PLGA-<b>11</b>, and PLGA-PEG-<b>12</b> polymer systems to fabricate nontargeted and targeted NPs as novel constructs and suitable carriers for PDAC therapy. The PLGA was chosen owing to its physicochemical properties as well as its biocompatibility and biodegradability. Moreover, modification of the NPâ² surface with PEG enables nonspecific interactions reduction, prolonging circulation time, and increasing accumulation in tumors due to the enhanced permeability and retention (EPR) effect.<a onclick="showRef(event, 'ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46">(43-46)</a> In particular, the hydrophilic ethylene glycol repeats of PEG confer to NPs enhanced solubility in serum, with reduced RES uptake and prolonged circulation time with respect to uncoated counterparts.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> Moreover, grafting with PEG prevents NP aggregation by increasing hydrophilicity via ether repeats, which form hydrogen bonds with solvent, and by modulating the steric distance and the amount of attraction between NPs, as well as those between tissue proteins and NPs. Modulation of the NP flexibility and the reduced accumulation in the liver are other key factors that influence extravasation, thus allowing for a favorable modulation of EPR effect.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">To optimize the fabrication of NPs and to ensure rapid precipitation of batches containing the hydrophilic PLGA-PEG copolymer, we used poly(epsilon-caprolactone) (PCL) mixture with PEGylated polymers to prepare PLGA-PEG-NH<sub>2</sub> and PLGA-PEG-<b>12</b> NPs. PCL is useful for controlled and sustained drug delivery due to its tunable mechanical properties, high permeability, and low toxicity.<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49-51)</a></div><div class="NLM_p">All batches of (<b>1</b>)-encapsulated NPs were successfully prepared using a modified nanoprecipitation method as described (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, stage 2).<a onclick="showRef(event, 'ref19 ref51'); return false;" href="javascript:void(0);" class="ref ref19 ref51">(19, 51)</a> During the precipitation in water, the polymers self-assembles to form NPs, in which the hydrophobic PLGA blocks would interact with the PCL into a core, thus minimizing their exposure to aqueous surroundings. Simultaneously, the hydrophilic COOH/NH<sub>2</sub> surface or PEG-NH<sub>2</sub> and PEG-<b>12</b> flexible moieties extend from the shell to stabilize the core by preventing degradation and aggregation.</div><div class="NLM_p">NPs generated from both polymer systems (i.e., PLGA- and PLGA-PEG-based NPs) were characterized for surface morphology with SEM, particle size, Î¶ potential, and encapsulation efficiency (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Average Diameter, Polydispersity Index, Î¶ Potential, Encapsulation Efficiency and Yield of Production of (<b>1</b>)-Loaded NPs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center" char="Â±">average diameter (nm)</th><th class="colsep0 rowsep0" align="center" char="Â±">polydispersity index</th><th class="colsep0 rowsep0" align="center" char="Â±">Î¶ potential (mV)</th><th class="colsep0 rowsep0" align="center" char="Â±">encapsulation efficiency (%)</th><th class="colsep0 rowsep0" align="center" char="Â±">yield of production (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLGA-A</td><td class="colsep0 rowsep0" align="char" char="Â±">155.8Â Â±Â 11.6<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="Â±">0.09Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char="Â±">â20.3Â Â±Â 1.2</td><td class="colsep0 rowsep0" align="char" char="Â±">14.33Â Â±Â 1.35<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="Â±">55.22Â Â±Â 6.82<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLGA-<b>11</b></td><td class="colsep0 rowsep0" align="char" char="Â±">220.1Â Â±Â 16.6<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="Â±">0.11Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="char" char="Â±">13.6Â Â±Â 1.3</td><td class="colsep0 rowsep0" align="char" char="Â±">16.49Â Â±Â 2.53<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="Â±">50.60Â Â±Â 1.60<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLGA-PEG-NH<sub>2</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="Â±">353.5Â Â±Â 27.0</td><td class="colsep0 rowsep0" align="char" char="Â±">0.15Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char="Â±">14.1Â Â±Â 2.1</td><td class="colsep0 rowsep0" align="char" char="Â±">20.12Â Â±Â 2.47<a class="ref internalNav" href="#t1fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="Â±">69.21Â Â±Â 2.35<a class="ref internalNav" href="#t1fn4" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLGA-PEG-<b>12</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="Â±">328.0Â Â±Â 30.7</td><td class="colsep0 rowsep0" align="char" char="Â±">0.12Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="char" char="Â±">10.2Â Â±Â 1.9</td><td class="colsep0 rowsep0" align="char" char="Â±">24.52Â Â±Â 0.36<a class="ref internalNav" href="#t1fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="Â±">64.03Â Â±Â 2.81<a class="ref internalNav" href="#t1fn4" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Formulation been performed with the addition of PCL polymer (see on the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Values presented are the mean Â± SD of three preparations.</p></div><div class="footnote" id="t1fn3"><sup>b</sup><p class="last">Significant differences from PLGA-PEG batches (<i>p</i> < 0.05).</p></div><div class="footnote" id="t1fn4"><sup>c</sup><p class="last">Significant differences from each other (<i>p</i> < 0.05).</p></div></div></div><div class="NLM_p"><a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> shows representative SEM images of PLGA-A- (a), PLGA-<b>11</b>- (b), PLGA-PEG-NH<sub>2</sub>/PCL- (c), and PLGA-PEG-<b>12</b>/PCL- (d) (<b>1</b>)-loaded NPs. All particles were characterized by similar morphological properties having smooth surface, spherical shape, and unimodal distribution. However, the NPs have different mean diameters [PLGA- (155.8 and 220.1 nm, for PLGA-A- and PLGA-<b>11</b> NPs, respectively) and PLGA-PEG/PCL- (353.5 and 328.0 nm, for PLGA-PEG-NH<sub>2</sub>/PCL- PLGA-PEG-<b>12</b>/PCL NPs, respectively)] (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>aâd).</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SEM images of PLGA-A- (a), PLGA-<b>11</b>- (b), PLGA-PEG-NH<sub>2</sub>/PCL- (c), and PLGA-PEG-<b>12</b>/PCL- (d) (<b>1</b>)-loaded NPs and corresponding particle size distribution. The scale bar is 200 nm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Î¶ potential was negative for PLGA-A NPs due to the negatively charged carboxyl groups on the terminal of PLGA-A. PLGA-PEG-NH<sub>2</sub>-, PLGA-<b>11</b>-, and PLGA-PEG-<b>12</b> NPs showed Î¶ potential between 10 and 14 mV due to their surface amine or amino acid funtionalities (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_p">Our statistical analysis highlighted that the amount of <b>1</b> loaded was significantly higher (<i>p</i> < 0.05) for PLGA-PEG-NH<sub>2</sub>- and PLGA-PEG-<b>12</b> NPs (ranging from 20% to 24%) than that for PLGA-A- and PLGA-<b>11</b> NPs (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). This difference is perhaps due to the higher hydrophilicity of the PEG conjugated polymer than that of PLGA counterparts.</div><div class="NLM_p last">We obtained 50â69% yield for all preparations over multiple experiments. The PLGA-PEG/PCL polymeric blended NPs produced yield of production values ranging from 64% (for PLGA-PEG-NH<sub>2</sub>/PCL NPs) to 69% (for PLGA-PEG-<b>12</b>/PCL NPs). The PLGA-based nanosystems yields were 50 and 55% for PLGA-A- and PLGA-<b>11</b> NPs, respectively. These differences can be attributed to the presence of the hydrophobic PCL and PLGA chains and the hydrophilic PEG moieties that can facilitate the incorporation of bioactive molecules into the polymeric matrix. Additionally, to evaluate the cellular uptake of the NPs, four batches (PLGA-A-, PLGA-PEG-NH<sub>2</sub>-, PLGA-<b>11</b>- and PLGA-PEG-<b>12</b> of fluorescent 6-coumarin (6C)-encaspulated NPs were obtained and characterized using the above-mentioned method (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Table S34</a>).</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vitro Kinetic Release of <b>1</b> from NPs</h3><div class="NLM_p">The in vitro release profiles of compound <b>1</b> from NPs are depicted in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>. The experiments were performed in phosphate-buffered saline (PBS) at pH 6.5 and 7.4 to simulate both the slightly acidic microenvironment of extracellular fluid in most tumors and the physiological conditions in normal tissues, respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The experiments were carried out by direct determination of <b>1</b> from different types of NPs in the release medium. The cumulative amount of <b>1</b> released from NPs indicated that the nanoencapsulation resulted in an effective release rate of <b>1</b> under both experimental conditions (i.e., PBS, pH 6.5 and 7.4, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a,b, respectively). NP formulations showed a similar release behavior, and this suggests that the pH of the medium did not significantly affect the release of <b>1</b> from the nanoformulations. In particular, PLGA-A-, PLGA-<b>11</b>, and PLGA-PEG-NH<sub>2</sub> NPs in both media shared similar kinetic release profiles. We observed a near 90% release of <b>1</b> from PLGA-PEG-NH<sub>2</sub> NPs within the first 2 h and a complete release within 4â6 h. We observed only 45â50% release of <b>1</b> from PLGA-PEG-<b>12</b> NPs within 3 h in both acidic and physiological medium and about 70â80% at 6 h. A possible explanation for this difference could be due to the presence of peptide <b>12</b> in PEGylated NPs potentially affecting degradation kinetics. More specifically, during the generation of NPs, the PLGA block can interact with PCL to produce a hydrophobic core. This construct might play a major role in stabilizing the core, whereas the other part of PEG-<b>12</b> protrude from the particle surface, forming an external hydrophilic pseudo-shield and thus preventing degradation.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro release profiles of <b>1</b> from nontargeted (PLGA-A and PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) NPs, detected at pH 6.5 (a) and 7.4 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Inhibition of Cell Proliferation</h3><div class="NLM_p">We compared the cytotoxicity of the targeted (<b>1</b>)-encapsulated NPs (PLGA-<b>11</b> and PLGA-PEG-<b>12</b> NPs) with those of the nontargeted particles (PLGA-A and PLGA-PEG-NH<sub>2</sub>) in MIA PaCa-2 cells using MTT assay (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). The PLGA-<b>11</b> and PLGA-PEG-<b>12</b> (<b>1</b>)-loaded NPs showed 70% and 87% growth inhibition, respectively. The nontargeted PLGA-A and PLGA-PEG-NH<sub>2</sub> NPs showed <30% and <50% growth inhibition (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>), suggesting that targeted NPs are significantly more effective than the nontargeted particles. In particular, we observed an improved antiproliferative activity for targeting Plec-1 by peptide <b>12</b> with (<b>1</b>)-loaded NPs. This behavior can be attributed to an active targeting to Plec-1 promoting an enhanced binding between NPs and the cells, thus resulting in increased accumulation and cell uptake through receptor mediated endocytosis.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro cytotoxicity of nontargeted (PLGA-A, PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) NPs. MIA PaCa-2 cell treated with (<b>1</b>)-loaded NPs (<b>1</b>, 2.8 Î¼M) for 72 h. (*) significantly differ from each other.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Surface Plasmon Resonance Binding Assays</h3><div class="NLM_p">The ability of the most effective anti-Plec-1 targeted NPs (PLGA-PEG-<b>12</b> NPs) to specifically bind Plec-1 protein, in comparison with the nontargeted ones (PLGA-PEG-NH<sub>2</sub> NPs), was assessed by real-time interaction analysis using surface plasmon resonance (SPR) experiments.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Kinetic and affinity evaluation and determination of binding specificity were conducted by immobilizing the Plec-1 protein on a sensor surface. The analyte (PLGA-PEG-<b>12</b> or PLGA-PEG-NH<sub>2</sub> NPs) was injected in solution over the surface. Changes in SPR response were analyzed, providing affinity binding results, expressed as response units (RU). A difference of about 350â400 RU was observed for NPs with and without peptide <b>12</b> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), with a significant increase in RU for PLGA-PEG-<b>12</b> NPs compared to PLGA-PEG-NH<sub>2</sub> NPs for binding to Plec-1. Indeed, sensorgrams revealed a slow association and dissociation processes. These results demonstrate good affinity for <b>12</b> targeted NPs toward Plec-1 protein, with only a residual interaction provided by the nontargeted NPs, thus supporting that this specific interaction can significantly contribute to the growth inhibition of MIA PaCa-2 cells by (<b>1</b>)-loaded NPs.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SPR-based comparative binding analysis of ligand-functionalized NPs. Sensorgrams showing binding of targeted PLGA-PEG-<b>12</b> and nontargeted PLGA-PEG-NH<sub>2</sub> NPs to Plec-1 protein. The experiment was performed using a Biacore T-200 system. Plec-1 was directly immobilized in the sensor chip by amine coupling (at 11000 RU), and NPs were flowed over the protein-coated chip at 5 mg/mL in assay buffer, with single cycle kinetics. Lines represent the best fitting of the associationâdissociation processes for targeted NPs (green line) and nontargeted NPs (blue line). Standard HBS-N buffer with 1 mg/mL BSA (pink line) was used as control. Data for affinity evaluation were obtained and expressed as difference in RU. Data shown are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cellular Uptake</h3><div class="NLM_p">The correlation between antiproliferative activity of the (<b>1</b>)-loaded NPs with cellular uptake by the cancer cells was further corroborated by internalization of 6-coumarin-loaded NPs, which were visualized by fluorescence microscopy. <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a> shows images (20Ã magnification) of cellular uptake efficiency of nontargeted and targeted NPs. In particular, after 1 h incubation, the targeted PLGA-<b>11</b> and PLGA-PEG-<b>12</b> NPs showed higher cellular uptake than PLGA-A and PLGA-PEG-NH<sub>2</sub>, respectively, with strong fluorescence in perinuclear space, thus confirming their accumulation and sustained retention by the cells.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Uptake assays for NPs. Panels show representative live cell fluorescence microscopy images of MIA PaCa-2 cells after exposure to nontargeted (PLGA-A, PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) dye-loaded NPs. Left panels: cells incubated with dye-loaded NPs for 1 h. Middle panels: red fluorescence of the nuclei stained with DRAQ5 dye. Right panels: cellular uptake visualized by overlaying images (20Ã magnification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Previously, we discovered a novel class of compounds displaying ROS-mediated decrease in Src/FAK and STAT3 phosphorylation resulting in efficient inhibition of cell proliferation, adhesion, and migration, ultimately leading to apoptosis. In an attempt to improve their pharmacological, PK, and distribution properties, we used a novel nanotechnology platform to selectively deliver our novel ROS-inducing compounds to PDAC cells.</div><div class="NLM_p last">We demonstrated that the MIA PaCa-2 cells are more sensitive to the targeted than the nontargeted particles. Furthermore, we observed that the targeted (<b>1</b>)-loaded NPs (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) efficiently bind to MIA PaCa-2 cells. In particular, these data indicate that functionalization of the NPs surface with peptides to selectively bind to Plec-1 or with nonspecific small molecules as targeting ligands efficiently increases their adhesion and uptake in PDAC cells in comparison to the nonfunctionalized particles. As expected, the NPs targeting Plec-1 demonstrated to be the most effective prototypes. These results also support the hypothesis that the primary role of targeting agents is to increase cellular uptake of NPs and their loading into tumor cells. These insights might constitute a suitable translational platform for development of powerful therapeutic tools to treat pancreatic cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Materials</h3><div class="NLM_p">Poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactide-<i>co</i>-glycolide) carboxylic acid end group, (PLGA-A, Purasorb Polymer PDLG 5002A, <i>M</i><sub>w</sub> â¼ 17,000) (lactide/glycolide ratio of 50:50, viscosity range: 0.20 dL/g in CHCl<sub>3</sub>) was kindly provided by Corbion Purac (Gorinchem, The Netherlands). Poly(epsilon-caprolactone) (PCL, <i>M</i><sub>w</sub> â¼ 80,000), poly(vinyl alcohol) (PVA, <i>M</i><sub>w</sub> 31,000â50,000), and 6-coumarin were purchased from Sigma-Aldrich (Steinheim, Germany). The heterobifunctional PEG polymer with a terminal amine and carboxylic acid functional group, NH<sub>2</sub>-PEG-COOH (<i>M</i><sub>w</sub> = 3400), the homobifunctional PEG polymers with both terminal amines NH<sub>2</sub>-PEG-NH<sub>2</sub> (HCl salt, <i>M</i><sub>w</sub> = 3500), and with a terminal amine and maleimide functionality NH<sub>2</sub>-PEG-mal (TFA salt, <i>M</i><sub>w</sub> = 3500) were purchased from JenKem Technology USA. The anti Plec-1 peptide (KTLLPTPC, <b>12</b>, lyophilized trifluoroacetate salt) was purchased from CASLO Laboratory ApS, c/o Scion Denmark Technical University, Lyngby, Denmark. The peptide was prepared by (Fmoc)-based solid-phase peptide synthesis using H-Cys(Trt)-CTC resin (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Figure S29</a>). The peptide <b>12</b> was purified by preparative reversed-phase high performance liquid chromatography (RP-HPLC) and quality controlled by analytical HPLC and mass spectrometry (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">Figures S29âS32</a> for details).</div><div class="NLM_p last">All solvents and other chemicals (used for the preparation of <b>1</b>) were purchased from Sigma-Aldrich or Carlo Erba (analytical grade and were used without further purification). Melting points (mp) were determined using an Electrothermal melting point or a KÃ¶fler apparatus and are uncorrected. Nuclear magnetic resonance (<sup>1</sup>H NMR, <sup>13</sup>C NMR) spectra were determined in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CDCl<sub>3</sub>/DMSO-<i>d</i><sub>6</sub> (in 3/1 ratio) and were recorded on 400 MHz Bruker Avance III. Chemical shifts are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) and used as an internal standard. Splitting patterns are designated as follow: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double doublet. The assignment of exchangeable protons (O<i>H</i> and N<i>H</i>) was confirmed by the addition of D<sub>2</sub>O. Mass spectra were obtained on a triple-quadrupole QqQ Varian 310-MS mass spectrometer, a Hewlett-Packard 5989 mass engine spectrometer, or a MALDI micro MX (Waters, Micromass) equipped with a reflectron analyzer. Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel F-254 plates. Flash chromatography purifications were performed on Merck Silica gel 60 (230â400 mesh ASTM) as a stationary phase. Molecular weights, polydispersity, and refractive indexes of polymers were determined by GPC-SEC using the instrument Viscotek 270 (for SEC-TDA, Alfatest, Italy) and were performed by Alfatestlab s.r.l. (Cinisello Balsamo, Mi, Italy). The purity of copolymers was determined by HPLC using an HP 1200 (Agilent Technologies, USA) system, equipped with a Hypersil BDS C18 column (Alltech Italy, 250 Ã 4.6 mm i.d., 5 Î¼m particle size); these materials were found to be >95% pure. Elemental analyses for <b>1</b>, <b>11</b>, and for all intermediates were performed on a PerkinElmer 2400 spectrometer at Laboratorio di Microanalisi, Dipartimento di Chimica, UniversitÃ  di Sassari (Italy), and were within Â±0.4% of the theoretical values.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis of 6-{[4-(Phenylcarbonyl)phenyl]amino}quinazoline-5,8-dione (<b>1</b>)</h3><div class="NLM_p last">A solution of quinazoline-5,8-dione (<b>2</b>, 0.22 g, 1.37 mmol), cerium(III) chloride heptahydrate (CeCl<sub>3</sub>Â·7H<sub>2</sub>O, 1.1 equiv), and 4-aminobenzophenone (<b>3</b>, 1.1 equiv) in absolute ethanol (20 mL) was stirred at room temperature for 3 h. Next, most of the ethanol was removed under vacuum, and water was added, followed by extraction with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated to dryness. The crude product was purified by flash chromatography (eluent: ethyl acetate) to give the expected product. Red-brown solid. Yield: 79%; mp 233â234 Â°C (lit; mp 233â236 Â°C).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 9.70 (s, 1H, H<sub>4</sub>), 9.54 (s, 1H, H<sub>2</sub>), 7.93 (d, 2H, ArâH), 7.80 (d, 2H, ArâH), 7.75 (s, 1H, NH), 7.64â7.61 (m, 1H, ArâH), 7.54â7.51 (m, 2H, ArâH), 7.41 (d, 2H, ArâH), 6.85 (s, 1H, H<sub>8</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 195.04, 180.77, 180.42, 163.87, 156.59, 153.99, 143.44, 140.25, 137.27, 132.71, 132.08, 129.93, 128.48, 123.29, 121.69, 106.37. MALDI-TOF: <i>m</i>/<i>z</i> 354 [M]<sup>+</sup>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Quinazoline-5,8-dione (<b>2</b>)</h3><div class="NLM_p last">A solution of 5,8-dimethoxyquinazoline (<b>7</b>, 0.50 g, 2.63 mmol) in (7:3) acetonitrile:water (13 mL) was cooled at 0 Â°C in an ice bath, and a solution of ceric ammonium nitrate [(NH<sub>4</sub>)<sub>2</sub>Ce(NO<sub>3</sub>)<sub>6</sub> (2.7 equiv) (9:1) acetonitrile:water (13 mL) was added dropwise. The reaction mixture was stirred for 20 min and, after monitoring with TLC (CHCl<sub>3</sub>/CH<sub>3</sub>OH 9.5:0.5), poured into ice/water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. Then, the organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated to dryness to give <b>2</b> as brown powder. Yield: 69%; mp: >320 Â°C. (lit; mp: >320 Â°C).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.68 (s, 1H), 9.43 (s, 1H), 7.28 (d, 1H), 7.18 (d, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 184.07, 182.88, 162.08, 156.27, 152.60, 139.46, 137.74, 124.61. ESI: <i>m</i>/<i>z</i> 161 [M + 1]<sup>+</sup>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 5,8-Dimethoxyquinazoline (<b>7</b>)</h3><div class="NLM_p last">Zinc powder (8.18 g, 125.13 mmol, 15.15 equiv) was added to a suspension of <i>N</i>,<i>N</i>â²-[(3,6-dimethoxy-2-nitrophenyl)methylene)]diformamide (<b>6</b>, 2.5 g, 8.26 mmol) in triturated ice (30 g) and glacial acetic acid (11.5 mL), under constant magnetic stirring. The reaction mixture was stirred for 2 h in ice bath and for 4 h at room temperature. Next, the reaction mixture was dropped (through filter paper) on cooled 50% NaOH (45 mL), and the yellow colored suspension thus formed was left without stirring for 1 h. Then, the suspension was filtered to give a yellow powder, which was solubilized in ethyl acetate, filtered, dried over anhydrous sodium sulfate, and concentrated to dryness yielding the desired compound <b>7</b>. Yield: 91%; mp: 116â117 Â°C (lit. mp 116â119 Â°C).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.64 (s, 1H), 9.28 (s, 1H), 7.38 (d, 1H), 7.09 (d, 1H), 3.98 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 154.88, 154.49, 148.35, 148.02, 141.60, 117.16, 113.59, 106.14, 56.11. GC-MS: <i>m</i>/<i>z</i> 190 [M]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>,<i>N</i>â²-[(3,6-Dimethoxy-2-nitrophenyl)methylene]diformamide (<b>6</b>)</h3><div class="NLM_p last">A solution of 3,6-dimethoxy-2-nitrobenzaldehyde (<b>5</b>, 4.0 g, 18.94 mmol) in formamide (H<sub>2</sub>NCHO, 66.5 equiv), heated at 40 Â°C, was exposed to dry HCl gas (1 h) until the temperature reached 80 Â°C. Then, the solution was cooled to room temperature, and water/ice was added. Pale yellow precipitate was formed, which was filtered, dried, and triturated with ethyl acetate and petroleum ether to yield the desired compound <b>6</b>. Yield: 90%; mp: 254â255 Â°C (lit; mp 254 Â°C).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.67 (d, 2H), 7.92 (s, 2H), 7.28 (s, 2H), 6.77 (t, 1H), 3.88 (s, 3H), 3.82 (s, 3H). NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.17, 150.77, 143.64, 139.60, 119.59, 114.33, 113.94, 57.02, 56.64, 48.51. ESI: <i>m</i>/<i>z</i> 284 [M + 1]<sup>+</sup>.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3,6-Dimethoxy-2-nitrobenzaldehyde (<b>5</b>)</h3><div class="NLM_p last">Nitric acid (91.83 mmol, 7.63 equiv), acetic anhydride (43.31 mmol, 3.6 equiv), and 2,5-dimethoxybenzaldehyde (<b>4</b>, 1.3 g, 12.03 mmol) were added at 0 Â°C with stirring, respectively. After 1.5 h stirring, the mixture was poured onto 10 mL ice/water. The resulting yellow solid was filtered, washed with cold water, and then purified by flash chromatography on silica gel using ethyl acetate-petroleum ether (1:1) to give first the regioisomer 2,5-dimethoxy-4-nitrobenzaldehyde, and then (by further elution with only ethyl acetate), the desired compound <b>5</b>. Yield: 68%; mp 165â167 Â°C (lit; mp 163â165 and 159 Â°C).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.26 (s, 1H), 7.70 (d, 1H), 7.49 (d, 1H), 3.96 (s, 3H), 3.87 (s, 3H). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 10.39 (s, 1H), 7.30 (d, 1H), 7.12 (d, 1H), 3.97 (s, 3H), 3.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.69, 166.22, 154.21, 153.42, 148.42, 123.73, 116.48, 57.14, 57.02. GC-MS: <i>m</i>/<i>z</i> 211 [M]<sup>+</sup>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis of 2-Amino-<i>N</i>-(3-aminopropyl)benzamide (<b>11</b>)</h3><div class="NLM_p last">The intermediate <i>tert</i>-butyl (3-(2-aminobenzamido)propyl)carbamate (<b>10</b>, 0.23 g, 0.78 mmol) was dissolved in 20 mL of 1:1 TFA and CH<sub>2</sub>Cl<sub>2</sub> solution in an ice bath (0 Â°C) and stirred at room temperature for 3 h. Then, the resulting solution was evaporated under reduced pressure. The colorless residue was triturated with dry diethyl ether to yield the desired compound <b>11</b> as brown oil (yield, 100%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.38 (brs, 1H, COâNH), 7.79 (brs, 3H, NH<sub>3</sub><sup>+</sup>), 7.50 (d, 1H, ArâH), 7.18 (t, 1H, ArâH), 6.75 (d, 1H, ArâH), 6.59 (t, 1H, ArâH), 3.29 (d, 2H, NHâC<i>H</i><sub>2</sub>), 2.84 (d, 2H, C<i>H</i><sub>2</sub>âNH<sub>2</sub>), 1.79 (t, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (100 MHz, DMSOâ<i>d</i><sub>6</sub>): Î´ 169.02, 148.25, 131.75, 128.04, 116.96, 115.51, 115.38, 36.91, 35.83, 27.42 (CF<sub>3</sub>COOH, 158.84, 158.49, 158.13, 157.78, 120.26, 117.37, 114.46, 111.55). MALDI-TOF: <i>m</i>/<i>z</i> 193 [M<sup>+</sup>].</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthesis of <i>tert</i>-Butyl (3-(2-aminobenzamido)propyl)carbamate (<b>10</b>)</h3><div class="NLM_p last">A mixture of isatoic anhydride (<b>9</b>, 0.22 g, 1.38 mmol), <i>tert</i>-butyl (3-aminopropyl)carbamate (<b>8</b>, 0.2 mL, 1.15 mmol), and potassium carbonate (0.32 g, 2.30 mmol, 2.0 equiv) in anhydrous THF (3 mL) was stirred at 70 Â°C for 20 h under nitrogen atmosphere. After cooling, water was added, and stirring was continued for 4 h. The reaction mixture was concentrated and extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, then concentrated, and triturated to give a white powder. Yield, 74%; mp 80â81 Â°C. <sup>1</sup>H NMR (400 MHz, DMSOâ<i>d</i><sub>6</sub>): Î´ 8.15 (brs, 1H, COâNH), 7.44 (d, 1H, ArâH), 7.12 (t, 1H, ArâH), 6.80 (brs, 1H, NHâCO), 6.68 (d, 1H, ArâH), 6.52 (t, 1H, ArâH), 6.36 (s, 2H, Ar-NH<sub>2</sub>), 3.20â3.19 (m, 2H, NHâC<i>H</i><sub>2</sub>), 2.97â2.96 (m, 2H, C<i>H</i><sub>2-</sub>NH<sub>2</sub>), 1.62â1.58 (m, 2H, CH<sub>2</sub>), 1.38 (s, 9H, CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, DMSOâ<i>d</i><sub>6</sub>): Î´ 168.78, 155.57, 149.50, 131.49, 127.90, 116.26, 114.86, 114.49, 77.45, 37.69, 36.44, 29.58, 28.23. MALDI-TOF: <i>m</i>/<i>z</i> 293 [M<sup>+</sup>].</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis of PLGA-NHS</h3><div class="NLM_p last">PLGA-NHS was prepared (yield, 94%) by using the previoulsy reported procedure,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and with the following conditions: PLGA-A (3.0 g, 0.166 mmol), <i>N</i>-hydroxysuccinimide (NHS, 0.077 g, 0.714 mmol), and 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC, 0.14 g, 0.664 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 5.23â5.20 (m, 1H, âOCâC<i>H</i>(CH<sub>3</sub>)Oâ, PLGA), 4.90â4.70 (m, 2H, âOCâC<i>H</i><sub>2</sub>Oâ, PLGA), 1.58 (brs, 3H, âOCâCH(C<i>H</i><sub>3</sub>)Oâ, PLGA).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Synthesis of Pseudodiblock Copolymer PLGA-<b>11</b></h3><div class="NLM_p last">To a solution of PLGA-NHS (0.50 g, 0.028 mmol) in anhydrous dimethylformamide (DMF, 3 mL), a solution of <b>11</b> (0.034 g, 0.111 mmol) in DMF (1.5 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 0.90 mL, 5.16 mmol) were added. The resulting mixture was magnetically stirred at room temperature for 24 h under nitrogen atmosphere. The desired pseudodiblock copolymer PLGA-<b>11</b> was obtained by precipitation from cold diethyl ether and subsequent vacuum drying (yield, 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 5.30â5.15 (m, 1H, âOCâC<i>H</i>(CH<sub>3</sub>)Oâ, PLGA), 4.95â4.65 (m, 2H, âOCâC<i>H</i><sub>2</sub>Oâ, PLGA), 1.61 (brs, 3H, âOCâCH(C<i>H</i><sub>3</sub>)Oâ, PLGA).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of PLGA-PEG-NH<sub>2</sub></h3><div class="NLM_p last">To a solution of PLGA-NHS (0.50 g, 0.028 mmol) in anhydrous CHCl<sub>3</sub> (2 mL) and NH<sub>2</sub>-PEG-NH<sub>2</sub> (0.49 g, 0.14 mmol) in anhydrous CHCl<sub>3</sub> (5 mL) was added DIPEA (0.9 mL, 5.17 mmol), and the solution was magnetically stirred at room temperature for 24 h under nitrogen atmosphere. The PLGA-PEG-NH<sub>2</sub> copolymer was obtained by precipitation with cold diethyl ether, dried under vacuum, and used for NP preparation without further treatment (yield, 89%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 5.30â5.12 (m, 1H, âOCâC<i>H</i>(CH<sub>3</sub>)Oâ PLGA), 4.90â4.62 (m, 2H, âOCâC<i>H</i><sub>2</sub>Oâ, PLGA), 3.65 (brs, 2H, âC<i>H</i><sub>2</sub>C<i>H</i><sub>2</sub>Oâ, PEG), 1.58 (brs, 3H, âOCâCH(C<i>H</i><sub>3</sub>)Oâ, PLGA).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Synthesis of PLGA-PEG-<b>12</b></h3><div class="NLM_p last">PLGA-PEG-mal (0.47 g, 0.022 mmol) and peptide KTLLPTPC (<b>12</b>, 0.02 g, 0.023 mmol) were dissolved in 15 mL of 1:1 solution of acetonitrile and DMF. The resulting reaction was stirred for 24 h under nitrogen atmosphere. The desired pseudotriblock copolymer was obtained by precipitation with cold diethyl ether, then dried under vacuum, and used for NP preparation without further treatment (yield, 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 5.28â5.10 (m, 1H, âOCâC<i>H</i>(CH<sub>3</sub>)Oâ, PLGA), 4.88â4.64 (m, 2H, âOCâC<i>H</i><sub>2</sub>Oâ, PLGA), 3.64 (brs, 2H, âC<i>H</i><sub>2</sub>C<i>H</i><sub>2</sub>Oâ, PEG), 1.58 (brs, 3H, âOCâCH(C<i>H</i><sub>3</sub>)Oâ, PLGA).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthesis of PLGA-PEG-mal</h3><div class="NLM_p last">To a solution of PLGA-NHS (0.51 g, 0.029 mmol) in anhydrous CHCl<sub>3</sub> (3 mL) and NH<sub>2</sub>-PEG-maleimide (0.40 g, 0.11 mmol) in anhydrous CHCl<sub>3</sub> (2 mL) was added DIPEA (0.92 mL, 5.31 mmol), and the solution was magnetically stirred at room temperature for 24 h under nitrogen atmosphere. The PLGA-PEG-mal copolymer was obtained by precipitation with cold diethyl ether, then dried under vacuum, and used for NP preparation without further treatment (yield, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 5.32â5.10 (m, 1H, âOCâC<i>H</i>(CH<sub>3</sub>)Oâ PLGA), 4.93â4.63 (m, 2H, âOCâC<i>H</i><sub>2</sub>Oâ, PLGA), 3.64 (brs, 2H, âC<i>H</i><sub>2</sub>C<i>H</i><sub>2</sub>Oâ, PEG), 1.58 (brs, 3H, âOCâCH(C<i>H</i><sub>3</sub>)Oâ, PLGA).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Nanoformulation and Characterization of Nontargeted and <b>11</b>- and <b>12</b>-Targeted NPs</h3><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Preparation of (<b>1</b>)-Loaded PLGA-A and PLGA-<b>11</b> NPs</h4><div class="NLM_p last">Targeted (PLGA-<b>11</b>) and nontargeted (PLGA-A) NPs were prepared using a modified solvent displacement method as previously described.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Briefly, polymer (PLGA-A or PLGA-<b>11</b>) (99.5 mg) and <b>1</b> (0.5 mg) were codissolved in acetonitrile (6.0 mL) and added dropwise into 20 mL of PVA 1% (w/v) solution under rapid magnetic stirring. The resulting suspension was treated as reported,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> with minimal modifications (i.e., centrifugation was conducted at 13000 rpm, and pellets suspended in a minimal volume of water before storage). Batches without <b>1</b> were prepared and used as comparison.</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Preparation of (<b>1</b>)-Loaded PLGA-PEG-NH<sub>2</sub> and PLGA-PEG-<b>12</b> NPs</h4><div class="NLM_p last">The PLGA-PEG-<b>12</b> conjugate (or the PLGA-PEG-NH<sub>2</sub> copolymer for nontargeted particles) (19.9 mg), PCL (79.6 mg), and <b>1</b> (0.5 mg) were codissolved in 3 mL of acetonitrile and added dropwise to 3 mL of distilled water under magnetic stirring. Samples were treated as reported above. Batches without <b>1</b> were prepared and used for comparison.</div></div><div id="sec4_14_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Preparation of 6-Coumarin-Loaded NPs</h4><div class="NLM_p last">The preparation of NPs loaded with 6-coumarin was the same as that of NPs without dye, except that 6-coumarin (0.5 mg) was additionally added to acetonitrile containing polymers (total weight 100 mg) before nanoprecipitation.</div></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Characterization of Nanoparticles</h3><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Morphology, Size, and Î¶ Potential</h4><div class="NLM_p">The morphology of NPs was characterized by SEM (model DSM 962, Carl Zeiss Inc., Jena, Germany). A drop of NPs aqueous suspension was placed on a glass cover slide and dried under vacuum for 12 h. Next, the slides were mounted on aluminum stub, and the samples were then analyzed at 20 kV acceleration voltage after gold sputtering, under an argon atmosphere.</div><div class="NLM_p">Mean diameter and polydispersity index of NPs were measured by using photon correlation spectroscopy (Zetasizer Nano ZS, Malvern Instruments, U.K.) at 25 Â°C and a scattering angle of 90Â° after dilution of samples with Milli-Q water (1.0 mg of NPs/2.0 mL). Each sample was measured in triplicate.</div><div class="NLM_p last">The Î¶ potential of the NPs was detected at 25 Â°C with a Zeta Plus analyzer (Brookhaven, USA). The samples were diluted with distilled water (1.0 mg of NPs/2.0 mL) and sonicated for several minutes before measurement. All data were obtained with the average of three measurements.</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Determination of <b>1</b> Content in NPs and Yields of Production</h3><div class="NLM_p">The amount of the encapsulated <b>1</b> into NPs was determined by dissolving a weighted amount (10 mg) of dried (<b>1</b>)-loaded NPs in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and measured using an HPLC method, according with a procedure previously reported by us,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> with the following modification: the mobile phase consisting of solvent A/solvent B (60/40 v/v), where solvent A was TFA in water (0.1/99.9 v/v) and solvent B was acetonitrile/water/TFA (95/0.43/0.07 v/v), both prepared daily and degassed by sonication for 30 min, and filtered before use. Elution was performed at a flow rate of 0.2 mL/min. The injection volume was 25 Î¼L, and the wavelength for UV detection was 255 nm. The total analysis time was 20 min, and the retention time of <b>1</b> was 8.3 min. The calibration curves were found to be linear in the range of 2.5â100 Î¼g/mL (<i>y</i> = 777.56<i>x</i> â 303.23, <i>R</i><sup>2</sup> = 0.9999). The yields of production were expressed as the weight percentage of the final product after drying, regarding the initial total amount of solid materials used for the preparation.</div><div class="NLM_p last">The amount of 6-coumarin encapsulated was determined using the same procedure already described by us,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> with UVâvis spectroscopy analysis conducted at 450 nm.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> In Vitro Kinetics Release of <b>1</b> from NPs</h3><div class="NLM_p last">Formulation of PLGA-A, PLGA-<b>11</b>, PLGA-PEG-NH<sub>2</sub>, and PLGA-PEG-<b>12</b> (<b>1</b>)-loaded NPs was chosen for the next step of the study. Aliquots of (<b>1</b>)-loaded NPs in original suspensions (containing about 1.0 Î¼g of <b>1</b>) were dispersed in 2.0 mL of PBS at different pHs (pH 6.5 and pH 7.4) containing 0.1% w/v Tween-80 (used to improve the solubility of <b>1</b> in PBS) and continuously shaken at 37 Â°C. At various time points, the suspension was centrifuged at 13,000 rpm for 2 min, and 1.0 mL aliquots of medium were taken from supernatant and replaced with fresh solution. The collected samples were extracted with 0.2 mL dichloromethane, evaporated, and reconstituted in 100 Î¼L mobile phase. The concentration of <b>1</b> released from the NPs was determined by HPLC assay as described above and corrected for the dilution due to the addition of fresh medium.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Cell Culture</h3><div class="NLM_p last">Pancreatic cancer cell line (MIA PaCa-2) was purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in culture under 35 passages and tested regularly for <i>Mycoplasma</i> contamination using Plasmo Test (InvivoGen, San Diego, CA, USA). MIA PaCa-2 cell line was maintained in appropriate growth media DMEM (Cellgro, Mediatech, Manassas, VA, USA) containing 10% heat-inactivated FBS (Gemini Bioproducts, West Sacramento, CA, USA) at 37 Â°C in a humidified atmosphere of 5% CO<sub>2</sub>. For subculture and experiments, cells were washed with 1 Ã Dulbeccoâs PBS (DPBS, Cellgro), detached using 0.025% trypsin-EDTA (Cellgro), collected in growth media, and centrifuged. All experiments were performed in growth media using subconfluent cells in the exponential growth phase.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Cytotoxicity Assay</h3><div class="NLM_p last">Cytotoxicity was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Briefly, cells were seeded in 96-well tissue culture treated plates and allowed to adhere overnight. Cells were subsequently treated with vehicle or 100 Î¼L of a suspension of (<b>1</b>)-loaded NPs in serum-free culture medium to a final concentration of 2.8 of Î¼M <b>1</b>, then incubated in medium at 37 Â°C for required amount of time. After 72 h, MTT (0.3 mg/mL) was added to each well. Cells were incubated with MTT for 3 h at 37 Â°C. After removal of the supernatant, DMSO was added, and the absorbance was read at 570 nm. All assays were done in triplicate. Percent cytotoxicity was calculated by comparing the absorbance from treated wells to that of the control wells using following formula: % cytotoxicity =100(1 â [abs (drug treated)/abs (control)]).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Surface Plasmon Resonance Binding Assays</h3><div class="NLM_p">Binding experiments were performed using a Biacore T-200 instrument (Biacore, Uppsala, Sweden) at 25 Â°C. 11000 RU of the human Plec-1 partial ORF (4384â4493 a.a.) recombinant protein with GST-tag at N-terminal (37.84 kDa, from Abnova Corporation, Taiwan) were directly immobilized on the <i>N</i>-ethyl-<i>N</i>-(3-(dimethylamino)propyl) carbodiimide (EDC) and <i>N</i>-hydroxysuccinimide (NHS) activated flow cell2 of the CM5 chip (GE certified) in water. The flow rate of the 10 mM sodium acetate buffer (pH 5.0), used for capturing the protein, was 5 Î¼L/min. The unoccupied sites were blocked with 1 M ethanolamine.</div><div class="NLM_p last">NPs were diluted to 5 mg/mL in standard HBS-N buffer [10 mM HEPES buffer (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.05% P20 (polyoxyethylenesorbitan), and 1 mg/mL BSA], sonicated with 5 s pulses three times and kept on ice until ready. Comparative binding analysis was performed using analyte NPs flowed over the chip at single analyte concentration, with a flow rate of 30 Î¼L/min. Binding of analyte to the immobilized protein was monitored in real time.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Fluorescence Microscopy</h3><div class="NLM_p">Cells were seeded on clear bottom black plates and allowed to adhere overnight. Following which cells were treated with indicated samples for 1h at 37 Â°C. After this, cells were washed with 1Ã PBS to remove excess nanoparticles and dye. Cells were then imaged using BD Pathway 435 high-content bioimager (BD Biosciences) using 20Ã objective.</div><div id="sec4_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Statistical Analysis</h4><div class="NLM_p last">The data for preparation and characterization of NPs as well as drug release studies were processed and analyzed by Origin software (version 7.0 SR0, OriginLab Corporation, USA). The statistical analysis, evaluated by a Studentâs <i>t</i>-test and <i>p</i>-values <0.05, was considered statistically significant. The data obtained from cytotoxicity assays were processed by one-way analysis of variance (ANOVA) followed by a posthoc âNewmanâKeuls multiple comparison testâ to detect differences of means among treatments with significance defined as <i>p</i> < 0.05.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01571">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01571" class="ext-link">10.1021/acs.jmedchem.5b01571</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">MS and NMR spectra, elemental analyses, for compounds <b>1</b>, <b>2</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>10</b>, <b>11</b>. NMR spectra for polymers PLGA-<b>11</b>, PLGA-PEG-NH<sub>2</sub>, and PLGA-PEG-<b>12</b>. <sup>1</sup>H NMR spectrum for peptide <b>12</b>. Synthesis and characterization of <b>12</b>. Characterization details of 6C-loaded NPs. GPC-SEC data (molecular weights, polydispersity, and refractive indexes) for PLGA-PEG-NH<sub>2</sub> and PLGA-PEG-<b>12</b> polymers (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Additional compound data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf">jm5b01571_si_001.pdf (2.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_002.csv">jm5b01571_si_002.csv (0.31 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01571" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nouri Neamati</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, Translational Oncology
Program, University of Michigan, Ann Arbor, Michigan 48109, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dbb5bebab6baafb29baeb6b2b8b3f5bebfae"><span class="__cf_email__" data-cfemail="f79992969a96839eb7829a9e949fd9929382">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Sechi</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Pharmacy, University of
Sassari, 07100 Sassari, Italy</span>;Â 
    <span class="hlFld-Affiliation affiliation">Laboratory
of Nanomedicine, University of Sassari, c/c Porto Conte Ricerche, 07041 Alghero, Italy</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2e434f5c4741005d4b4d46476e5b40475d5d00475a"><span class="__cf_email__" data-cfemail="f895998a9197d68b9d9b9091b88d96918b8bd6918c">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vanna Sanna</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Pharmacy, University of
Sassari, 07100 Sassari, Italy</span>;Â 
    <span class="hlFld-Affiliation affiliation">Laboratory
of Nanomedicine, University of Sassari, c/c Porto Conte Ricerche, 07041 Alghero, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Salvatore Nurra</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Pharmacy, University of
Sassari, 07100 Sassari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicolino Pala</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Pharmacy, University of
Sassari, 07100 Sassari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Salvatore Marceddu</span> - <span class="hlFld-Affiliation affiliation">Istituto
di Scienze delle Produzioni Alimentari (ISPA)-CNR, sez. di Sassari, 07040 Baldinca, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Divya Pathania</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, California 90089, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d131e2718-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04478" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04478" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge the Regione Autonoma della Sardegna for financial support grant CRP 25920, awarded to M.S. within the frame of âLegge regionale n. 7/2007, promozione della ricerca scientifica e dellâinnovazione tecnologica in Sardegna, AnnualitÃ  2010â, and the Fondazione Banco di Sardegna for its partial support. The work in N.N. laboratory was supported by the National Cancer Institute Grant CA188252. The authors thank Dr. Anna Maria Roggio for her help with mass and HPLC analysis, the Purac Biomaterials (Gorinchem, Netherlands) for providing the PLGA polymer, the Precision Antibody (Columbia, MD, USA), the CASLO Laboratory ApS, c/o Scion Denmark Technical University (Lyngby, Denmark), and the Alfatestlab s.r.l. (MI, Italia) for their helpful technical assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> Abbreviations Used</h2><tr><td class="NLM_term">NPs</td><td class="NLM_def"><p class="first last">nanoparticles</p></td></tr><tr><td class="NLM_term">PLGA</td><td class="NLM_def"><p class="first last">poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactide-<i>co</i>-glycolide)</p></td></tr><tr><td class="NLM_term">PLGA-PEG</td><td class="NLM_def"><p class="first last">poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactic-<i>co</i>-glycolic acid)-<i>block</i>-poly(ethylene glycol)</p></td></tr><tr><td class="NLM_term">PCL</td><td class="NLM_def"><p class="first last">poly(epsilon-caprolactone)</p></td></tr><tr><td class="NLM_term">PaCa</td><td class="NLM_def"><p class="first last">pancreatic cancer</p></td></tr><tr><td class="NLM_term">PDAC</td><td class="NLM_def"><p class="first last">ductal adenocarcinoma</p></td></tr><tr><td class="NLM_term">QDs</td><td class="NLM_def"><p class="first last">quinazolinedione-based compounds</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">Plec-1</td><td class="NLM_def"><p class="first last">Plectin-1</p></td></tr><tr><td class="NLM_term">PTP</td><td class="NLM_def"><p class="first last">KTLLPTP peptide</p></td></tr><tr><td class="NLM_term">Cys-PTP</td><td class="NLM_def"><p class="first last">KTLLPTPC peptide</p></td></tr><tr><td class="NLM_term">2ABA</td><td class="NLM_def"><p class="first last">2-amino-<i>N</i>-(3-aminopropyl)benzamide</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">fluorenylmethyloxycarbonyl</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">GPC</td><td class="NLM_def"><p class="first last">gel permeation chromatography</p></td></tr><tr><td class="NLM_term">SEC</td><td class="NLM_def"><p class="first last">size exclusion chromatography</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">RES</td><td class="NLM_def"><p class="first last">reticuloendothelial system</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ryan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span> </span><span class="NLM_article-title">Pancreatic adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1049</span><span class="refDoi">Â DOI: 10.1056/NEJMra1404198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMra1404198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25207767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Olt7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1039-1049&author=D.+P.+Ryanauthor=T.+S.+Hongauthor=N.+Bardeesy&title=Pancreatic+adenocarcinoma&doi=10.1056%2FNEJMra1404198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic adenocarcinoma</span></div><div class="casAuthors">Ryan, David P.; Hong, Theodore S.; Bardeesy, Nabeel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1049, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1-TPh2I8RbVg90H21EOLACvtfcHk0lhO7Yok3ISabA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Olt7rK&md5=c916814b3ce1e14f3a93b9a0b05cd286</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1404198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1404198%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DD.%2BP.%26aulast%3DHong%26aufirst%3DT.%2BS.%26aulast%3DBardeesy%26aufirst%3DN.%26atitle%3DPancreatic%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1039%26epage%3D1049%26doi%3D10.1056%2FNEJMra1404198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics, <b>2016</b></span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">â</span> <span class="NLM_lpage">30</span><span class="refDoi">Â DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eZfv4iX4HUtOrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Malvezzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertuccio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Vecchia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, E.</span><span> </span><span class="NLM_article-title">European cancer mortality predictions for the year 2014</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1650</span><span class="NLM_x">â</span> <span class="NLM_lpage">1656</span><span class="refDoi">Â DOI: 10.1093/annonc/mdu138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1093%2Fannonc%2Fmdu138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24759568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC2cnmtFCmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1650-1656&author=M.+Malvezziauthor=P.+Bertuccioauthor=F.+Leviauthor=C.+La+Vecchiaauthor=E.+Negri&title=European+cancer+mortality+predictions+for+the+year+2014&doi=10.1093%2Fannonc%2Fmdu138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">European cancer mortality predictions for the year 2014</span></div><div class="casAuthors">Malvezzi M; Bertuccio P; Negri E; Levi F; La Vecchia C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1650-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  From most recent available data, we projected cancer mortality statistics for 2014, for the European Union (EU) and its six more populous countries.  Specific attention was given to pancreatic cancer, the only major neoplasm showing unfavorable trends in both sexes.  PATIENTS AND METHODS:  Population and death certification data from stomach, colorectum, pancreas, lung, breast, uterus, prostate, leukemias and total cancers were obtained from the World Health Organisation database and Eurostat.  Figures were derived for the EU, France, Germany, Italy, Poland, Spain and the UK.  Projected 2014 numbers of deaths by age group were obtained by linear regression on estimated numbers of deaths over the most recent time period identified by a joinpoint regression model.  RESULTS:  In the EU in 2014, 1,323,600 deaths from cancer are predicted (742,500 men and 581,100 women), corresponding to standardized death rates of 138.1/100,000 men and 84.7/100,000 women, falling by 7% and 5%, respectively, since 2009.  In men, predicted rates for the three major cancers (lung, colorectum and prostate cancer) are lower than in 2009, falling by 8%, 4% and 10%, respectively.  In women, breast and colorectal cancers had favorable trends (-9% and -7%), but female lung cancer rates are predicted to rise 8%.  Pancreatic cancer is the only neoplasm with a negative outlook in both sexes.  Only in the young (25-49 years), EU trends become more favorable in men, while women keep registering slight predicted rises.  CONCLUSIONS:  Cancer mortality predictions for 2014 confirm the overall favorable cancer mortality trend in the EU, translating to an overall 26% fall in men since its peak in 1988, and 20% in women, and the avoidance of over 250,000 deaths in 2014 compared with the peak rate.  Notable exceptions are female lung cancer and pancreatic cancer in both sexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS98DOyzhftHXwOGIfWJ7-GfW6udTcc2eZKAGlWQ2MNJLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnmtFCmsw%253D%253D&md5=088023e13e2ca45a7ee20668d8031f80</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu138%26sid%3Dliteratum%253Aachs%26aulast%3DMalvezzi%26aufirst%3DM.%26aulast%3DBertuccio%26aufirst%3DP.%26aulast%3DLevi%26aufirst%3DF.%26aulast%3DLa%2BVecchia%26aufirst%3DC.%26aulast%3DNegri%26aufirst%3DE.%26atitle%3DEuropean%2520cancer%2520mortality%2520predictions%2520for%2520the%2520year%25202014%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1650%26epage%3D1656%26doi%3D10.1093%2Fannonc%2Fmdu138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">New insights into pancreatic cancer biology</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">x135</span><span class="NLM_x">â</span> <span class="NLM_lpage">x138</span><span class="refDoi">Â DOI: 10.1093/annonc/mds313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1093%2Fannonc%2Fmds313" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=x135-x138&author=M.+Hidalgo&title=New+insights+into+pancreatic+cancer+biology&doi=10.1093%2Fannonc%2Fmds313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds313%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DNew%2520insights%2520into%2520pancreatic%2520cancer%2520biology%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dx135%26epage%3Dx138%26doi%3D10.1093%2Fannonc%2Fmds313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Pancreatic cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">â</span> <span class="NLM_lpage">1617</span><span class="refDoi">Â DOI: 10.1056/NEJMra0901557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMra0901557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20427809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsV2ns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=1605-1617&author=M.+Hidalgo&title=Pancreatic+cancer&doi=10.1056%2FNEJMra0901557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic cancer</span></div><div class="casAuthors">Hidalgo, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1605-1617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on a recent progress in understanding and management of pancreatic cancer.  Topics included are the biol. of pancreatic cancer, clin. presentation, diagnosis, staging, and management of early and advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSTq-bB-IhrVg90H21EOLACvtfcHk0livntAW0hYkXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsV2ns7o%253D&md5=3663d7b19672fa1d11aef6640c0bb4e9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0901557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0901557%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DPancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D1605%26epage%3D1617%26doi%3D10.1056%2FNEJMra0901557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Conroy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desseigne, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ychou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimbaud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becouarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raoul, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourgou-Bourgade, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Fouchardiere, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachet, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khemissa-Akouz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pere-Verge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assenat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauffert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montoto-Grillot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducreux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groupe Tumeurs Digestives of, U.; Intergroup, P.</span><span> </span><span class="NLM_article-title">FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1817</span><span class="NLM_x">â</span> <span class="NLM_lpage">1825</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1011923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMoa1011923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21561347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvF2jsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1817-1825&author=T.+Conroyauthor=F.+Desseigneauthor=M.+Ychouauthor=O.+Boucheauthor=R.+Guimbaudauthor=Y.+Becouarnauthor=A.+Adenisauthor=J.+L.+Raoulauthor=S.+Gourgou-Bourgadeauthor=C.+de+la+Fouchardiereauthor=J.+Bennounaauthor=J.+B.+Bachetauthor=F.+Khemissa-Akouzauthor=D.+Pere-Vergeauthor=C.+Delbaldoauthor=E.+Assenatauthor=B.+Chauffertauthor=P.+Michelauthor=C.+Montoto-Grillotauthor=M.+Ducreuxauthor=Groupe+Tumeurs+Digestives+of%2C+U.%3B+Intergroup%2C+P.&title=FOLFIRINOX+versus+gemcitabine+for+metastatic+pancreatic+cancer&doi=10.1056%2FNEJMoa1011923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FOLFIRINOX versus gemcitabine or metastatic pancreatic cancer</span></div><div class="casAuthors">Conroy, Thierry; Desseigne, Francoise; Ychou, Marc; Bouche, Olivier; Guimbaud, Rosine; Becouarn, Yves; Adenis, Antoine; Raoul, Jean-Luc; Gourgou-Bourgade, Sophie; de la Fouchardiere, Christelle; Bennouna, Jaafar; Bachet, Jean-Baptiste; Khemissa-Akouz, Faiza; Pere-Verge, Denis; Delbaldo, Catherine; Assenat, Eric; Chauffert, Bruno; Michel, Pierre; Montoto-Grillot, Christine; Ducreux, Michel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1817-1825</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.  METHODS We randomly assigned 342 patients with an Eastern Cooperative Oncol. Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-h continuous infusion, every 2 wk) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 wk and then weekly for 3 of 4 wk.  Six months of chemotherapy were recommended in both groups in patients who had a response.  The primary end point was overall survival.  RESULTS The median overall survival was 11.1 mo in the FOLFIRINOX group as compared with 6.8 mo in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P < 0.001).  Median progression-free survival was 6.4 mo in the FOLFIRINOX group and 3.3 mo in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P < 0.001).  The objective response rate was 31.60% in the FOLFIRINOX group vs. 9.4% in the gemcitabine group (P < 0.001).  More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia.  At 6 mo, 31% of the patients in the FOLFIRINOX group had a definitive degrdn. of the quality of life vs. 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P < 0.001).  CONCLUSIONS As compared with gemcitabine, FOLFIRINOX was assocd. with a survival advantage and had increased toxicity.  FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGyDR85GUgOrVg90H21EOLACvtfcHk0livntAW0hYkXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvF2jsrw%253D&md5=a1a7135a6c97c4dc47233465ce0defd5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011923%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DDesseigne%26aufirst%3DF.%26aulast%3DYchou%26aufirst%3DM.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DGuimbaud%26aufirst%3DR.%26aulast%3DBecouarn%26aufirst%3DY.%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DRaoul%26aufirst%3DJ.%2BL.%26aulast%3DGourgou-Bourgade%26aufirst%3DS.%26aulast%3Dde%2Bla%2BFouchardiere%26aufirst%3DC.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DBachet%26aufirst%3DJ.%2BB.%26aulast%3DKhemissa-Akouz%26aufirst%3DF.%26aulast%3DPere-Verge%26aufirst%3DD.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DAssenat%26aufirst%3DE.%26aulast%3DChauffert%26aufirst%3DB.%26aulast%3DMichel%26aufirst%3DP.%26aulast%3DMontoto-Grillot%26aufirst%3DC.%26aulast%3DDucreux%26aufirst%3DM.%26aulast%3D%26atitle%3DFOLFIRINOX%2520versus%2520gemcitabine%2520for%2520metastatic%2520pancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1817%26epage%3D1825%26doi%3D10.1056%2FNEJMoa1011923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Di Marco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cicilia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobili, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchiarelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasco, G.</span><span> </span><span class="NLM_article-title">Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review)</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1183</span><span class="NLM_x">â</span> <span class="NLM_lpage">1192</span><span class="refDoi">Â DOI: 10.3892/or_00000749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.3892%2For_00000749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20372829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVKhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1183-1192&author=M.+Di+Marcoauthor=R.+Di+Ciciliaauthor=M.+Macchiniauthor=E.+Nobiliauthor=S.+Vecchiarelliauthor=G.+Brandiauthor=G.+Biasco&title=Metastatic+pancreatic+cancer%3A+is+gemcitabine+still+the+best+standard+treatment%3F+%28Review%29&doi=10.3892%2For_00000749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (review)</span></div><div class="casAuthors">Di Marco, MariaCristina; Di Cicilia, Roberto; Macchini, Marina; Nobili, Elisabetta; Vecchiarelli, Silvia; Brandi, Giovanni; Biasco, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1183-1192</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world.  Surgery remains the only treatment offering an advantage in terms of overall survival (5-yr survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis.  Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life.  Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved.  Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients.  This study examines the principal clin. trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPtsYDEHN5LVg90H21EOLACvtfcHk0ljsJvK7tYTj5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVKhs7s%253D&md5=ae09fcaa5c1559646c184cb114ba7577</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3892%2For_00000749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000749%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DM.%26aulast%3DDi%2BCicilia%26aufirst%3DR.%26aulast%3DMacchini%26aufirst%3DM.%26aulast%3DNobili%26aufirst%3DE.%26aulast%3DVecchiarelli%26aufirst%3DS.%26aulast%3DBrandi%26aufirst%3DG.%26aulast%3DBiasco%26aufirst%3DG.%26atitle%3DMetastatic%2520pancreatic%2520cancer%253A%2520is%2520gemcitabine%2520still%2520the%2520best%2520standard%2520treatment%253F%2520%2528Review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2010%26volume%3D23%26spage%3D1183%26epage%3D1192%26doi%3D10.3892%2For_00000749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arena, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiorean, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjulandin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laheru, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglesias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renschler, M. F.</span><span> </span><span class="NLM_article-title">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1691</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1304369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMoa1304369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24131140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCjsb7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1691-1703&author=D.+D.+Von+Hoffauthor=T.+Ervinauthor=F.+P.+Arenaauthor=E.+G.+Chioreanauthor=J.+Infanteauthor=M.+Mooreauthor=T.+Seayauthor=S.+A.+Tjulandinauthor=W.+W.+Maauthor=M.+N.+Salehauthor=M.+Harrisauthor=M.+Reniauthor=S.+Dowdenauthor=D.+Laheruauthor=N.+Baharyauthor=R.+K.+Ramanathanauthor=J.+Taberneroauthor=M.+Hidalgoauthor=D.+Goldsteinauthor=E.+Van+Cutsemauthor=X.+Weiauthor=J.+Iglesiasauthor=M.+F.+Renschler&title=Increased+survival+in+pancreatic+cancer+with+nab-paclitaxel+plus+gemcitabine&doi=10.1056%2FNEJMoa1304369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</span></div><div class="casAuthors">Von Hoff, Daniel D.; Ervin, Thomas; Arena, Francis P.; Chiorean, E. Gabriela; Infante, Jeffrey; Moore, Malcolm; Seay, Thomas; Tjulandin, Sergei A.; Ma, Wen Wee; Saleh, Mansoor N.; Harris, Marion; Reni, Michele; Dowden, Scot; Laheru, Daniel; Bahary, Nathan; Ramanathan, Ramesh K.; Tabernero, Josep; Hidalgo, Manuel; Goldstein, David; Van Cutsem, Eric; Wei, Xinyu; Iglesias, Jose; Renschler, Markus F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clin. activity was noted in patients with advanced pancreatic cancer.  We conducted a phase 3 study of the efficacy and safety of the combination vs. gemcitabine monotherapy in patients with metastatic pancreatic cancer.  METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 wk or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 wk (cycle 1) and then on days 1, 8, and 15 every 4 wk (cycle 2 and subsequent cycles).  Patients received the study treatment until disease progression.  The primary end point was overall survival; secondary end points were progression-free survival and overall response rate.  RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430).  The median overall survival was 8.5 mo in the nab-paclitaxel-gemcitabine group as compared with 6.7 mo in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001).  The survival rate was 35% in the nab-paclitaxel-gemcitabine group vs. 22% in the gemcitabine group at 1 yr, and 9% vs. 4% at 2 years.  The median progression-free survival was 5.5 mo in the nab-paclitaxel-gemcitabine group, as compared with 3.7 mo in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% vs. 7% in the two groups (P<0.001).  The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%).  Febrile neutropenia occurred in 3% vs. 1% of the patients in the two groups.  In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.  CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCXpODbQZ6dLVg90H21EOLACvtfcHk0ljsJvK7tYTj5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCjsb7I&md5=b1169c7e9879c08061dd9e9389dc36fe</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1304369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1304369%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DArena%26aufirst%3DF.%2BP.%26aulast%3DChiorean%26aufirst%3DE.%2BG.%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DM.%26aulast%3DSeay%26aufirst%3DT.%26aulast%3DTjulandin%26aufirst%3DS.%2BA.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DSaleh%26aufirst%3DM.%2BN.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DReni%26aufirst%3DM.%26aulast%3DDowden%26aufirst%3DS.%26aulast%3DLaheru%26aufirst%3DD.%26aulast%3DBahary%26aufirst%3DN.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DIglesias%26aufirst%3DJ.%26aulast%3DRenschler%26aufirst%3DM.%2BF.%26atitle%3DIncreased%2520survival%2520in%2520pancreatic%2520cancer%2520with%2520nab-paclitaxel%2520plus%2520gemcitabine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1304369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Srinivasarao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliford, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">219</span><span class="refDoi">Â DOI: 10.1038/nrd4519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+design+of+ligand-targeted+cancer+therapeutics+and+imaging+agents&doi=10.1038%2Fnrd4519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0lg-6V_GaPNKog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520design%2520of%2520ligand-targeted%2520cancer%2520therapeutics%2520and%2520imaging%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D203%26epage%3D219%26doi%3D10.1038%2Fnrd4519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">Active targeting schemes for nanoparticle systems in cancer therapeutics</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">â</span> <span class="NLM_lpage">1626</span><span class="refDoi">Â DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+targeting+schemes+for+nanoparticle+systems+in+cancer+therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0lg-6V_GaPNKog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520targeting%2520schemes%2520for%2520nanoparticle%2520systems%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennink, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, G.</span><span> </span><span class="NLM_article-title">Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">187</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2011.09.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.jconrel.2011.09.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21945285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2012&pages=175-187&author=T.+Lammersauthor=F.+Kiesslingauthor=W.+E.+Henninkauthor=G.+Storm&title=Drug+targeting+to+tumors%3A+principles%2C+pitfalls+and+%28pre-%29+clinical+progress&doi=10.1016%2Fj.jconrel.2011.09.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress</span></div><div class="casAuthors">Lammers, Twan; Kiessling, Fabian; Hennink, Wim E.; Storm, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many different systems and strategies were evaluated for drug targeting to tumors over the years.  Routinely used systems include liposomes, polymers, micelles, nanoparticles and antibodies, and examples of strategies are passive drug targeting, active drug targeting to cancer cells, active drug targeting to endothelial cells and triggered drug delivery.  Significant progress was made in this area of research both at the preclin. and at the clin. level, and a no. of (primarily passively tumor-targeted) nanomedicine formulations were approved for clin. use.  Significant progress was also made with regard to better understanding the (patho-) physiol. principles of drug targeting to tumors.  This has led to the identification of several important pitfalls in tumor-targeted drug delivery, including (I) overinterpretation of the EPR effect; (II) poor tumor and tissue penetration of nanomedicines; (III) misunderstanding of the potential usefulness of active drug targeting; (IV) irrational formulation design, based on materials which are too complex and not broadly applicable; (V) insufficient incorporation of nanomedicine formulations in clin. relevant combination regimens; (VI) negligence of the notion that the highest medical need relates to metastasis, and not to solid tumor treatment; (VII) insufficient integration of non-invasive imaging techniques and theranostics, which could be used to personalize nanomedicine-based therapeutic interventions; and (VIII) lack of (efficacy analyses in) proper animal models, which are physiol. more relevant and more predictive for the clin. situation.  These insights strongly suggest that besides making ever more nanomedicine formulations, future efforts should also address some of the conceptual drawbacks of drug targeting to tumors, and that strategies should be developed to overcome these shortcomings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzCGIHDCrMbVg90H21EOLACvtfcHk0lg-6V_GaPNKog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtbY%253D&md5=b2f501f088ef8b19a6fbe7ee2290ab69</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.09.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.09.063%26sid%3Dliteratum%253Aachs%26aulast%3DLammers%26aufirst%3DT.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DHennink%26aufirst%3DW.%2BE.%26aulast%3DStorm%26aufirst%3DG.%26atitle%3DDrug%2520targeting%2520to%2520tumors%253A%2520principles%252C%2520pitfalls%2520and%2520%2528pre-%2529%2520clinical%2520progress%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D161%26spage%3D175%26epage%3D187%26doi%3D10.1016%2Fj.jconrel.2011.09.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrettini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taheri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1840</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">â</span> <span class="NLM_lpage">343</span><span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.bbagen.2013.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23954204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOls77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=332-343&author=D.+Pathaniaauthor=M.+Sechiauthor=M.+Palombaauthor=V.+Sannaauthor=F.+Berrettiniauthor=A.+Siasauthor=L.+Taheriauthor=N.+Neamati&title=Design+and+discovery+of+novel+quinazolinedione-based+redox+modulators+as+therapies+for+pancreatic+cancer&doi=10.1016%2Fj.bbagen.2013.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer</span></div><div class="casAuthors">Pathania, Divya; Sechi, Mario; Palomba, Michele; Sanna, Vanna; Berrettini, Francesco; Sias, Angela; Taheri, Laleh; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">332-343</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Altered cellular bioenergetics and oxidative stress are emerging hallmarks of most cancers including pancreatic cancer.  Elevated levels of intrinsic reactive oxygen species (ROS) in tumors make them more susceptible to exogenously induced oxidative stress.  Excessive oxidative insults overwhelm their adaptive antioxidant capacity and trigger ROS-mediated cell death.  Recently, we have discovered a novel class of quinazolinediones that exert their cytotoxic effects by modulating ROS-mediated signaling.  Cytotoxic potential was detd. by colorimetric and colony formation assays.  An XF24 Extracellular Flux Analyzer, and colorimetric and fluorescent techniques were used to assess the bioenergetics and oxidative stress effects, resp.  Mechanism was detd. by Western blots.  Compd. 3a (6-[(2-acetylphenyl)amino]quinazoline-5,8-dione) was identified through a medium throughput screen of â¼ 1000 highly diverse inhouse compds. and chemotherapeutic agents for their ability to alter cellular bioenergetics.  Further structural optimizations led to the discovery of a more potent analog, 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) that displayed anti-proliferative activities in low micromolar range in both drug-sensitive and drug-resistant cancer cells.  Treatment with 3b causes Akt activation resulting in increased cellular oxygen consumption and oxidative stress in pancreatic cancer cells.  Moreover, oxidative stress induced by 3b promoted activation of stress kinases (p38/JNK) resulting in cancer cell death.  Treatment with antioxidants was able to reduce cell death confirming ROS-mediated cytotoxicity.  In conclusion, our novel quinazolinediones are promising lead compds. that selectively induce ROS-mediated cell death in cancer cells and warrant further preclin. studies.  Since 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) exerts Akt-dependent ROS-mediated cell death, it might provide potential therapeutic options for chemoresistant and Akt-overexpressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtv5xHFya9e7Vg90H21EOLACvtfcHk0lg-6V_GaPNKog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOls77E&md5=cbbcaca46c9dab2968538df71746ee0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DPalomba%26aufirst%3DM.%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DBerrettini%26aufirst%3DF.%26aulast%3DSias%26aufirst%3DA.%26aulast%3DTaheri%26aufirst%3DL.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DDesign%2520and%2520discovery%2520of%2520novel%2520quinazolinedione-based%2520redox%2520modulators%2520as%2520therapies%2520for%2520pancreatic%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D332%26epage%3D343%26doi%3D10.1016%2Fj.bbagen.2013.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span><span class="refDoi">Â DOI: 10.1111/bph.12855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1111%2Fbph.12855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25047070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=50-63&author=D.+Pathaniaauthor=Y.+Kuangauthor=M.+Sechiauthor=N.+Neamati&title=Mechanisms+underlying+the+cytotoxicity+of+a+novel+quinazolinedione-based+redox+modulator%2C+QD232%2C+in+pancreatic+cancer+cells&doi=10.1111%2Fbph.12855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells</span></div><div class="casAuthors">Pathania, Divya; Kuang, Yuting; Sechi, Mario; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pancreatic cancer is characterized by alterations in several key signalling proteins, including increased expression and activity of the Src tyrosine kinase and focal adhesion kinase (FAK), which have been linked to its chemoresistance.  Sustained Src inhibition reactivates survival pathways regulated by the transcription factor STAT3, also leading to resistance.  Therefore, simultaneously targeting Src/FAK and STAT3 signalling could provide an important strategy for treating pancreatic cancer.  Recently, we described novel quinazolinediones that increased generation of reactive oxygen species (ROS) and were cytotoxic in pancreatic cancer cells.  Here, we have investigated effects of our lead compd., QD232, on Src/FAK and STAT3 signalling.  Exptl. Approach : The major signalling pathways affected by QD232 in pancreatic cancer cell lines were identified by Kinexus proteomic anal.  Changes in key signalling proteins were confirmed by Western blotting.  Cell migration was assessed by Boyden chamber and wound healing assays.  Direct inhibition of kinase activity in vitro was assayed with a panel of 92 oncogenic kinases.  Safety and efficacy of QD232 were detd. in a xenograft mouse model of pancreatic cancer.  Key Results : QD232 potently inhibited Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.  Furthermore, QD232 arrested cell cycle progression and induced apoptosis in these cells at low micromolar concns.  Effects of QD232 on Src/FAK and STAT3 phosphorylation were blocked by N-acetylcysteine or glutathione.  Conclusions and Implications : QD232 is a novel compd. with a unique, ROS-dependent mechanism, effective in drug-resistant cancer cell lines.  This compd. shows potential as therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT3-x-z_lL3rVg90H21EOLACvtfcHk0lj5pPKkGz3wSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLvK&md5=6471c264193699d9d78bd0f2c596008b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fbph.12855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12855%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DMechanisms%2520underlying%2520the%2520cytotoxicity%2520of%2520a%2520novel%2520quinazolinedione-based%2520redox%2520modulator%252C%2520QD232%252C%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D50%26epage%3D63%26doi%3D10.1111%2Fbph.12855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">â</span> <span class="NLM_lpage">674</span><span class="refDoi">Â DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lj5pPKkGz3wSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1250</span><span class="NLM_x">â</span> <span class="NLM_lpage">1275</span><span class="refDoi">Â DOI: 10.1016/j.addr.2009.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2009.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19716393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWmu7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1250-1275&author=D.+Pathaniaauthor=M.+Millardauthor=N.+Neamati&title=Opportunities+in+discovery+and+delivery+of+anticancer+drugs+targeting+mitochondria+and+cancer+cell+metabolism&doi=10.1016%2Fj.addr.2009.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism</span></div><div class="casAuthors">Pathania, Divya; Millard, Melissa; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1250-1275</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cancer cells are characterized by self-sufficiency in the absence of growth signals, their ability to evade apoptosis, resistance to anti-growth signals, sustained angiogenesis, uncontrolled proliferation, and invasion and metastasis.  Alterations in cellular bioenergetics are an emerging hallmark of cancer.  The mitochondrion is the major organelle implicated in the cellular bioenergetic and biosynthetic changes accompanying cancer.  These bioenergetic modifications contribute to the invasive, metastatic and adaptive properties typical in most tumors.  Moreover, mitochondrial DNA mutations complement the bioenergetic changes in cancer.  Several cancer management therapies have been proposed that target tumor cell metab. and mitochondria.  Glycolytic inhibitors serve as a classical example of cancer metab. targeting agents.  Several TCA cycle and OXPHOS inhibitors are being tested for their anticancer potential.  Moreover, agents targeting the PDC/PDK (pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase) interaction are being studied for reversal of Warburg effect.  Targeting of the apoptotic regulatory machinery of mitochondria is another potential anticancer field in need of exploration.  Addnl., oxidative phosphorylation uncouplers, potassium channel modulators, and mitochondrial redox are under investigation for their anticancer potential.  To this end there is an increased demand for agents that specifically hit their target.  Delocalized lipophilic cations have shown tremendous potential in delivering anticancer agents selectively to tumor cells.  This review provides an overview of the potential anticancer agents that act by targeting cancer cell metab. and mitochondria, and also brings us face to face with the emerging opportunities in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUD_gbQnpA7Vg90H21EOLACvtfcHk0lj5pPKkGz3wSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWmu7nI&md5=b9d407cf595c188ada0e9f71cf17bd24</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DMillard%26aufirst%3DM.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DOpportunities%2520in%2520discovery%2520and%2520delivery%2520of%2520anticancer%2520drugs%2520targeting%2520mitochondria%2520and%2520cancer%2520cell%2520metabolism%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D1250%26epage%3D1275%26doi%3D10.1016%2Fj.addr.2009.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Storz, P.</span><span> </span><span class="NLM_article-title">Reactive oxygen species in tumor progression</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="NLM_x">â</span> <span class="NLM_lpage">1896</span><span class="refDoi">Â DOI: 10.2741/1667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2741%2F1667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=15769673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVygsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1881-1896&author=P.+Storz&title=Reactive+oxygen+species+in+tumor+progression&doi=10.2741%2F1667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species in tumor progression</span></div><div class="casAuthors">Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1881-1896</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The generation of reactive oxygen radicals in mammalian cells profoundly affects numerous crit. cellular functions, and the absence of efficient cellular detoxification mechanisms which remove these radicals can result in several human diseases.  Growing evidence suggests that reactive oxygen species (ROS) within cells act as second messengers in intracellular signaling cascades which induce and maintain the oncogenic phenotype of cancer cells.  ROS are tumorigenic by virtue of their ability to increase cell proliferation, survival, cellular migration, and also by inducing DNA damage leading to genetic lesions that initiate tumorigenicity and sustain subsequent tumor progression.  However, it is also known that ROS can induce cellular senescence and cell death and can therefore function as anti-tumorigenic agents.  Therefore, the mechanisms by which cells respond to reactive oxygen species depends on the mol. background of cell and tissues, the location of ROS prodn. and the concn. of individual ROS species.  Carcinoma cells produce ROS at elevated rates in vitro, and in vivo many tumors appear persistent to oxidative stress.  Thus, the finding that a diet rich in antioxidants or the elimination of ROS by antioxidant compds. prevents the development of certain cancers provided the setting for subsequent investigation of the tumorigenic actions of reactive oxygen species.  This review outlines the current knowledge on the various roles of ROS in tumor development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUvdFCyy2MXLVg90H21EOLACvtfcHk0lidWTiHIQJ6qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVygsbw%253D&md5=0cdf71e6b16a45d706ed441c4f93b4ec</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2741%2F1667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1667%26sid%3Dliteratum%253Aachs%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DReactive%2520oxygen%2520species%2520in%2520tumor%2520progression%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2005%26volume%3D10%26spage%3D1881%26epage%3D1896%26doi%3D10.2741%2F1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shackelford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paules, R. S.</span><span> </span><span class="NLM_article-title">Oxidative stress and cell cycle checkpoint function</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">â</span> <span class="NLM_lpage">1404</span><span class="refDoi">Â DOI: 10.1016/S0891-5849(00)00224-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0891-5849%2800%2900224-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10924858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlWgtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1387-1404&author=R.+E.+Shackelfordauthor=W.+K.+Kaufmannauthor=R.+S.+Paules&title=Oxidative+stress+and+cell+cycle+checkpoint+function&doi=10.1016%2FS0891-5849%2800%2900224-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and cell cycle checkpoint function</span></div><div class="casAuthors">Shackelford, R. E.; Kaufmann, W. K.; Paules, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1404</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review is given with 275 refs. on biol. important reactive O species (ROS) and their sources, the cell cycle, checkpoints, and current knowledge about the effects of ROS on initiating checkpoint responses.  Oxidative stress and the damage that results from it were implicated in a wide no. of disease processes including atherosclerosis, autoimmune disorders, neuronal degeneration, and cancer.  ROS are ubiquitous and occur naturally in all aerobic species, coming from both exogenous and endogenous sources.  ROS are quite reactive and readily damage biol. mols., including DNA.  While the damaging effects of ROS on DNA were intensively studied, the effects of oxidative damage on cell cycle checkpoint function have not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPLFMHhEUiLVg90H21EOLACvtfcHk0lidWTiHIQJ6qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlWgtb0%253D&md5=9eed0a63dfd7eddc36f2fbf6510d44e6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0891-5849%2800%2900224-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0891-5849%252800%252900224-0%26sid%3Dliteratum%253Aachs%26aulast%3DShackelford%26aufirst%3DR.%2BE.%26aulast%3DKaufmann%26aufirst%3DW.%2BK.%26aulast%3DPaules%26aufirst%3DR.%2BS.%26atitle%3DOxidative%2520stress%2520and%2520cell%2520cycle%2520checkpoint%2520function%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2000%26volume%3D28%26spage%3D1387%26epage%3D1404%26doi%3D10.1016%2FS0891-5849%2800%2900224-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Trachootham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span> </span><span class="NLM_article-title">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">591</span><span class="refDoi">Â DOI: 10.1038/nrd2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19478820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=579-591&author=D.+Trachoothamauthor=J.+Alexandreauthor=P.+Huang&title=Targeting+cancer+cells+by+ROS-mediated+mechanisms%3A+a+radical+therapeutic+approach%3F&doi=10.1038%2Fnrd2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span></div><div class="casAuthors">Trachootham, Dunyaporn; Alexandre, Jerome; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-591</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increased generation of reactive oxygen species (ROS) and an altered redox status have long been obsd. in cancer cells, and recent studies suggest that this biochem. property of cancer cells can be exploited for therapeutic benefits.  Cancer cells in advanced stage tumors frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacol. ROS insults.  However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance.  Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications.  We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobgIa2fgBPBrVg90H21EOLACvtfcHk0lidWTiHIQJ6qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D&md5=d50931b8de8bcab62d376becc768a71c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2803%26sid%3Dliteratum%253Aachs%26aulast%3DTrachootham%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DTargeting%2520cancer%2520cells%2520by%2520ROS-mediated%2520mechanisms%253A%2520a%2520radical%2520therapeutic%2520approach%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D579%26epage%3D591%26doi%3D10.1038%2Fnrd2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintus, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punzoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadino, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marceddu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzzau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Targeted biocompatible nanoparticles for the delivery of (â)-epigallocatechin 3-gallate to prostate cancer cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1321</span><span class="NLM_x">â</span> <span class="NLM_lpage">1332</span><span class="refDoi">Â DOI: 10.1021/jm1013715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1321-1332&author=V.+Sannaauthor=G.+P.+Pintusauthor=A.+M.+Roggioauthor=S.+Punzoniauthor=A.+M.+Posadinoauthor=A.+Arcaauthor=S.+Marcedduauthor=P.+Bandieraauthor=S.+Uzzauauthor=M.+Sechi&title=Targeted+biocompatible+nanoparticles+for+the+delivery+of+%28%E2%88%92%29-epigallocatechin+3-gallate+to+prostate+cancer+cells&doi=10.1021%2Fjm1013715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1013715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013715%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DPintus%26aufirst%3DG.%2BP.%26aulast%3DRoggio%26aufirst%3DA.%2BM.%26aulast%3DPunzoni%26aufirst%3DS.%26aulast%3DPosadino%26aufirst%3DA.%2BM.%26aulast%3DArca%26aufirst%3DA.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DBandiera%26aufirst%3DP.%26aulast%3DUzzau%26aufirst%3DS.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520biocompatible%2520nanoparticles%2520for%2520the%2520delivery%2520of%2520%2528%25E2%2588%2592%2529-epigallocatechin%25203-gallate%2520to%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1321%26epage%3D1332%26doi%3D10.1021%2Fjm1013715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Davis, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span> </span><span class="NLM_article-title">Nanoparticle therapeutics: an emerging treatment modality for cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span><span class="refDoi">Â DOI: 10.1038/nrd2614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd2614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18758474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGgtL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=771-782&author=M.+E.+Davisauthor=Z.+G.+Chenauthor=D.+M.+Shin&title=Nanoparticle+therapeutics%3A+an+emerging+treatment+modality+for+cancer&doi=10.1038%2Fnrd2614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle therapeutics: an emerging treatment modality for cancer</span></div><div class="casAuthors">Davis, Mark E.; Chen, Zhuo; Shin, Dong M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">771-782</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several nanoscaled systems for cancer therapy are approved or in clin. trials.  Here, Davis and colleagues discuss the key properties of nanotherapeutics for cancer, summarize clin. findings with first- and second-generation nanoparticles, and discuss the issues involved in translating exptl. nanotherapeutics to the clinic.  Nanoparticles - particles in the size range 1-100 nm - are emerging as a class of therapeutics for cancer.  Early clin. results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake.  Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities.  While large nos. of preclin. studies have been published, the emphasis here is placed on preclin. and clin. studies that are likely to affect clin. investigations and their implications for advancing the treatment of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPcHJcwgk8l7Vg90H21EOLACvtfcHk0lgKTSftekQjuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGgtL%252FJ&md5=620da7abb91f82d2e0c5bd516e9d9e8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2614%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DShin%26aufirst%3DD.%2BM.%26atitle%3DNanoparticle%2520therapeutics%253A%2520an%2520emerging%2520treatment%2520modality%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D771%26epage%3D782%26doi%3D10.1038%2Fnrd2614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Peer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margalit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Nanocarriers as an emerging platform for cancer therapy</span> <span class="citation_source-journal">Nat. Nanotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">760</span><span class="refDoi">Â DOI: 10.1038/nnano.2007.387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnnano.2007.387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18654426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyktL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=751-760&author=D.+Peerauthor=J.+M.+Karpauthor=S.+Hongauthor=O.+C.+Farokhzadauthor=R.+Margalitauthor=R.+Langer&title=Nanocarriers+as+an+emerging+platform+for+cancer+therapy&doi=10.1038%2Fnnano.2007.387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers as an emerging platform for cancer therapy</span></div><div class="casAuthors">Peer, Dan; Karp, Jeffrey M.; Hong, Seungpyo; Farokhzad, Omid C.; Margalit, Rimona; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">751-760</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. has the potential to revolutionize cancer diagnosis and therapy.  Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients.  Several therapeutic nanocarriers were approved for clin. use.  However, to date, there are only a few clin. approved nanocarriers that incorporate mols. to selectively bind and target cancer cells.  This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic.  The authors detail the arsenal of nanocarriers and mols. available for selective tumor targeting, and emphasize the challenges in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSaHhszNVn2LVg90H21EOLACvtfcHk0lgKTSftekQjuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyktL%252FI&md5=5f24033175e23e13d59e4a5b38753cad</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnnano.2007.387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnnano.2007.387%26sid%3Dliteratum%253Aachs%26aulast%3DPeer%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DMargalit%26aufirst%3DR.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DNanocarriers%2520as%2520an%2520emerging%2520platform%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2007%26volume%3D2%26spage%3D751%26epage%3D760%26doi%3D10.1038%2Fnnano.2007.387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Impact of nanotechnology on drug delivery</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span><span class="refDoi">Â DOI: 10.1021/nn900002m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn900002m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFGisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=16-20&author=O.+C.+Farokhzadauthor=R.+Langer&title=Impact+of+nanotechnology+on+drug+delivery&doi=10.1021%2Fnn900002m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Nanotechnology on Drug Delivery</span></div><div class="casAuthors">Farokhzad, Omid C.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-20</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. is the engineering and manufg. of materials at the at. and mol. scale.  In its strictest definition from the National Nanotechnol. Initiative, nanotechnol. refers to structures roughly in the 1-100 nm size regime in at least one dimension.  Despite this size restriction, nanotechnol. commonly refers to structures that are up to several hundred nanometers in size and that are developed by top-down or bottom-up engineering of individual components.  Herein, we focus on the application of nanotechnol. to drug delivery and highlight several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYU9UEZANnYLVg90H21EOLACvtfcHk0lgKTSftekQjuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFGisQ%253D%253D&md5=092946aed00c4a9f740df6505b2e805c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fnn900002m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn900002m%26sid%3Dliteratum%253Aachs%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DImpact%2520of%2520nanotechnology%2520on%2520drug%2520delivery%26jtitle%3DACS%2520Nano%26date%3D2009%26volume%3D3%26spage%3D16%26epage%3D20%26doi%3D10.1021%2Fnn900002m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Nicolas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couvreur, P.</span><span> </span><span class="NLM_article-title">Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">â</span> <span class="NLM_lpage">1235</span><span class="refDoi">Â DOI: 10.1039/C2CS35265F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1039%2FC2CS35265F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23238558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosV2gsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1147-1235&author=J.+Nicolasauthor=S.+Muraauthor=D.+Brambillaauthor=N.+Mackiewiczauthor=P.+Couvreur&title=Design%2C+functionalization+strategies+and+biomedical+applications+of+targeted+biodegradable%2Fbiocompatible+polymer-based+nanocarriers+for+drug+delivery&doi=10.1039%2FC2CS35265F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery</span></div><div class="casAuthors">Nicolas, Julien; Mura, Simona; Brambilla, Davide; Mackiewicz, Nicolas; Couvreur, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1147-1235</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Design and functionalization strategies for multifunctional nanocarriers (e.g., nanoparticles, micelles, polymersomes) based on biodegradable/biocompatible polymers intended to be employed for active targeting and drug delivery are reviewed.  This review will focus on the nature of the polymers involved in the prepn. of targeted nanocarriers, the synthesis methods to achieve the desired macromol. architecture, the selected coupling strategy, the choice of the homing mols. (vitamins, hormones, peptides, proteins, etc.), as well as the various strategies to display them at the surface of nanocarriers.  The resulting morphologies and the main colloidal features will be given as well as an overview of the biol. activities, with a special focus on the main in vivo achievements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb7as5d7CfKLVg90H21EOLACvtfcHk0ljK5lRcNuyERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosV2gsQ%253D%253D&md5=70975cbcd347c244774cfc534cc00a4b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2FC2CS35265F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CS35265F%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas%26aufirst%3DJ.%26aulast%3DMura%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DD.%26aulast%3DMackiewicz%26aufirst%3DN.%26aulast%3DCouvreur%26aufirst%3DP.%26atitle%3DDesign%252C%2520functionalization%2520strategies%2520and%2520biomedical%2520applications%2520of%2520targeted%2520biodegradable%252Fbiocompatible%2520polymer-based%2520nanocarriers%2520for%2520drug%2520delivery%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2013%26volume%3D42%26spage%3D1147%26epage%3D1235%26doi%3D10.1039%2FC2CS35265F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamaly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span><span class="refDoi">Â DOI: 10.1021/ar200054n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar200054n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvValtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=1123-1134&author=J.+Shiauthor=Z.+Xiaoauthor=N.+Kamalyauthor=O.+C.+Farokhzad&title=Self-assembled+targeted+nanoparticles%3A+evolution+of+technologies+and+bench+to+bedside+translation&doi=10.1021%2Far200054n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation</span></div><div class="casAuthors">Shi, Jinjun; Xiao, Zeyu; Kamaly, Nazila; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1123-1134</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoparticles (NPs) have become an important tool in many industries including healthcare.  The use of NPs for drug delivery and imaging has introduced exciting opportunities for the improvement of disease diagnosis and treatment.  Over the past two decades, several first-generation therapeutic NP products have entered the market.  Despite the lack of controlled release and mol. targeting properties in these products, they improved the therapeutic benefit of clin. validated drugs by enhancing drug tolerability and/or efficacy.  NP-based imaging agents have also improved the sensitivity and specificity of different diagnostic modalities.  The introduction of controlled-release properties and targeting ligands toward the development of next-generation NPs should enable the development of safer and more effective therapeutic NPs and facilitate their application in theranostic nanomedicine.  Targeted and controlled-release NPs can drastically alter the pharmacol. characteristics of their payload, including their pharmacokinetic and, in some cases, their pharmacodynamic properties.  As a result, these NPs can improve drug properties beyond what can be achieved through classic medicinal chem.  Despite their enormous potential, the translation of targeted NPs into clin. development has faced considerable challenges.  One significant problem has been the difficulty in developing targeted NPs with optimal biophysicochem. properties while using robust processes that facilitate scale-up and manufg.  Recently, efforts have focused on developing NPs through self-assembly or high-throughput processes to facilitate the development and screening of NPs with these distinct properties and the subsequent scale-up of their manuf.  We have also undertaken parallel efforts to integrate addnl. functionality within therapeutic and imaging NPs, including the ability to carry more than one payload, to respond to environmental triggers, and to provide real-time feedback.  In addn., novel targeting approaches are being developed to enhance the tissue-, cell-, or subcellular-specific delivery of NPs for a myriad of important diseases.  These include the selection of internalizing ligands for enhanced receptor-mediated NP uptake and the development of extracellular targeting ligands for vascular tissue accumulation of NPs.  In this Account, we primarily review the evolution of marketed NP technologies.  We also recount our efforts in the design and optimization of NPs for medical applications, which formed the foundation for the clin. translation of the first-in-man targeted and controlled-release NPs (BIND-014) for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD3GVCH7nem7Vg90H21EOLACvtfcHk0ljK5lRcNuyERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvValtb0%253D&md5=247786da97b882db196826de1ede004c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Far200054n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far200054n%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DSelf-assembled%2520targeted%2520nanoparticles%253A%2520evolution%2520of%2520technologies%2520and%2520bench%2520to%2520bedside%2520translation%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2011%26volume%3D44%26spage%3D1123%26epage%3D1134%26doi%3D10.1021%2Far200054n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pala, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Targeted therapy using nanotechnology: focus on cancer</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">â</span> <span class="NLM_lpage">483</span><span class="refDoi">Â DOI: 10.2147/IJN.S36654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2147%2FIJN.S36654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24531078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12lsb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=V.+Sannaauthor=N.+Palaauthor=M.+Sechi&title=Targeted+therapy+using+nanotechnology%3A+focus+on+cancer&doi=10.2147%2FIJN.S36654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy using nanotechnology: focus on cancer</span></div><div class="casAuthors">Sanna, Vanna; Pala, Nicolino; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-483, 17</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in nanotechnol. and biotechnol. have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy.  Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small mols., a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biol. targets.  Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions.  However, several obstacles, including difficulty in achieving the optimal combination of physicochem. parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy.  In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific mol. targets overexpressed on different cancer cells.  In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clin. testing for patients with solid tumors.  BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochem. properties needed for successful tumor eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqINXgpClbCz7Vg90H21EOLACvtfcHk0ljK5lRcNuyERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12lsb%252FK&md5=89e099f88b74db9de2c4ff0f951306c1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2147%2FIJN.S36654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S36654%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DPala%26aufirst%3DN.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520therapy%2520using%2520nanotechnology%253A%2520focus%2520on%2520cancer%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.2147%2FIJN.S36654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">544</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span><span class="refDoi">Â DOI: 10.1007/978-1-59745-483-4_37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-1-59745-483-4_37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19488725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2009&pages=589-598&author=F.+Guauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation%2Fpreparation+of+functionalized+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1007%2F978-1-59745-483-4_37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Gu, Frank; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">Micro and Nano Technologies in Bioanalysis</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues.  Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles.  Here we describe the prepn. of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine RNA aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells.  We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo.  This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfC9f0Yuf8k7Vg90H21EOLACvtfcHk0lidSFveg4t_QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D&md5=3dcd84c203b87965a94afd69c590004e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-483-4_37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-483-4_37%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%252Fpreparation%2520of%2520functionalized%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D544%26spage%3D589%26epage%3D598%26doi%3D10.1007%2F978-1-59745-483-4_37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Alexis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Nanoparticle technologies for cancer therapy</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.1007/978-3-642-00477-3_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-3-642-00477-3_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20217526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Chsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2010&pages=55-86&author=F.+Alexisauthor=E.+M.+Pridgenauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Nanoparticle+technologies+for+cancer+therapy&doi=10.1007%2F978-3-642-00477-3_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle technologies for cancer therapy</span></div><div class="casAuthors">Alexis, Frank; Pridgen, Eric M.; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">Drug Delivery</span>),
    <span class="NLM_cas:pages">55-86</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Nanoparticles as drug delivery systems enable unique approaches for cancer treatment.  Over the last two decades, a large no. of nanoparticle delivery systems have been developed for cancer therapy, including org. and inorg. materials.  Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater no. of nanoparticle platforms are currently in the preclin. stages of development.  More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease.  In this chapter, we will review the available preclin. and clin. nanoparticle technol. platforms and their impact for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJARaLb7HsCrVg90H21EOLACvtfcHk0lidSFveg4t_QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Chsrs%253D&md5=42d99169ff1e1d31f5edd2f023fe71c1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00477-3_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00477-3_2%26sid%3Dliteratum%253Aachs%26aulast%3DAlexis%26aufirst%3DF.%26aulast%3DPridgen%26aufirst%3DE.%2BM.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DNanoparticle%2520technologies%2520for%2520cancer%2520therapy%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D197%26spage%3D55%26epage%3D86%26doi%3D10.1007%2F978-3-642-00477-3_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kamaly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valencia, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic-Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Targeted polymeric therapeutic nanoparticles: design, development and clinical translation</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2971</span><span class="NLM_x">â</span> <span class="NLM_lpage">3010</span><span class="refDoi">Â DOI: 10.1039/c2cs15344k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1039%2Fc2cs15344k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=22388185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Cks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=2971-3010&author=N.+Kamalyauthor=Z.+Xiaoauthor=P.+M.+Valenciaauthor=A.+F.+Radovic-Morenoauthor=O.+C.+Farokhzad&title=Targeted+polymeric+therapeutic+nanoparticles%3A+design%2C+development+and+clinical+translation&doi=10.1039%2Fc2cs15344k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polymeric therapeutic nanoparticles: design, development and clinical translation</span></div><div class="casAuthors">Kamaly, Nazila; Xiao, Zeyu; Valencia, Pedro M.; Radovic-Moreno, Aleksandar F.; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2971-3010</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Polymeric materials have been used in a range of pharmaceutical and biotechnol. products for more than 40 years.  These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopedic implants, macroscale and microscale drug delivery systems such as microparticles and wafers used as controlled drug release depots, to multifunctional nanoparticles (NPs) capable of targeting, and controlled release of therapeutic and diagnostic agents.  These newer generations of targeted and controlled release polymeric NPs are now engineered to navigate the complex in vivo environment, and incorporate functionalities for achieving target specificity, control of drug concn. and exposure kinetics at the tissue, cell, and subcellular levels.  Indeed this optimization of drug pharmacol. as aided by careful design of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to drug enhancements that are traditionally achieved by medicinal chem.  In this regard, polymeric NPs have the potential to result in a highly differentiated new class of therapeutics, distinct from the original active drugs used in their compn., and distinct from first generation NPs that largely facilitated drug formulation.  A greater flexibility in the design of drug mols. themselves may also be facilitated following their incorporation into NPs, as drug properties (soly., metab., plasma binding, biodistribution, target tissue accumulation) will no longer be constrained to the same extent by drug chem. compn., but also become in-part the function of the physicochem. properties of the NP.  The combination of optimally designed drugs with optimally engineered polymeric NPs opens up the possibility of improved clin. outcomes that may not be achievable with the administration of drugs in their conventional form.  In this crit. review, we aim to provide insights into the design and development of targeted polymeric NPs and to highlight the challenges assocd. with the engineering of this novel class of therapeutics, including considerations of NP design optimization, development and biophysicochem. properties.  Addnl., we highlight some recent examples from the literature, which demonstrate current trends and novel concepts in both the design and utility of targeted polymeric NPs (444 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh4tt5gwv2KbVg90H21EOLACvtfcHk0lidSFveg4t_QQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Cks7w%253D&md5=15ea25b2595c963c1f584e198c3594b5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc2cs15344k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2cs15344k%26sid%3Dliteratum%253Aachs%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DValencia%26aufirst%3DP.%2BM.%26aulast%3DRadovic-Moreno%26aufirst%3DA.%2BF.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DTargeted%2520polymeric%2520therapeutic%2520nanoparticles%253A%2520design%252C%2520development%2520and%2520clinical%2520translation%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D2971%26epage%3D3010%26doi%3D10.1039%2Fc2cs15344k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Siu, D.</span><span> </span><span class="NLM_article-title">Cancer therapy using tumor-associated antigens to reduce side effects</span> <span class="citation_source-journal">Clin. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">198</span><span class="refDoi">Â DOI: 10.1007/s10238-009-0047-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2Fs10238-009-0047-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19408102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotl2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=181-198&author=D.+Siu&title=Cancer+therapy+using+tumor-associated+antigens+to+reduce+side+effects&doi=10.1007%2Fs10238-009-0047-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy using tumor-associated antigens to reduce side effects</span></div><div class="casAuthors">Siu, David</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-198</span>CODEN:
                <span class="NLM_cas:coden">CEMLBA</span>;
        ISSN:<span class="NLM_cas:issn">1591-8890</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia Srl</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. antigens recently have become very popular in cancer therapy.  They can be targeted to reduce side effects of traditional cancer therapy.  In this review, ten promising tumor-assocd. antigens are being discussed in detail.  The characteristics of each one are being reviewed in detail.  Monoclonal antibodies attached to traditional anticancer agents can target a specific type of cancer cells thereby reducing the amt. of traditional anticancer agents reaching normal tissues.  This sort of cancer targeting can be a very attractive anticancer therapy because it substantially reduces the amt. of side effects normally caused by traditional anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5LcT0jKKm0LVg90H21EOLACvtfcHk0lgDzZGBemFc1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotl2ks78%253D&md5=104533c423cb5c4c7f5f23a4cfb049a4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10238-009-0047-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10238-009-0047-z%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DD.%26atitle%3DCancer%2520therapy%2520using%2520tumor-associated%2520antigens%2520to%2520reduce%2520side%2520effects%26jtitle%3DClin.%2520Exp.%2520Med.%26date%3D2009%26volume%3D9%26spage%3D181%26epage%3D198%26doi%3D10.1007%2Fs10238-009-0047-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Steinbock, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiche, G.</span><span> </span><span class="NLM_article-title">Plectin: a cytolinker by design</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.1515/BC.1999.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1515%2FBC.1999.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1999&pages=151-158&author=F.+A.+Steinbockauthor=G.+Wiche&title=Plectin%3A+a+cytolinker+by+design&doi=10.1515%2FBC.1999.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1515%2FBC.1999.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.1999.023%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbock%26aufirst%3DF.%2BA.%26aulast%3DWiche%26aufirst%3DG.%26atitle%3DPlectin%253A%2520a%2520cytolinker%2520by%2520design%26jtitle%3DBiol.%2520Chem.%26date%3D1999%26volume%3D380%26spage%3D151%26epage%3D158%26doi%3D10.1515%2FBC.1999.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bausch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-del, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warshaw, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thayer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. A.</span><span> </span><span class="NLM_article-title">Plectin-1 as a novel biomarker for pancreatic cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">309</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-0999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1158%2F1078-0432.CCR-10-0999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21098698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=302-309&author=D.+Bauschauthor=S.+Thomasauthor=M.+Mino-Kenudsonauthor=C.+C.+Fernandez-delauthor=T.+W.+Bauerauthor=M.+Williamsauthor=A.+L.+Warshawauthor=S.+P.+Thayerauthor=K.+A.+Kelly&title=Plectin-1+as+a+novel+biomarker+for+pancreatic+cancer&doi=10.1158%2F1078-0432.CCR-10-0999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Plectin-1 as a Novel Biomarker for Pancreatic Cancer</span></div><div class="casAuthors">Bausch, Dirk; Thomas, Stephanie; Mino-Kenudson, Mari; Fernandez-del, Castillo Carlos; Bauer, Todd W.; Williams, Mark; Warshaw, Andrew L.; Thayer, Sarah P.; Kelly, Kimberly A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-309</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We are in great need of specific biomarkers to detect pancreatic ductal adenocarcinoma (PDAC) at an early stage, ideally before invasion.  Plectin-1 (Plec1) was recently identified as one such biomarker.  However, its suitability as a specific biomarker for human pancreatic cancer, and its usability as an imaging target, remain to be assessed.  Specimens of human PDAC, chronic pancreatitis, and normal pancreata were evaluated by immunohistochem. and Western blot anal.  To validate Plec1 as an imaging target, Plec1-targeting peptides (tPTP) were used as a contrast agent for single photon emission computed tomog. in an orthotopic and liver metastasis murine model of PDAC.  Plec1 expression was noted to be pos. in all PDACs but neg. in benign tissues.  Plec1 expression increases during pancreatic carcinogenesis.  It was found to be misexpressed in only 0% to 3.85% of early PDAC precursor lesions (PanIN I/II) but in 60% of PanIN III lesions.  Plec1 expression was further noted to be retained in all metastatic foci assayed and clearly highlighted these metastatic deposits in lymph nodes, liver, and peritoneum.  In vivo imaging using tPTP specifically highlighted the primary and metastatic tumors.  Biodistribution studies performed after imaging show that the primary pancreatic tumors and liver metastases retained 1.9- to 2.9-fold of tPTP over normal pancreas and 1.7-fold over normal liver.  Plec1 is the first biomarker to identify primary and metastatic PDAC by imaging and may also detect preinvasive PanIN III lesions.  Strategies designed to image Plec1 could therefore improve detection and staging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv2vNc3hj3WLVg90H21EOLACvtfcHk0lgDzZGBemFc1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyqsg%253D%253D&md5=e9af1df96c81b82792d2f7a2e46ea030</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0999%26sid%3Dliteratum%253Aachs%26aulast%3DBausch%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFernandez-del%26aufirst%3DC.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BW.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWarshaw%26aufirst%3DA.%2BL.%26aulast%3DThayer%26aufirst%3DS.%2BP.%26aulast%3DKelly%26aufirst%3DK.%2BA.%26atitle%3DPlectin-1%2520as%2520a%2520novel%2520biomarker%2520for%2520pancreatic%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D302%26epage%3D309%26doi%3D10.1158%2F1078-0432.CCR-10-0999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kelly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anbazhagan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurumurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alencar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e85</span><span class="refDoi">Â DOI: 10.1371/journal.pmed.0050085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1371%2Fjournal.pmed.0050085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18416599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BD1c3osFaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=e85&author=K.+A.+Kellyauthor=N.+Bardeesyauthor=R.+Anbazhaganauthor=S.+Gurumurthyauthor=J.+Bergerauthor=H.+Alencarauthor=R.+A.+Depinhoauthor=U.+Mahmoodauthor=R.+Weissleder&title=Targeted+nanoparticles+for+imaging+incipient+pancreatic+ductal+adenocarcinoma&doi=10.1371%2Fjournal.pmed.0050085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Kelly Kimberly A; Bardeesy Nabeel; Anbazhagan Rajesh; Gurumurthy Sushma; Berger Justin; Alencar Herlen; Depinho Ronald A; Mahmood Umar; Weissleder Ralph</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies.  The development of molecular markers and imaging probes for incipient PDAC would enable earlier detection and guide the development of interventive therapies.  Here we sought to identify novel molecular markers and to test their potential as targeted imaging agents.  METHODS AND FINDINGS:  Here, a phage display approach was used in a mouse model of PDAC to screen for peptides that specifically bind to cell surface antigens on PDAC cells.  These screens yielded a motif that distinguishes PDAC cells from normal pancreatic duct cells in vitro, which, upon proteomics analysis, identified plectin-1 as a novel biomarker of PDAC.  To assess their utility for in vivo imaging, the plectin-1 targeted peptides (PTP) were conjugated to magnetofluorescent nanoparticles.  In conjunction with intravital confocal microscopy and MRI, these nanoparticles enabled detection of small PDAC and precursor lesions in engineered mouse models.  CONCLUSIONS:  Our approach exploited a well-defined model of PDAC, enabling rapid identification and validation of PTP.  The developed specific imaging probe, along with the discovery of plectin-1 as a novel biomarker, may have clinical utility in the diagnosis and management of PDAC in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMjW_qppa_E6_dlEzl_fBafW6udTcc2ebOBQM9DORewrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3osFaksg%253D%253D&md5=fa17efd85b718f7207674f1434f6b99f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0050085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0050085%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DK.%2BA.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DAnbazhagan%26aufirst%3DR.%26aulast%3DGurumurthy%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DAlencar%26aufirst%3DH.%26aulast%3DDepinho%26aufirst%3DR.%2BA.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DTargeted%2520nanoparticles%2520for%2520imaging%2520incipient%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DPLoS%2520Med.%26date%3D2008%26volume%3D5%26spage%3De85%26doi%3D10.1371%2Fjournal.pmed.0050085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtatland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, L.</span><span> </span><span class="NLM_article-title">Cell-specific targeting of nanoparticles by multivalent attachment of small molecules</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">â</span> <span class="NLM_lpage">1423</span><span class="refDoi">Â DOI: 10.1038/nbt1159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnbt1159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=16244656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyis7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1418-1423&author=R.+Weisslederauthor=K.+Kellyauthor=E.+Y.+Sunauthor=T.+Shtatlandauthor=L.+Josephson&title=Cell-specific+targeting+of+nanoparticles+by+multivalent+attachment+of+small+molecules&doi=10.1038%2Fnbt1159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific targeting of nanoparticles by multivalent attachment of small molecules</span></div><div class="casAuthors">Weissleder, Ralph; Kelly, Kimberly; Sun, Eric Yi; Shtatland, Timur; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1418-1423</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nanomaterials with precise biol. functions have considerable potential for use in biomedical applications.  Here the authors investigate whether multivalent attachment of small mols. can increase specific binding affinity and reveal new biol. properties of such nanomaterials.  The authors describe the parallel synthesis of a library comprising 146 nanoparticles decorated with different synthetic small mols.  Using fluorescent magnetic nanoparticles, the authors rapidly screened the library against different cell lines and discovered a series of nanoparticles with high specificity for endothelial cells, activated human macrophages or pancreatic cancer cells.  Hits from the last-mentioned screen were shown to target pancreatic cancer in vivo.  The method and described materials could facilitate development of functional nanomaterials for applications such as differentiating cell lines, detecting distinct cellular states and targeting specific cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgZjQM3_dzhrVg90H21EOLACvtfcHk0lhgAUXFMiQ-sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyis7jM&md5=6aa04aee374b7cb17eaf499b7cfaa475</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnbt1159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1159%26sid%3Dliteratum%253Aachs%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DE.%2BY.%26aulast%3DShtatland%26aufirst%3DT.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DCell-specific%2520targeting%2520of%2520nanoparticles%2520by%2520multivalent%2520attachment%2520of%2520small%2520molecules%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1418%26epage%3D1423%26doi%3D10.1038%2Fnbt1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Polymers for the sustained release of proteins and other macromolecules</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span><span class="refDoi">Â DOI: 10.1038/263797a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2F263797a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=995197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADyaE2sXnvVKntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1976&pages=797-800&author=R.+Langerauthor=J.+Folkman&title=Polymers+for+the+sustained+release+of+proteins+and+other+macromolecules&doi=10.1038%2F263797a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polymers for the sustained release of proteins and other macromolecules</span></div><div class="casAuthors">Langer, Robert; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">797-800</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An increase in the ratio of polymer:water (â¤10% polymer concn.) in the casting soln. of poly(vinyl alc.) decreased the rate at which soybean trypsin inhibitor (I) [9078-38-0] (mol. wt. 21,000) was released from the casting soln. in Ringer's soln. at 37Â°.  Similar effects were obsd. with the polymers Hydron-S [25249-16-5] and ethylene-vinyl acetate copolymer (II) [24937-78-8].  In these slow-release systems, a large percentage of protein was released during the first hour of incubation, and the rate of release was retarded in polymer 'sandwiches'.  Proteins and macromols. released from the polymers were >80% biol.-active, as shown with I, alk. phosphatase [9001-78-9], tumor angiogenesis factor, and lysozyme [9001-63-2].  Hydron and II caused no inflammation when implanted into the cornea of rabbits; poly(vinyl alc.) [9002-89-5] however produced inflammation which could be greatly reduced, but not eliminated, by exhaustive washing with alc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVUsmFV61sHLVg90H21EOLACvtfcHk0lhgAUXFMiQ-sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXnvVKntQ%253D%253D&md5=b3738fc0a8377e8255499eb8a8a47840</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2F263797a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F263797a0%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DPolymers%2520for%2520the%2520sustained%2520release%2520of%2520proteins%2520and%2520other%2520macromolecules%26jtitle%3DNature%26date%3D1976%26volume%3D263%26spage%3D797%26epage%3D800%26doi%3D10.1038%2F263797a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Gref, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamitake, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peracchia, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trubetskoy, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torchilin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Biodegradable long-circulating polymeric nanospheres</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1600</span><span class="NLM_x">â</span> <span class="NLM_lpage">1603</span><span class="refDoi">Â DOI: 10.1126/science.8128245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1126%2Fscience.8128245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=8128245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADyaK2cXit1KktLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1600-1603&author=R.+Grefauthor=Y.+Minamitakeauthor=M.+T.+Peracchiaauthor=V.+Trubetskoyauthor=V.+Torchilinauthor=R.+Langer&title=Biodegradable+long-circulating+polymeric+nanospheres&doi=10.1126%2Fscience.8128245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable long-circulating polymer nanospheres</span></div><div class="casAuthors">Gref, Ruxandra; Minamitake, Yoshiharu; Peracchia, Maria Teresa; Trubetskoy, Vladimir; Torchilin, Vladimir; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5153</span>),
    <span class="NLM_cas:pages">1600-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging.  Conventional carriers, however, cannot generally be used because they are eliminated by the reticuloendothelial system within seconds or minutes after i.v. injection.  To address these limitations, monodisperse biodegradable nanospheres were developed from amphiphilic copolymers composed of two biocompatible blocks.  The nanospheres exhibited dramatically increased blood circulation times and reduced liver accumulation in mice.  Furthermore, they entrapped up to 45 percent by wt. of the drug in the dense core in a one-step procedure and could be freeze-dried and easily redispersed without additives in aq. solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAaowcQZQFbVg90H21EOLACvtfcHk0lhgAUXFMiQ-sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXit1KktLc%253D&md5=298696ca173279294f37833ed1c9d74e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.8128245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8128245%26sid%3Dliteratum%253Aachs%26aulast%3DGref%26aufirst%3DR.%26aulast%3DMinamitake%26aufirst%3DY.%26aulast%3DPeracchia%26aufirst%3DM.%2BT.%26aulast%3DTrubetskoy%26aufirst%3DV.%26aulast%3DTorchilin%26aufirst%3DV.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DBiodegradable%2520long-circulating%2520polymeric%2520nanospheres%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1600%26epage%3D1603%26doi%3D10.1126%2Fscience.8128245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherifi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richie, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">6315</span><span class="NLM_x">â</span> <span class="NLM_lpage">6320</span><span class="refDoi">Â DOI: 10.1073/pnas.0601755103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1073%2Fpnas.0601755103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=16606824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=6315-6320&author=O.+C.+Farokhzadauthor=J.+Chengauthor=B.+A.+Teplyauthor=I.+Sherifiauthor=S.+Jonauthor=P.+W.+Kantoffauthor=J.+P.+Richieauthor=R.+Langer&title=Targeted+nanoparticle-aptamer+bioconjugates+for+cancer+chemotherapy+in+vivo&doi=10.1073%2Fpnas.0601755103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo</span></div><div class="casAuthors">Farokhzad, Omid C.; Cheng, Jianjun; Teply, Benjamin A.; Sherifi, Ines; Jon, Sangyong; Kantoff, Philip W.; Richie, Jerome P.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6315-6320</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technol.  Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2'-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells.  These Dtxl-encapsulated nanoparticle aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004).  The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body wt. loss (BWL) in vivo [body wt. loss of 7.7Â±4% vs. 18Â±5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, resp. (mean Â± SD); n = 7].  After a single intratumoral injection of Dxtl-NP-Apt bioconjugates, complete tumor redn. was obsd. in five of seven LNCaP xenograft nude mice (initial tumor vol. of â300 mm3), and 100% of these animals survived our 109-day study.  In contrast, two of seven mice in the Dtxl-NP group had complete tumor redn. with 109-day survivability of only 57%.  Dtxl alone had a survivability of only 14%.  Saline and nanoparticles without drug were similarly nonefficacious.  This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwutpDjrmArVg90H21EOLACvtfcHk0lhgAUXFMiQ-sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamsbk%253D&md5=9661fe3f15194c6bf0e2df010c028796</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601755103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601755103%26sid%3Dliteratum%253Aachs%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DSherifi%26aufirst%3DI.%26aulast%3DJon%26aufirst%3DS.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DRichie%26aufirst%3DJ.%2BP.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DTargeted%2520nanoparticle-aptamer%2520bioconjugates%2520for%2520cancer%2520chemotherapy%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D6315%26epage%3D6320%26doi%3D10.1073%2Fpnas.0601755103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic- Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2586</span><span class="NLM_x">â</span> <span class="NLM_lpage">2591</span><span class="refDoi">Â DOI: 10.1073/pnas.0711714105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1073%2Fpnas.0711714105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Ojtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2586-2591&author=F.+Guauthor=L.+Zhangauthor=B.+A.+Teplyauthor=N.+Mannauthor=A.+Wangauthor=A.+F.+Radovic-+Morenoauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Precise+engineering+of+targeted+nanoparticles+by+using+self-assembled+biointegrated+block+copolymers&doi=10.1073%2Fpnas.0711714105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers</span></div><div class="casAuthors">Gu, Frank; Zhang, Liangfang; Teply, Benjamin A.; Mann, Nina; Wang, Andrew; Radovic-Moren, Aleksandar F.; Langer, Robert; Farkokhzad, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2586-2591</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">There has been progressively heightened interest in the development of targeted nanoparticles (NPs) for differential delivery and controlled release of drugs.  Despite nearly three decades of research, approaches to reproducibly formulate targeted NPs with the optimal biophysicochem. properties have remained elusive.  A central challenge has been defining the optimal interplay of parameters that confer mol. targeting, immune evasion, and drug release to overcome the physiol. barriers in vivo.  Here, we report a strategy for narrowly changing the biophysicochem. properties of NPs in a reproducible manner, thereby enabling systematic screening of optimally formulated drug-encapsulated targeted NPs.  NPs were formulated by the self-assembly of an amphiphilic triblock copolymer composed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer (PCa) cells, enabling, resp., controlled drug release, "stealth" properties for immune evasion, and cell-specific targeting.  Fine-tuning of NP size and drug release kinetics was further accomplished by controlling the copolymer compn.  By using distinct ratios of PLGA-b-PEG-b-Apt triblock copolymer with PLGA-b-PEG diblock copolymer lacking the A10 Apt, we developed a series of targeted NPs with increasing Apt densities that inversely affected the amt. of PEG exposure on NP surface and identified the narrow range of Apt d. when the NPs were maximally targeted and maximally stealth, resulting in most efficient PCa cell uptake in vitro and in vivo.  This approach may contribute to further development of targeted NPs as highly selective and effective therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYtEUpGFDqbVg90H21EOLACvtfcHk0lgoRRXrkGPJ0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Ojtb8%253D&md5=f761176b38055c0dfaf3da272490ed78</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711714105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711714105%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DMann%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DRadovic-%2BMoreno%26aufirst%3DA.%2BF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DPrecise%2520engineering%2520of%2520targeted%2520nanoparticles%2520by%2520using%2520self-assembled%2520biointegrated%2520block%2520copolymers%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2586%26epage%3D2591%26doi%3D10.1073%2Fpnas.0711714105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">544</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span><span class="refDoi">Â DOI: 10.1007/978-1-59745-483-4_37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-1-59745-483-4_37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19488725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2009&pages=589-598&author=F.+Guauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation%2Fpreparation+of+functionalized+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1007%2F978-1-59745-483-4_37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Gu, Frank; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">Micro and Nano Technologies in Bioanalysis</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues.  Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles.  Here we describe the prepn. of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine RNA aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells.  We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo.  This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfC9f0Yuf8k7Vg90H21EOLACvtfcHk0lgoRRXrkGPJ0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D&md5=3dcd84c203b87965a94afd69c590004e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-483-4_37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-483-4_37%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%252Fpreparation%2520of%2520functionalized%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D544%26spage%3D589%26epage%3D598%26doi%3D10.1007%2F978-1-59745-483-4_37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Otsuka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span> </span><span class="NLM_article-title">PEGylated nanoparticles for biological and pharmaceutical applications</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">â</span> <span class="NLM_lpage">419</span><span class="refDoi">Â DOI: 10.1016/S0169-409X(02)00226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0169-409X%2802%2900226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=12628324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Cgurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=403-419&author=H.+Otsukaauthor=Y.+Nagasakiauthor=K.+Kataoka&title=PEGylated+nanoparticles+for+biological+and+pharmaceutical+applications&doi=10.1016%2FS0169-409X%2802%2900226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylated nanoparticles for biological and pharmaceutical applications</span></div><div class="casAuthors">Otsuka, Hidenori; Nagasaki, Yukio; Kataoka, Kazunori</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-419</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The utility of polymeric micelles formed through the multimol. assembly of block copolymer was comprehensively described as novel core-shell typed colloidal carriers for drug and gene targeting.  Particularly, novel approaches for the formation of functionalized poly(ethylene glycol) (PEG) layers as hydrophilic outer shell were focused to attain receptor-mediated drug and gene delivery through PEG-conjugated ligands with a minimal non-specific interaction with other proteins.  Surface organization of block copolymer micelles with crosslinking core was also described from a standpoint of the prepn. of a new functional surface-coating with a unique macromol. architecture.  The micelle-attached surface and the thin hydrogel layer made by layered micelles exhibited nonfouling properties and worked as the reservoir for hydrophobic reagents.  Furthermore, the potential utility of multimol. assembly derived from heterobifunctional PEGs and block copolymers were explored to systematically modify the properties of metal and semiconductor nanostructures by controlling their structure and their surface properties, making them extremely attractive for use in biol. and biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqW3GfbUZRpLVg90H21EOLACvtfcHk0lgoRRXrkGPJ0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Cgurg%253D&md5=dfcf439976d122febdd6691ac8218ba3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900226-0%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DY.%26aulast%3DKataoka%26aufirst%3DK.%26atitle%3DPEGylated%2520nanoparticles%2520for%2520biological%2520and%2520pharmaceutical%2520applications%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D403%26epage%3D419%26doi%3D10.1016%2FS0169-409X%2802%2900226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Avgoustakis, K.</span><span> </span><span class="NLM_article-title">PEGylated poly(lactide) and poly(lactide-coglycolide) nanoparticles: Preparation, properties and possible applications in drug delivery</span> <span class="citation_source-journal">Curr. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">333</span><span class="refDoi">Â DOI: 10.2174/1567201043334605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2174%2F1567201043334605" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=321-333&author=K.+Avgoustakis&title=PEGylated+poly%28lactide%29+and+poly%28lactide-coglycolide%29+nanoparticles%3A+Preparation%2C+properties+and+possible+applications+in+drug+delivery&doi=10.2174%2F1567201043334605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1567201043334605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567201043334605%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustakis%26aufirst%3DK.%26atitle%3DPEGylated%2520poly%2528lactide%2529%2520and%2520poly%2528lactide-coglycolide%2529%2520nanoparticles%253A%2520Preparation%252C%2520properties%2520and%2520possible%2520applications%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2004%26volume%3D1%26spage%3D321%26epage%3D333%26doi%3D10.2174%2F1567201043334605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunaryo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadapakkam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casciato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">PEGylation strategies for active targeting of PLA/PLGA nanoparticles</span> <span class="citation_source-journal">J. Biomed. Mater. Res., Part A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">â</span> <span class="NLM_lpage">276</span><span class="refDoi">Â DOI: 10.1002/jbm.a.32247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1002%2Fjbm.a.32247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18980197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVekurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2009&pages=263-276&author=T.+Betancourtauthor=J.+D.+Byrneauthor=N.+Sunaryoauthor=S.+W.+Crowderauthor=M.+Kadapakkamauthor=S.+Patelauthor=S.+Casciatoauthor=L.+Brannon-Peppas&title=PEGylation+strategies+for+active+targeting+of+PLA%2FPLGA+nanoparticles&doi=10.1002%2Fjbm.a.32247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation strategies for active targeting of PLA/PLGA nanoparticles</span></div><div class="casAuthors">Betancourt, Tania; Byrne, James D.; Sunaryo, Nicole; Crowder, Spencer W.; Kadapakkam, Meena; Patel, Shefali; Casciato, Shelly; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Materials Research, Part A</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">91A</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-276</span>CODEN:
                <span class="NLM_cas:coden">JBMRCH</span>;
        ISSN:<span class="NLM_cas:issn">1549-3296</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This work evaluates various techniques for the incorporation of poly(ethylene glycol) (PEG) onto biodegradable nanoparticles (NPs) of poly(lactic-co-glycolic acid) (PLGA) or poly(lactic acid) (PLA) with the purpose of providing a functional site for surface conjugation of targeting agents and for improving surface properties.  The techniques compared were based on NP prepn. with blends of PLGA and poloxemer or with block copolymers of PLGA/PLA with PEG.  Blending of PLGA with poloxamer 407 resulted in the incorporation of the latter to up to a 43 wt % content.  Direct conjugation of heterofunctional NH2-PEG-COOH to the surface of premade NPs was not highly effective.  Prepn. of copolymers of PLGA with PEG was detd. to be more effective and versatile by polymn. of lactide and glycolide dimers onto the hydroxyl group of heterofunctional OH-PEG-COOH than by conjugation of the premade polymers with carbodiimide chem.  NPs prepd. with these copolymers confirmed the surface localization of PEG and proved to be useful for conjugation of mouse Ig as a model targeting agent. Â© 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ59mcOfs9ZrVg90H21EOLACvtfcHk0lieRBQQo7w3-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVekurzK&md5=ff7538d6803b6b2f1f54657e1afbe5f5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjbm.a.32247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm.a.32247%26sid%3Dliteratum%253Aachs%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DSunaryo%26aufirst%3DN.%26aulast%3DCrowder%26aufirst%3DS.%2BW.%26aulast%3DKadapakkam%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DCasciato%26aufirst%3DS.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DPEGylation%2520strategies%2520for%2520active%2520targeting%2520of%2520PLA%252FPLGA%2520nanoparticles%26jtitle%3DJ.%2520Biomed.%2520Mater.%2520Res.%252C%2520Part%2520A%26date%3D2009%26volume%3D91%26spage%3D263%26epage%3D276%26doi%3D10.1002%2Fjbm.a.32247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherifi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy-Nissenbaum, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic-Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">â</span> <span class="NLM_lpage">876</span><span class="refDoi">Â DOI: 10.1016/j.biomaterials.2006.09.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.biomaterials.2006.09.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=17055572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BD28nlsVehtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=869-876&author=J.+Chengauthor=B.+A.+Teplyauthor=I.+Sherifiauthor=J.+Sungauthor=G.+Lutherauthor=F.+X.+Guauthor=E.+Levy-Nissenbaumauthor=A.+F.+Radovic-Morenoauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation+of+functionalized+PLGA-PEG+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1016%2Fj.biomaterials.2006.09.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Cheng Jianjun; Teply Benjamin A; Sherifi Ines; Sung Josephine; Luther Gaurav; Gu Frank X; Levy-Nissenbaum Etgar; Radovic-Moreno Aleksandar F; Langer Robert; Farokhzad Omid C</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">869-76</span>
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    </div><div class="casAbstract">Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner.  Herein we have developed NPs from carboxy-terminated poly(d,L-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent.  We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied).  NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer.  The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24h; NP-Apt 0.83%+/-0.21% vs.  NP 0.22%+/-0.07% of injected dose per gram of tissue; mean+/-SD, n=4, p=0.002).  The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUML4ghXv7uresJRIHUP1ofW6udTcc2eZ-7zk_SD6xorntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nlsVehtg%253D%253D&md5=ed5628a94eadd79fd28e3541e1e739b6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2006.09.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2006.09.047%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DSherifi%26aufirst%3DI.%26aulast%3DSung%26aufirst%3DJ.%26aulast%3DLuther%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DF.%2BX.%26aulast%3DLevy-Nissenbaum%26aufirst%3DE.%26aulast%3DRadovic-Moreno%26aufirst%3DA.%2BF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%2520of%2520functionalized%2520PLGA-PEG%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DBiomaterials%26date%3D2007%26volume%3D28%26spage%3D869%26epage%3D876%26doi%3D10.1016%2Fj.biomaterials.2006.09.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Alexis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Factors affecting the clearance and biodistribution of polymeric nanoparticles</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">â</span> <span class="NLM_lpage">515</span><span class="refDoi">Â DOI: 10.1021/mp800051m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800051m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wlurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=505-515&author=F.+Alexisauthor=E.+Pridgenauthor=L.+K.+Molnarauthor=O.+C.+Farokhzad&title=Factors+affecting+the+clearance+and+biodistribution+of+polymeric+nanoparticles&doi=10.1021%2Fmp800051m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles</span></div><div class="casAuthors">Alexis, Frank; Pridgen, Eric; Molnar, Linda K.; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-515</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoparticle (NP) drug delivery systems (5-250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biol. barriers and releasing a therapeutic load in the optimal dosage range.  Rapid clearance of circulating nanoparticles during systemic delivery is a crit. issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life.  In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation.  These factors include interactions with biol. barriers and tunable nanoparticle parameters, such as compn., size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization.  All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ijsyOkpfrVg90H21EOLACvtfcHk0lieRBQQo7w3-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wlurs%253D&md5=21f004c979978944d7a56d05fe4b319d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fmp800051m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800051m%26sid%3Dliteratum%253Aachs%26aulast%3DAlexis%26aufirst%3DF.%26aulast%3DPridgen%26aufirst%3DE.%26aulast%3DMolnar%26aufirst%3DL.%2BK.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFactors%2520affecting%2520the%2520clearance%2520and%2520biodistribution%2520of%2520polymeric%2520nanoparticles%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D505%26epage%3D515%26doi%3D10.1021%2Fmp800051m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, K.</span><span> </span><span class="NLM_article-title">Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">284</span><span class="refDoi">Â DOI: 10.1016/S0168-3659(99)00248-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0168-3659%2899%2900248-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10699287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtl2qsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=271-284&author=H.+Maedaauthor=J.+Wuauthor=T.+Sawaauthor=Y.+Matsumuraauthor=K.+Hori&title=Tumor+vascular+permeability+and+the+EPR+effect+in+macromolecular+therapeutics%3A+a+review&doi=10.1016%2FS0168-3659%2899%2900248-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review</span></div><div class="casAuthors">Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">271-284</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 55 refs.  Most solid tumors have unique pathophysiol. characteristics that are not obsd. in normal tissues or organs, such as extensive angiogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic drainage/recovery system, and greatly increased prodn. of a no. of permeability mediators.  The phenomenon now known as the enhanced permeability and retention (EPR) effect for lipid and macromol. agents has been obsd. to be universal in solid tumors.  Primarily, enhanced vascular permeability will sustain an adequate supply of nutrients and oxygen for rapid tumor growth.  The EPR effect also provides a great opportunity for more selective targeting of lipid- or polymer-conjugated anticancer drugs, such as SMANCS and PK-1, to the tumor.  In the present review, the basic characteristics of the EPR effect, particularly the factors involved, are described, as well as its modulation for improving delivery of macromol. drugs to the tumor.  Tumor-specific vascular physiol. is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGxDuzaxisLrVg90H21EOLACvtfcHk0lhMXE5UAgUHQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtl2qsLo%253D&md5=b26ddf9ebdfd3073209f882a4378cf8d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2899%2900248-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252899%252900248-5%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSawa%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DK.%26atitle%3DTumor%2520vascular%2520permeability%2520and%2520the%2520EPR%2520effect%2520in%2520macromolecular%2520therapeutics%253A%2520a%2520review%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2000%26volume%3D65%26spage%3D271%26epage%3D284%26doi%3D10.1016%2FS0168-3659%2899%2900248-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianopoulos, T.</span><span> </span><span class="NLM_article-title">Delivering nanomedicine to solid tumors</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">664</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2010.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrclinonc.2010.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20838415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCrsb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=653-664&author=R.+K.+Jainauthor=T.+Stylianopoulos&title=Delivering+nanomedicine+to+solid+tumors&doi=10.1038%2Fnrclinonc.2010.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Delivering nanomedicine to solid tumors</span></div><div class="casAuthors">Jain, Rakesh K.; Stylianopoulos, Triantafyllos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. offers great promise for the detection, prevention and treatment of cancer.  Current limitations of this technol. include the heterogeneous distribution of nanoparticles to tumors, caused in part by the physiol. barriers presented by the abnormal tumor vasculature and interstitial matrix.  This Review discusses these barriers and summarizes strategies that have been developed to overcome them.  It addnl. examines design considerations for the optimization of delivery of nanoparticles to tumors.  Recent advances in nanotechnol. have offered new hope for cancer detection, prevention, and treatment.  While the enhanced permeability and retention effect has served as a key rationale for using nanoparticles to treat solid tumors, it does not enable uniform delivery of these particles to all regions of tumors in sufficient quantities.  This heterogeneous distribution of therapeutics is a result of physiol. barriers presented by the abnormal tumor vasculature and interstitial matrix.  These barriers are likely to be responsible for the modest survival benefit offered by many FDA-approved nanotherapeutics and must be overcome for the promise of nanomedicine in patients to be realized.  Here, we review these barriers to the delivery of cancer therapeutics and summarize strategies that have been developed to overcome these barriers.  Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzsCeKPsAxSLVg90H21EOLACvtfcHk0lhMXE5UAgUHQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCrsb7P&md5=aa5d26883f983a0fd6d4cabdbe5457c6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.139%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DStylianopoulos%26aufirst%3DT.%26atitle%3DDelivering%2520nanomedicine%2520to%2520solid%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26spage%3D653%26epage%3D664%26doi%3D10.1038%2Fnrclinonc.2010.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Danquah, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahato, R. I.</span><span> </span><span class="NLM_article-title">Extravasation of polymeric nanomedicines across tumor vasculature</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">â</span> <span class="NLM_lpage">639</span><span class="refDoi">Â DOI: 10.1016/j.addr.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2010.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21144874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnmt1Chsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=623-639&author=M.+K.+Danquahauthor=X.+A.+Zhangauthor=R.+I.+Mahato&title=Extravasation+of+polymeric+nanomedicines+across+tumor+vasculature&doi=10.1016%2Fj.addr.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Extravasation of polymeric nanomedicines across tumor vasculature</span></div><div class="casAuthors">Danquah Michael K; Zhang Xin A; Mahato Ram I</div><div class="citationInfo"><span class="NLM_cas:title">Advanced drug delivery reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">623-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor microvasculature is fraught with numerous physiological barriers which hinder the efficacy of anticancer agents.  These barriers include chaotic blood supply, poor tumor vasculature permeability, limited transport across the interstitium due to high interstitial pressure and absence of lymphatic network.  Abnormal microvasculature also leads to hypoxia and acidosis which limits effectiveness of chemotherapy.  These barriers restrict drug or drug carrier extravasation which hampers tumor regression.  Targeting key features of the tumor microenvironment such as tumor microvessels, interstitial hypertension and tumor pH is a promising approach to improving the efficacy of anticancer drugs.  This review highlights the current knowledge on the distinct tumor microenvironment generated barriers which limit extravasation of drugs and focuses on modalities for overcoming these barriers using multi-functional polymeric carriers.  Special attention is given to utilizing polymeric nanomedicines to facilitate extravasation of anticancer drugs for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9p3ytq5U5bMkU0YCbOU3EfW6udTcc2eZnXDEAAm5WXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnmt1Chsw%253D%253D&md5=47f91381cc890d1cd3b23524146a99f9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DDanquah%26aufirst%3DM.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BA.%26aulast%3DMahato%26aufirst%3DR.%2BI.%26atitle%3DExtravasation%2520of%2520polymeric%2520nanomedicines%2520across%2520tumor%2520vasculature%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D623%26epage%3D639%26doi%3D10.1016%2Fj.addr.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Knop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenboom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U. S.</span><span> </span><span class="NLM_article-title">Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6288</span><span class="NLM_x">â</span> <span class="NLM_lpage">6308</span><span class="refDoi">Â DOI: 10.1002/anie.200902672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1002%2Fanie.200902672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20648499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6288-6308&author=K.+Knopauthor=R.+Hoogenboomauthor=D.+Fischerauthor=U.+S.+Schubert&title=Poly%28ethylene+glycol%29+in+drug+delivery%3A+pros+and+cons+as+well+as+potential+alternatives&doi=10.1002%2Fanie.200902672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives</span></div><div class="casAuthors">Knop, Katrin; Hoogenboom, Richard; Fischer, Dagmar; Schubert, Ulrich S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6288-6308</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Poly(ethylene glycol) (PEG) is the most used polymer and also the gold std. for stealth polymers in the emerging field of polymer-based drug delivery.  The properties that account for the overwhelming use of PEG in biomedical applications are outlined in this Review.  The first approved PEGylated products have already been on the market for 20 years.  A vast amt. of clin. experience has since been gained with this polymer-not only benefits, but possible side effects and complications have also been found.  The areas that might need consideration and more intensive and careful examn. can be divided into the following categories: hypersensitivity, unexpected changes in pharmacokinetic behavior, toxic side products, and an antagonism arising from the easy degrdn. of the polymer under mech. stress as a result of its ether structure and its non-biodegradability, as well as the resulting possible accumulation in the body.  These possible side effects will be discussed in this Review and alternative polymers will be evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbYINW5v_3rVg90H21EOLACvtfcHk0lhpOZZucai3rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLbN&md5=02ff87df9c11cf218d3799ecd259d2a0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.200902672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200902672%26sid%3Dliteratum%253Aachs%26aulast%3DKnop%26aufirst%3DK.%26aulast%3DHoogenboom%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DD.%26aulast%3DSchubert%26aufirst%3DU.%2BS.%26atitle%3DPoly%2528ethylene%2520glycol%2529%2520in%2520drug%2520delivery%253A%2520pros%2520and%2520cons%2520as%2520well%2520as%2520potential%2520alternatives%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D6288%26epage%3D6308%26doi%3D10.1002%2Fanie.200902672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Jokerst, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobovkina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zare, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhi, S. S.</span><span> </span><span class="NLM_article-title">Nanoparticle PEGylation for imaging and therapy</span> <span class="citation_source-journal">Nanomedicine (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">â</span> <span class="NLM_lpage">728</span><span class="refDoi">Â DOI: 10.2217/nnm.11.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2217%2Fnnm.11.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21718180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVajtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=715-728&author=J.+V.+Jokerstauthor=T.+Lobovkinaauthor=R.+N.+Zareauthor=S.+S.+Gambhi&title=Nanoparticle+PEGylation+for+imaging+and+therapy&doi=10.2217%2Fnnm.11.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle PEGylation for imaging and therapy</span></div><div class="casAuthors">Jokerst, Jesse V.; Lobovkina, Tatsiana; Zare, Richard N.; Gambhir, Sanjiv S.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">715-728</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanoparticles are an essential component in the emerging field of nanomedical imaging and therapy.  When deployed in vivo, these materials are typically protected from the immune system by polyethylene glycol (PEG).  A wide variety of strategies to coat and characterize nanoparticles with PEG has established important trends on PEG size, shape, d., loading level, mol. wt., charge and purifn.  Strategies to incorporate targeting ligands are also prevalent.  This article presents a background to investigators new to stealth nanoparticles, and suggests some key considerations needed prior to designing a nanoparticle PEGylation protocol and characterizing the performance features of the product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyisd8_v8G7Vg90H21EOLACvtfcHk0lhpOZZucai3rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVajtro%253D&md5=960e4aed2f95aae187beeb7d6e5eb882</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2217%2Fnnm.11.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.11.19%26sid%3Dliteratum%253Aachs%26aulast%3DJokerst%26aufirst%3DJ.%2BV.%26aulast%3DLobovkina%26aufirst%3DT.%26aulast%3DZare%26aufirst%3DR.%2BN.%26aulast%3DGambhi%26aufirst%3DS.%2BS.%26atitle%3DNanoparticle%2520PEGylation%2520for%2520imaging%2520and%2520therapy%26jtitle%3DNanomedicine%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D6%26spage%3D715%26epage%3D728%26doi%3D10.2217%2Fnnm.11.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Dash, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkimalla, V. B.</span><span> </span><span class="NLM_article-title">Polymeric modification and its implication in drug delivery: poly-Îµ-caprolactone (PCL) as a model polymer</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2365</span><span class="NLM_x">â</span> <span class="NLM_lpage">2379</span><span class="refDoi">Â DOI: 10.1021/mp3001952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp3001952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKqurbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2365-2379&author=T.+K.+Dashauthor=V.+B.+Konkimalla&title=Polymeric+modification+and+its+implication+in+drug+delivery%3A+poly-%CE%B5-caprolactone+%28PCL%29+as+a+model+polymer&doi=10.1021%2Fmp3001952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric Modification and Its Implication in Drug Delivery: Poly-Îµ-caprolactone (PCL) as a Model Polymer</span></div><div class="casAuthors">Dash, Tapan K.; Konkimalla, V. Badireenath</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2365-2379</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Biodegradable polymers provided the opportunity to explore beyond conventional drug delivery and turned out to be the focus of current drug delivery.  In spite of availability of diverse class of polymers, several of these polymers lack important physicochem. and biol. properties, limiting their widespread application in pharmaceutical drug delivery.  However, most polymers in the form of blends, copolymers and functionally modified polymers have exhibited their applicability to overcome specific limitations and to produce novel and/or functionalized formulations for drug delivery as well as tissue engineering.  This review aims to provide the need of polymeric modification, approaches adopted to modify and their scope.  Special emphasis has been given to synthetic polyester PCL, as it is widely demonstrated in its modified form to overcome its problem of hydrophobicity and much slower degrdn. over the past decade.  Past studies show a significantly higher utility of modified form of PCL in comparison to its native form.  From the statistical anal. of these modifications and the formulations prepd., we present a basic understanding of the impact of selective modifications on the formulation design.  In conclusion, we remark that a thorough understanding of the polymer and its modification has a huge potential to be the future trend for drug delivery and tissue engineering applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQlbrULkIU97Vg90H21EOLACvtfcHk0lhpOZZucai3rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKqurbN&md5=14a0dc7e32ffe00d9b30a1bf93c27e2e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fmp3001952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp3001952%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DT.%2BK.%26aulast%3DKonkimalla%26aufirst%3DV.%2BB.%26atitle%3DPolymeric%2520modification%2520and%2520its%2520implication%2520in%2520drug%2520delivery%253A%2520poly-%25CE%25B5-caprolactone%2520%2528PCL%2529%2520as%2520a%2520model%2520polymer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2365%26epage%3D2379%26doi%3D10.1021%2Fmp3001952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactic-<i>co</i>-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3871</span><span class="NLM_x">â</span> <span class="NLM_lpage">3881</span><span class="refDoi">Â DOI: 10.1021/mp400342f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400342f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWru7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=3871-3881&author=V.+Sannaauthor=I.+A.+Siddiquiauthor=M.+Sechiauthor=H.+Mukhtar&title=Resveratrol-loaded+nanoparticles+based+on+poly%28epsilon-caprolactone%29+and+poly%28d%2Cl-lactic-co-glycolic+acid%29-poly%28ethylene+glycol%29+blend+for+prostate+cancer+treatment&doi=10.1021%2Fmp400342f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol-Loaded Nanoparticles Based on Poly(epsilon-caprolactone) and Poly(D,L-lactic-co-glycolic acid)-Poly(ethylene glycol) Blend for Prostate Cancer Treatment</span></div><div class="casAuthors">Sanna, Vanna; Siddiqui, Imtiaz Ahmad; Sechi, Mario; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3871-3881</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoencapsulation of antiproliferative and chemopreventive phytoalexin trans-resveratrol (RSV) is likely to provide protection against degrdn., enhancement of bioavailability, improvement in intracellular penetration and control delivery.  In this study, polymeric nanoparticles (NPs) encapsulating RSV (nano-RSV) as novel prototypes for prostate cancer (PCa) treatment were designed, characterized and evaluated using human PCa cells.  Nanosystems, composed of a biocompatible blend of poly-(Îµ-caprolactone) (PCL) and poly-(D,L-lactic-co-glycolic acid)-poly-(ethylene glycol) conjugate (PLGA-PEG-COOH), were prepd. by a nanopptn. method, and characterized in terms of morphol., particle size and zeta potential, encapsulation efficiency, thermal analyses, and in vitro release studies.  Cellular uptake of NPs was then evaluated in PCa cell lines DU-145, PC-3, and LNCaP using confocal fluorescence microscopy, and antiproliferative efficacy was assessed using MTT assay.  With encapsulation efficiencies ranging from 74% to 98%, RSV was successfully loaded in PCL:PLGA-PEG-COOH NPs, which showed an av. diam. of 150 nm.  NPs were able to control the RSV release at pH 6.5 and 7.4, mimicking the acidic tumoral microenvironment and physiol. conditions, resp., with only 55% of RSV released within 7 h.  In gastrointestinal simulated fluids, NPs released about 55% of RSV in the first 2 h in acidic medium, and their total RSV content within the subsequent 5 h at pH 7.4.  Confocal fluorescence microscopy observations revealed that NPs were efficiently taken up by PCa cell lines.  Furthermore, nano-RSV significantly improved the cytotoxicity compared to that of free RSV toward all three cell lines, at all tested concns. (from 10 Î¼M to 40 Î¼M), proving a consistent sensitivity toward both the androgen-independent DU-145 and hormone-sensitive LNCaP cells.  Our findings support the potential use of developed nanoprototypes for the controlled delivery of bioactive RSV for PCa chemoprevention/chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8l3WqXmfGjbVg90H21EOLACvtfcHk0lhpOZZucai3rA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWru7jJ&md5=0f4de236624b2c98fab90da0fedc4033</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fmp400342f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400342f%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DSiddiqui%26aufirst%3DI.%2BA.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DResveratrol-loaded%2520nanoparticles%2520based%2520on%2520poly%2528epsilon-caprolactone%2529%2520and%2520poly%2528d%252Cl-lactic-co-glycolic%2520acid%2529-poly%2528ethylene%2520glycol%2529%2520blend%2520for%2520prostate%2520cancer%2520treatment%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D3871%26epage%3D3881%26doi%3D10.1021%2Fmp400342f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadino, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marceddu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzzau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Novel docetaxel-loaded nanoparticles based on poly(lactide-<i>co</i>-caprolactone) and poly(lactide-<i>co</i>-glycolide-<i>co</i>-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies</span> <span class="citation_source-journal">Nanoscale Res. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">260</span><span class="refDoi">Â DOI: 10.1186/1556-276X-6-260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1186%2F1556-276X-6-260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21711774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2msbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=260&issue=1&author=V.+Sannaauthor=A.+M.+Roggioauthor=A.+M.+Posadinoauthor=A.+Cossuauthor=S.+Marcedduauthor=A.+Marianiauthor=V.+Alzariauthor=S.+Uzzauauthor=G.+Pintusauthor=M.+Sechi&title=Novel+docetaxel-loaded+nanoparticles+based+on+poly%28lactide-co-caprolactone%29+and+poly%28lactide-co-glycolide-co-caprolactone%29+for+prostate+cancer+treatment%3A+formulation%2C+characterization+and+cytotoxicity+studies&doi=10.1186%2F1556-276X-6-260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies</span></div><div class="casAuthors">Sanna, Vanna; Roggio, Anna Maria; Posadino, Anna Maria; Cossu, Annalisa; Marceddu, Salvatore; Mariani, Alberto; Alzari, Valeria; Uzzau, Sergio; Pintus, Gianfranco; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale Research Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">260, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NRLAAD</span>;
        ISSN:<span class="NLM_cas:issn">1556-276X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Docetaxel (Dtx) chemotherapy is the optional treatment in patients with hormone-refractory metastatic prostate cancer, and Dtx-loaded polymeric nanoparticles (NPs) have the potential to induce durable clin. responses.  However, alternative formulations are needed to overcome the serious side effects, also due to the adjuvant used, and to improve the clin. efficacy of the drug.  In the present study, two novel biodegradable block-copolymers, poly(lactide-co-caprolactone) (PLA-PCL) and poly (lactide-co-caprolactone-co-glycolide) (PLGA-PCL), were explored for the formulation of Dtx-loaded NPs and compared with PLA- and PLGA-NPs.  The nanosystems were prepd. by an original nanopptn. method, using Pluronic F-127 as surfactant agent, and were characterized in terms of morphol., size distribution, encapsulation efficiency, cryst. structure, and in vitro release.  To evaluate the potential anticancer efficacy of a nanoparticulate system, in vitro cytotoxicity studies on human prostate cancer cell line (PC3) were carried out.  NPs were found to be of spherical shape with an av. diam. in the range of 100 to 200 nm and a unimodal particle size distribution.  Dtx was incorporated into the PLGA-PCL NPs with higher (p < 0.05) encapsulation efficiency than that of other polymers.  Differential scanning calorimetry suggested that Dtx was molecularly dispersed in the polymeric matrixes.  In vitro drug release study showed that release profiles of Dtx varied on the bases of characteristics of polymers used for formulation.  PLA-PCL and PLGA-PCL drug loaded NPs shared an overlapping release profiles, and are able to release about 90% of drug within 6 h, when compared with PLA- and PLGA-NPs.  Moreover, cytotoxicity studies demonstrated advantages of the Dtx-loaded PLGA-PCL NPs over pure Dtx in both time- and concn.-dependent manner.  In particular, an increase of 20% of PC3 growth inhibition was detd. by PLGA-PCL NPs with respect to free drug after 72 h incubation and at all tested Dtx concn.  In summary, PLGA-PCL copolymer may be considered as an attractive and promising polymeric material for the formulation of Dtx NPs as delivery system for prostate cancer treatment, and can also be pursued as a validated system in a more large context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHj03YXUg277Vg90H21EOLACvtfcHk0ljUdsuAnoDDYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2msbbM&md5=0dfef9f67391b71dc54a729f384101e9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1186%2F1556-276X-6-260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1556-276X-6-260%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DRoggio%26aufirst%3DA.%2BM.%26aulast%3DPosadino%26aufirst%3DA.%2BM.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DMariani%26aufirst%3DA.%26aulast%3DAlzari%26aufirst%3DV.%26aulast%3DUzzau%26aufirst%3DS.%26aulast%3DPintus%26aufirst%3DG.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DNovel%2520docetaxel-loaded%2520nanoparticles%2520based%2520on%2520poly%2528lactide-co-caprolactone%2529%2520and%2520poly%2528lactide-co-glycolide-co-caprolactone%2529%2520for%2520prostate%2520cancer%2520treatment%253A%2520formulation%252C%2520characterization%2520and%2520cytotoxicity%2520studies%26jtitle%3DNanoscale%2520Res.%2520Lett.%26date%3D2011%26volume%3D6%26issue%3D1%26spage%3D260%26doi%3D10.1186%2F1556-276X-6-260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Patching, S. G.</span><span> </span><span class="NLM_article-title">Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1838</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">55</span><span class="refDoi">Â DOI: 10.1016/j.bbamem.2013.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.bbamem.2013.04.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23665295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslWrtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1838&publication_year=2014&pages=43-55&author=S.+G.+Patching&title=Surface+plasmon+resonance+spectroscopy+for+characterisation+of+membrane+protein-ligand+interactions+and+its+potential+for+drug+discovery&doi=10.1016%2Fj.bbamem.2013.04.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery</span></div><div class="casAuthors">Patching, Simon G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1838</span>
        (<span class="NLM_cas:issue">1PA</span>),
    <span class="NLM_cas:pages">43-55</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Surface plasmon resonance (SPR) spectroscopy is a rapidly developing technique for the study of ligand binding interactions with membrane proteins, which are the major mol. targets for validated drugs and for current and foreseeable drug discovery.  SPR is label-free and capable of measuring real-time quant. binding affinities and kinetics for membrane proteins interacting with ligand mols. using relatively small quantities of materials and has potential to be medium-throughput.  The conventional SPR technique requires one binding component to be immobilized on a sensor chip while the other binding component in soln. is flowed over the sensor surface; a binding interaction is detected using an optical method that measures small changes in refractive index at the sensor surface.  This review first describes the basic SPR expt. and the challenges that have to be considered for performing SPR expts. that measure membrane protein-ligand binding interactions, most importantly having the membrane protein in a lipid or detergent environment that retains its native structure and activity.  It then describes a wide-range of membrane protein systems for which ligand binding interactions have been characterised using SPR, including the major drug targets G protein-coupled receptors, and how challenges have been overcome for achieving this.  Finally it describes some recent advances in SPR-based technol. and future potential of the technique to screen ligand binding in the discovery of drugs.  This article is part of a Special Issue entitled: Structural and biophys. characterization of membrane protein-ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKHXrfkR3d3rVg90H21EOLACvtfcHk0ljUdsuAnoDDYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslWrtr8%253D&md5=5b1def21c34b67529fd472e796861252</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2013.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2013.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DPatching%26aufirst%3DS.%2BG.%26atitle%3DSurface%2520plasmon%2520resonance%2520spectroscopy%2520for%2520characterisation%2520of%2520membrane%2520protein-ligand%2520interactions%2520and%2520its%2520potential%2520for%2520drug%2520discovery%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2014%26volume%3D1838%26spage%3D43%26epage%3D55%26doi%3D10.1016%2Fj.bbamem.2013.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tanmay Kulkarni, Debabrata Mukhopadhyay, <span class="NLM_string-name hlFld-ContribAuthor">Santanu Bhattacharya</span>. </span><span class="cited-content_cbyCitation_article-title">Nanomechanical Insight of Pancreatic Cancer Cell Membrane during Receptor Mediated Endocytosis of Targeted Gold Nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Bio Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (1)
                                     , 984-994. <a href="https://doi.org/10.1021/acsabm.0c01443" title="DOI URL">https://doi.org/10.1021/acsabm.0c01443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsabm.0c01443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsabm.0c01443%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Bio%2520Materials%26atitle%3DNanomechanical%252BInsight%252Bof%252BPancreatic%252BCancer%252BCell%252BMembrane%252Bduring%252BReceptor%252BMediated%252BEndocytosis%252Bof%252BTargeted%252BGold%252BNanoparticles%26aulast%3DKulkarni%26aufirst%3DTanmay%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06112020%26date%3D17122020%26date%3D30122020%26volume%3D4%26issue%3D1%26spage%3D984%26epage%3D994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anas Ahmad, Farheen Khan, Rakesh Kumar Mishra, <span class="NLM_string-name hlFld-ContribAuthor">Rehan Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10475-10496. <a href="https://doi.org/10.1021/acs.jmedchem.9b00511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPrecision%252BCancer%252BNanotherapy%25253A%252BEvolving%252BRole%252Bof%252BMultifunctional%252BNanoparticles%252Bfor%252BCancer%252BActive%252BTargeting%26aulast%3DAhmad%26aufirst%3DAnas%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23032019%26date%3D01082019%26date%3D24072019%26volume%3D62%26issue%3D23%26spage%3D10475%26epage%3D10496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dong Young Kim, Pham Duy Quang Dao, <span class="NLM_string-name hlFld-ContribAuthor">Chan Sik Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrimidine- and Quinazoline-Fused Benzimidazole-4,7-diones Using Combinatorial Cyclocondensation and Oxidation. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (12)
                                     , 17456-17465. <a href="https://doi.org/10.1021/acsomega.8b02755" title="DOI URL">https://doi.org/10.1021/acsomega.8b02755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b02755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b02755%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Bof%252BPyrimidine-%252Band%252BQuinazoline-Fused%252BBenzimidazole-4%25252C7-diones%252BUsing%252BCombinatorial%252BCyclocondensation%252Band%252BOxidation%26aulast%3DKim%26aufirst%3DDong%2BYoung%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D11102018%26date%3D20112018%26volume%3D3%26issue%3D12%26spage%3D17456%26epage%3D17465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pham Duy
Quang Dao, Son Long Ho, <span class="NLM_string-name hlFld-ContribAuthor">Chan Sik Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-Fused Benzimidazole-4,7-diones via Sequential Copper-Catalyzed CâN Coupling/Cyclization and Oxidation. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (5)
                                     , 5643-5653. <a href="https://doi.org/10.1021/acsomega.8b00805" title="DOI URL">https://doi.org/10.1021/acsomega.8b00805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00805%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Bof%252BN-Fused%252BBenzimidazole-4%25252C7-diones%252Bvia%252BSequential%252BCopper-Catalyzed%252BC%2525E2%252580%252593N%252BCoupling%25252FCyclization%252Band%252BOxidation%26aulast%3DDao%26aufirst%3DPham%2BDuy%2BQuang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25042018%26date%3D15052018%26volume%3D3%26issue%3D5%26spage%3D5643%26epage%3D5653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron Y.  Mochizuki</span>, <span class="hlFld-ContribAuthor ">Isaura M.  Frost</span>, <span class="hlFld-ContribAuthor ">Melina B.  Mastrodimos</span>, <span class="hlFld-ContribAuthor ">Ashley S.  Plant</span>, <span class="hlFld-ContribAuthor ">Anthony C.  Wang</span>, <span class="hlFld-ContribAuthor ">Theodore B.  Moore</span>, <span class="hlFld-ContribAuthor ">Robert M.  Prins</span>, <span class="hlFld-ContribAuthor ">Paul S.  Weiss</span>, and <span class="hlFld-ContribAuthor ">Steven J.  Jonas</span>  . </span><span class="cited-content_cbyCitation_article-title">Precision Medicine in Pediatric Neurooncology: A Review. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 11-28. <a href="https://doi.org/10.1021/acschemneuro.7b00388" title="DOI URL">https://doi.org/10.1021/acschemneuro.7b00388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.7b00388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.7b00388%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DPrecision%252BMedicine%252Bin%252BPediatric%252BNeurooncology%25253A%252BA%252BReview%26aulast%3DMochizuki%26aufirst%3DAaron%2BY.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09102017%26date%3D04122017%26date%3D27122017%26date%3D17012018%26date%3D04122017%26volume%3D9%26issue%3D1%26spage%3D11%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Zhang</span>, <span class="hlFld-ContribAuthor ">Haoyue  Xiang</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Fang  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, and <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">CâH Trifluoromethylation of 2-Substituted/Unsubstituted Aminonaphthoquinones at Room Temperature with Bench-Stable (CF3SO2)2Zn: Synthesis and Antiproliferative Evaluation. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (13)
                                     , 6795-6800. <a href="https://doi.org/10.1021/acs.joc.7b00940" title="DOI URL">https://doi.org/10.1021/acs.joc.7b00940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b00940%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DC%2525E2%252580%252593H%252BTrifluoromethylation%252Bof%252B2-Substituted%25252FUnsubstituted%252BAminonaphthoquinones%252Bat%252BRoom%252BTemperature%252Bwith%252BBench-Stable%252B%252528CF3SO2%2525292Zn%25253A%252BSynthesis%252Band%252BAntiproliferative%252BEvaluation%26aulast%3DLi%26aufirst%3DJing%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D19042017%26date%3D14062017%26date%3D07072017%26date%3D07062017%26volume%3D82%26issue%3D13%26spage%3D6795%26epage%3D6800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilaria  Monaco</span>, <span class="hlFld-ContribAuthor ">Simona  Camorani</span>, <span class="hlFld-ContribAuthor ">David  Colecchia</span>, <span class="hlFld-ContribAuthor ">Erica  Locatelli</span>, <span class="hlFld-ContribAuthor ">Pierpaolo  Calandro</span>, <span class="hlFld-ContribAuthor ">Anais  Oudin</span>, <span class="hlFld-ContribAuthor ">Simone  Niclou</span>, <span class="hlFld-ContribAuthor ">Claudio  Arra</span>, <span class="hlFld-ContribAuthor ">Mario  Chiariello</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, and <span class="hlFld-ContribAuthor ">Mauro  Comes Franchini</span>  . </span><span class="cited-content_cbyCitation_article-title">Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the BloodâBrain Barrier. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4510-4516. <a href="https://doi.org/10.1021/acs.jmedchem.7b00527" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00527%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAptamer%252BFunctionalization%252Bof%252BNanosystems%252Bfor%252BGlioblastoma%252BTargeting%252Bthrough%252Bthe%252BBlood%2525E2%252580%252593Brain%252BBarrier%26aulast%3DMonaco%26aufirst%3DIlaria%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07042017%26date%3D10052017%26date%3D25052017%26date%3D04052017%26volume%3D60%26issue%3D10%26spage%3D4510%26epage%3D4516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxime  Donzel</span>, <span class="hlFld-ContribAuthor ">Deniz  Karabiyikli</span>, <span class="hlFld-ContribAuthor ">Leandro  Cotos</span>, <span class="hlFld-ContribAuthor ">Mourad  Elhabiri</span>, <span class="hlFld-ContribAuthor ">Elisabeth  DavioudâCharvet</span>. </span><span class="cited-content_cbyCitation_article-title">Direct CâH Radical Alkylation of 1,4âQuinones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (25)
                                     , 3622-3633. <a href="https://doi.org/10.1002/ejoc.202100452" title="DOI URL">https://doi.org/10.1002/ejoc.202100452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100452%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDirect%252BC%2525E2%252588%252592H%252BRadical%252BAlkylation%252Bof%252B1%25252C4%2525E2%252580%252590Quinones%26aulast%3DDonzel%26aufirst%3DMaxime%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D25%26spage%3D3622%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanan  Panchal</span>, <span class="hlFld-ContribAuthor ">Rakesh Kumar  Sahoo</span>, <span class="hlFld-ContribAuthor ">Umesh  Gupta</span>, <span class="hlFld-ContribAuthor ">Akash  Chaurasiya</span>. </span><span class="cited-content_cbyCitation_article-title">Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2021,</strong> <em>95 </em>, 107508. <a href="https://doi.org/10.1016/j.intimp.2021.107508" title="DOI URL">https://doi.org/10.1016/j.intimp.2021.107508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2021.107508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2021.107508%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DRole%252Bof%252Btargeted%252Bimmunotherapy%252Bfor%252Bpancreatic%252Bductal%252Badenocarcinoma%252B%252528PDAC%252529%252Btreatment%25253A%252BAn%252Boverview%26aulast%3DPanchal%26aufirst%3DKanan%26date%3D2021%26volume%3D95%26spage%3D107508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manzar  Abbas</span>, <span class="hlFld-ContribAuthor ">Muhammad  Ovais</span>, <span class="hlFld-ContribAuthor ">Sudip  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Arbab  Ali</span>, <span class="hlFld-ContribAuthor ">Muhammad  Hanif</span>, <span class="hlFld-ContribAuthor ">Chunying  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Nanotechnology for cancer drug design, delivery, and theranostics applications. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-26. <a href="https://doi.org/10.1016/B978-0-12-821467-1.00004-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-821467-1.00004-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821467-1.00004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821467-1.00004-5%26sid%3Dliteratum%253Aachs%26atitle%3DNanotechnology%252Bfor%252Bcancer%252Bdrug%252Bdesign%25252C%252Bdelivery%25252C%252Band%252Btheranostics%252Bapplications%26aulast%3DAbbas%26aufirst%3DManzar%26date%3D2021%26spage%3D1%26epage%3D26%26pub%3DElsevier%26atitle%3DBiogenic%252BNanoparticles%252Bfor%252BCancer%252BTheranostics%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Wiche</span>, <span class="hlFld-ContribAuthor ">Maria J.  CastaÃ±Ã³n</span>. </span><span class="cited-content_cbyCitation_article-title">Intermediate Filament Linker Proteins: Plectin and BPAG1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-819460-7.00263-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-819460-7.00263-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819460-7.00263-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819460-7.00263-2%26sid%3Dliteratum%253Aachs%26atitle%3DIntermediate%252BFilament%252BLinker%252BProteins%25253A%252BPlectin%252Band%252BBPAG1%26aulast%3DWiche%26aufirst%3DGerhard%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BLife%252BSciences%26date%3D2021%26volume%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jung Pyo  Kwak</span>, <span class="hlFld-ContribAuthor ">Pham Duy Quang  Dao</span>, <span class="hlFld-ContribAuthor ">Chan Sik  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-Aminoquinazoline- and 2-Aminopyrimidine-Fused Hybrid Scaffolds by Copper-Catalyzed C(
              sp
              2
              )-N Coupling and Cyclization Followed by Oxidation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (23)
                                     , 3468-3474. <a href="https://doi.org/10.1002/ejoc.202000427" title="DOI URL">https://doi.org/10.1002/ejoc.202000427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202000427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202000427%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2-Aminoquinazoline-%252Band%252B2-Aminopyrimidine-Fused%252BHybrid%252BScaffolds%252Bby%252BCopper-Catalyzed%252BC%252528%252Bsp%252B2%252B%252529-N%252BCoupling%252Band%252BCyclization%252BFollowed%252Bby%252BOxidation%26aulast%3DKwak%26aufirst%3DJung%2BPyo%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D23%26spage%3D3468%26epage%3D3474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Levente E.  DÃ³kus</span>, <span class="hlFld-ContribAuthor ">Eszter  LajkÃ³</span>, <span class="hlFld-ContribAuthor ">Ivan  RanÄeloviÄ</span>, <span class="hlFld-ContribAuthor ">DiÃ¡na  MezÅ</span>, <span class="hlFld-ContribAuthor ">Gitta  Schlosser</span>, <span class="hlFld-ContribAuthor ">LÃ¡szlÃ³  KÅhidai</span>, <span class="hlFld-ContribAuthor ">JÃ³zsef  TÃ³vÃ¡ri</span>, <span class="hlFld-ContribAuthor ">GÃ¡bor  MezÅ</span>. </span><span class="cited-content_cbyCitation_article-title">Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 576. <a href="https://doi.org/10.3390/pharmaceutics12060576" title="DOI URL">https://doi.org/10.3390/pharmaceutics12060576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics12060576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics12060576%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DPhage%252BDisplay-Based%252BHoming%252BPeptide-Daunomycin%252BConjugates%252Bfor%252BSelective%252BDrug%252BTargeting%252Bto%252BPANC-1%252BPancreatic%252BCancer%26aulast%3DD%25C3%25B3kus%26aufirst%3DLevente%2BE.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pham Duy Quang  Dao</span>, <span class="hlFld-ContribAuthor ">Chan Sik  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Construction of Trinuclear N-Fused Hybrid Scaffolds Using Cyclic Ureas as New Building Blocks. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (3)
                                     , 330-338. <a href="https://doi.org/10.1002/ejoc.201901588" title="DOI URL">https://doi.org/10.1002/ejoc.201901588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCopper-Catalyzed%252BConstruction%252Bof%252BTrinuclear%252BN-Fused%252BHybrid%252BScaffolds%252BUsing%252BCyclic%252BUreas%252Bas%252BNew%252BBuilding%252BBlocks%26aulast%3DDao%26aufirst%3DPham%2BDuy%2BQuang%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D3%26spage%3D330%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juana Andrea  Ibacache</span>, <span class="hlFld-ContribAuthor ">Jaime A.  Valderrama</span>, <span class="hlFld-ContribAuthor ">Judith  FaÃºndes</span>, <span class="hlFld-ContribAuthor ">Alex  Danimann</span>, <span class="hlFld-ContribAuthor ">Francisco J.  Recio</span>, <span class="hlFld-ContribAuthor ">CÃ©sar A.  ZÃºÃ±iga</span>. </span><span class="cited-content_cbyCitation_article-title">Green Synthesis and Electrochemical Properties of Mono- and Dimers Derived from Phenylaminoisoquinolinequinones. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4378. <a href="https://doi.org/10.3390/molecules24234378" title="DOI URL">https://doi.org/10.3390/molecules24234378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234378%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DGreen%252BSynthesis%252Band%252BElectrochemical%252BProperties%252Bof%252BMono-%252Band%252BDimers%252BDerived%252Bfrom%252BPhenylaminoisoquinolinequinones%26aulast%3DIbacache%26aufirst%3DJuana%2BAndrea%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zar Chi  Soe</span>, <span class="hlFld-ContribAuthor ">Wenquan  Ou</span>, <span class="hlFld-ContribAuthor ">Milan  Gautam</span>, <span class="hlFld-ContribAuthor ">Kishwor  Poudel</span>, <span class="hlFld-ContribAuthor ">Bo Kyun  Kim</span>, <span class="hlFld-ContribAuthor ">Le Minh  Pham</span>, <span class="hlFld-ContribAuthor ">Cao Dai  Phung</span>, <span class="hlFld-ContribAuthor ">Jee-Heon  Jeong</span>, <span class="hlFld-ContribAuthor ">Sung Giu  Jin</span>, <span class="hlFld-ContribAuthor ">Han-Gon  Choi</span>, <span class="hlFld-ContribAuthor ">Sae Kwang  Ku</span>, <span class="hlFld-ContribAuthor ">Chul Soon  Yong</span>, <span class="hlFld-ContribAuthor ">Jong Oh  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Folate-Functionalized PEGylated Zein Nanoparticles for Ligand-Directed Delivery of Paclitaxel. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (11)
                                     , 562. <a href="https://doi.org/10.3390/pharmaceutics11110562" title="DOI URL">https://doi.org/10.3390/pharmaceutics11110562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics11110562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics11110562%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DDevelopment%252Bof%252BFolate-Functionalized%252BPEGylated%252BZein%252BNanoparticles%252Bfor%252BLigand-Directed%252BDelivery%252Bof%252BPaclitaxel%26aulast%3DSoe%26aufirst%3DZar%2BChi%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D11%26spage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong Young  Kim</span>, <span class="hlFld-ContribAuthor ">Pham Duy Quang  Dao</span>, <span class="hlFld-ContribAuthor ">Nam Sik  Yoon</span>, <span class="hlFld-ContribAuthor ">Chan Sik  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrroloneâ and IsoindolinoneâFused Benzimidazoleâ4,7âdiones by Stepwise PalladiumâCatalyzed Carbonylative Cyclization and Oxidation. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 1726-1731. <a href="https://doi.org/10.1002/ajoc.201900423" title="DOI URL">https://doi.org/10.1002/ajoc.201900423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900423%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BPyrrolone%2525E2%252580%252590%252Band%252BIsoindolinone%2525E2%252580%252590Fused%252BBenzimidazole%2525E2%252580%2525904%25252C7%2525E2%252580%252590diones%252Bby%252BStepwise%252BPalladium%2525E2%252580%252590Catalyzed%252BCarbonylative%252BCyclization%252Band%252BOxidation%26aulast%3DKim%26aufirst%3DDong%2BYoung%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D1726%26epage%3D1731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahalingam  Mahalakshmi</span>, <span class="hlFld-ContribAuthor ">Ponnuchamy  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Phloroglucinol-conjugated gold nanoparticles targeting mitochondrial membrane potential of human cervical (HeLa) cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2019,</strong> <em>219 </em>, 450-456. <a href="https://doi.org/10.1016/j.saa.2019.04.060" title="DOI URL">https://doi.org/10.1016/j.saa.2019.04.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2019.04.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2019.04.060%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DPhloroglucinol-conjugated%252Bgold%252Bnanoparticles%252Btargeting%252Bmitochondrial%252Bmembrane%252Bpotential%252Bof%252Bhuman%252Bcervical%252B%252528HeLa%252529%252Bcancer%252Bcell%252Blines%26aulast%3DMahalakshmi%26aufirst%3DMahalingam%26date%3D2019%26volume%3D219%26spage%3D450%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thi Duyen  Diep</span>, <span class="hlFld-ContribAuthor ">Pham Duy Quang  Dao</span>, <span class="hlFld-ContribAuthor ">Chan Sik  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Binuclear Isoquinoline- and Pyridine-Fused Benzimidazole-4,7-diones by Magnetic MOF-199-Catalyzed C-C Coupling/Cyclization Followed by Oxidation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (25)
                                     , 4071-4079. <a href="https://doi.org/10.1002/ejoc.201900635" title="DOI URL">https://doi.org/10.1002/ejoc.201900635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900635%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BBinuclear%252BIsoquinoline-%252Band%252BPyridine-Fused%252BBenzimidazole-4%25252C7-diones%252Bby%252BMagnetic%252BMOF-199-Catalyzed%252BC-C%252BCoupling%25252FCyclization%252BFollowed%252Bby%252BOxidation%26aulast%3DDiep%26aufirst%3DThi%2BDuyen%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D25%26spage%3D4071%26epage%3D4079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinpeng  Han</span>, <span class="hlFld-ContribAuthor ">Likun  Xiong</span>, <span class="hlFld-ContribAuthor ">Xingyu  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Yuan</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Dayong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Bio-functional electrospun nanomaterials: From topology design to biological applications. </span><span class="cited-content_cbyCitation_journal-name">Progress in Polymer Science</span><span> <strong>2019,</strong> <em>91 </em>, 1-28. <a href="https://doi.org/10.1016/j.progpolymsci.2019.02.006" title="DOI URL">https://doi.org/10.1016/j.progpolymsci.2019.02.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.progpolymsci.2019.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.progpolymsci.2019.02.006%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Polymer%2520Science%26atitle%3DBio-functional%252Belectrospun%252Bnanomaterials%25253A%252BFrom%252Btopology%252Bdesign%252Bto%252Bbiological%252Bapplications%26aulast%3DHan%26aufirst%3DJinpeng%26date%3D2019%26volume%3D91%26spage%3D1%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danielle M.  Valcourt</span>, <span class="hlFld-ContribAuthor ">Jenna  Harris</span>, <span class="hlFld-ContribAuthor ">Rachel S.  Riley</span>, <span class="hlFld-ContribAuthor ">Megan  Dang</span>, <span class="hlFld-ContribAuthor ">Jianxin  Wang</span>, <span class="hlFld-ContribAuthor ">Emily S.  Day</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in targeted nanotherapeutics: From bioconjugation to biomimicry. </span><span class="cited-content_cbyCitation_journal-name">Nano Research</span><span> <strong>2018,</strong> <em>11 </em>
                                    (10)
                                     , 4999-5016. <a href="https://doi.org/10.1007/s12274-018-2083-z" title="DOI URL">https://doi.org/10.1007/s12274-018-2083-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12274-018-2083-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12274-018-2083-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNano%2520Research%26atitle%3DAdvances%252Bin%252Btargeted%252Bnanotherapeutics%25253A%252BFrom%252Bbioconjugation%252Bto%252Bbiomimicry%26aulast%3DValcourt%26aufirst%3DDanielle%2BM.%26date%3D2018%26date%3D2018%26volume%3D11%26issue%3D10%26spage%3D4999%26epage%3D5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramanathan  Devenderan</span>, <span class="hlFld-ContribAuthor ">Pitchumani  Kasi</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free, base promoted sp
              2
              CâH functionalization in the sulfonamidation of 1,4-naphthoquinones. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (29)
                                     , 5294-5300. <a href="https://doi.org/10.1039/C8OB00818C" title="DOI URL">https://doi.org/10.1039/C8OB00818C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB00818C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB00818C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DMetal-free%25252C%252Bbase%252Bpromoted%252Bsp%252B2%252BC%2525E2%252580%252593H%252Bfunctionalization%252Bin%252Bthe%252Bsulfonamidation%252Bof%252B1%25252C4-naphthoquinones%26aulast%3DDevenderan%26aufirst%3DRamanathan%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D29%26spage%3D5294%26epage%3D5300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Borowa-Mazgaj</span>, <span class="hlFld-ContribAuthor ">Anna  MrÃ³z</span>, <span class="hlFld-ContribAuthor ">Ewa  Augustin</span>, <span class="hlFld-ContribAuthor ">Ewa  Paluszkiewicz</span>, <span class="hlFld-ContribAuthor ">Zofia  Mazerska</span>. </span><span class="cited-content_cbyCitation_article-title">The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2017,</strong> <em>142 </em>, 21-38. <a href="https://doi.org/10.1016/j.bcp.2017.06.124" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.06.124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.06.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.06.124%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252Boverexpression%252Bof%252BCPR%252Band%252BP450%252B3A4%252Bin%252Bpancreatic%252Bcancer%252Bcells%252Bchanges%252Bthe%252Bmetabolic%252Bprofile%252Band%252Bincreases%252Bthe%252Bcytotoxicity%252Band%252Bpro-apoptotic%252Bactivity%252Bof%252Bacridine%252Bantitumor%252Bagent%25252C%252BC-1748%26aulast%3DBorowa-Mazgaj%26aufirst%3DBarbara%26date%3D2017%26volume%3D142%26spage%3D21%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E K  von der Heide</span>, <span class="hlFld-ContribAuthor ">M  Neumann</span>, <span class="hlFld-ContribAuthor ">S  Vosberg</span>, <span class="hlFld-ContribAuthor ">A R  James</span>, <span class="hlFld-ContribAuthor ">M P  Schroeder</span>, <span class="hlFld-ContribAuthor ">J  Ortiz-Tanchez</span>, <span class="hlFld-ContribAuthor ">K  Isaakidis</span>, <span class="hlFld-ContribAuthor ">C  Schlee</span>, <span class="hlFld-ContribAuthor ">M  Luther</span>, <span class="hlFld-ContribAuthor ">K  JÃ¶hrens</span>, <span class="hlFld-ContribAuthor ">I  Anagnostopoulos</span>, <span class="hlFld-ContribAuthor ">L H  Mochmann</span>, <span class="hlFld-ContribAuthor ">D  Nowak</span>, <span class="hlFld-ContribAuthor ">W K  Hofmann</span>, <span class="hlFld-ContribAuthor ">P A  Greif</span>, <span class="hlFld-ContribAuthor ">C D  Baldus</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2017,</strong> <em>31 </em>
                                    (5)
                                     , 1069-1078. <a href="https://doi.org/10.1038/leu.2016.324" title="DOI URL">https://doi.org/10.1038/leu.2016.324</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2016.324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2016.324%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DMolecular%252Balterations%252Bin%252Bbone%252Bmarrow%252Bmesenchymal%252Bstromal%252Bcells%252Bderived%252Bfrom%252Bacute%252Bmyeloid%252Bleukemia%252Bpatients%26aulast%3Dvon%2Bder%2BHeide%26aufirst%3DE%2BK%26date%3D2017%26date%3D2016%26volume%3D31%26issue%3D5%26spage%3D1069%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krishnendu  Pal</span>, <span class="hlFld-ContribAuthor ">Farah  Al-suraih</span>, <span class="hlFld-ContribAuthor ">Roberto  Gonzalez-Rodriguez</span>, <span class="hlFld-ContribAuthor ">Shamit Kumar  Dutta</span>, <span class="hlFld-ContribAuthor ">Enfeng  Wang</span>, <span class="hlFld-ContribAuthor ">H. Shaun  Kwak</span>, <span class="hlFld-ContribAuthor ">Thomas R.  Caulfield</span>, <span class="hlFld-ContribAuthor ">Jeffery L.  Coffer</span>, <span class="hlFld-ContribAuthor ">Santanu  Bhattacharya</span>. </span><span class="cited-content_cbyCitation_article-title">Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. </span><span class="cited-content_cbyCitation_journal-name">Nanoscale</span><span> <strong>2017,</strong> <em>9 </em>
                                    (40)
                                     , 15622-15634. <a href="https://doi.org/10.1039/C7NR03172F" title="DOI URL">https://doi.org/10.1039/C7NR03172F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7NR03172F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7NR03172F%26sid%3Dliteratum%253Aachs%26jtitle%3DNanoscale%26atitle%3DMultifaceted%252Bpeptide%252Bassisted%252Bone-pot%252Bsynthesis%252Bof%252Bgold%252Bnanoparticles%252Bfor%252Bplectin-1%252Btargeted%252Bgemcitabine%252Bdelivery%252Bin%252Bpancreatic%252Bcancer%26aulast%3DPal%26aufirst%3DKrishnendu%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D40%26spage%3D15622%26epage%3D15634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the designed targeted PLGA-<b>11</b>- and PLGA-PEG-<b>12</b>-(<b>1</b>)-loaded NPs. Materials: chemical structure of QD242 (<b>1</b>), the low molecular weight organic molecule targeting ligand 2ABA (<b>11</b>), the cysteine-containing Plec-1 targeting peptide Cys-PTP (<b>12</b>), PLGA, and PLGA-PEG polymers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route for the Preparation of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (A) (<i>i</i>) CeCl<sub>3</sub>Â·7H<sub>2</sub>O, abs EtOH, O<sub>2</sub>, room temp, 3 h. (B) (<i>i</i>) conc. HNO<sub>3</sub>, (CH<sub>3</sub>CO)<sub>2</sub>O, 0 Â°C, 1.5 h; (<i>ii</i>) H<sub>2</sub>NCHO, HCl<sub>(g)</sub>, from 40 to 80 Â°C, 1 h; (<i>iii</i>) glacial CH<sub>3</sub>COOH, Zn, 0 Â°C for 2 h, room temp for 4 h; (<i>iv</i>) (NH<sub>4</sub>)<sub>2</sub>Ce(NO<sub>3</sub>)<sub>6</sub>, CH<sub>3</sub>CN/H<sub>2</sub>O, 0 Â°C, 20 min.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of Ligand <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) K<sub>2</sub>CO<sub>3</sub>, THF, N<sub>2</sub>, 70 Â°C for 20 h; (<i>ii</i>) TFA:CH<sub>2</sub>Cl<sub>2</sub> (1:1), 0 Â°C for 3 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Copolymer PLGA-<b>11</b> (Stage 1) and Nanoformulation (Stage 2)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) NHS, CH<sub>2</sub>Cl<sub>2</sub>, EDC, N<sub>2</sub>, room temp for 12 h; (<i>ii</i>) <b>11</b>, DIPEA, DMF, N<sub>2</sub>, room temp for 24 h.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Characterization of PLGA-<b>11</b> polymer. UV spectra comparison of PLGA-NHS (black line), <b>11</b> (red line), and PLGA-<b>11</b> (blue line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Copolymer PLGA-PEG-NH<sub>2</sub><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) CHCl<sub>3</sub>, DIPEA, N<sub>2</sub>, room temp for 24 h.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0014.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Copolymer PLGA-PEG-<b>12</b> (Stage 1) and Nanoformulation (Stage 2)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (<i>i</i>) CHCl<sub>3</sub>, DIPEA, N<sub>2</sub>, room temp for 24 h; (<i>ii</i>) <b>12</b> (KTLLPTPC), ACN:DMF (1:1), N<sub>2</sub>, room temp for 24 h.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Characterization of PLGA-PEG-<b>12</b> polymer. UV spectra comparison of PLGA-PEG-mal (green line), <b>12</b> (red line), and PLGA-PEG-<b>12</b> (blue line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SEM images of PLGA-A- (a), PLGA-<b>11</b>- (b), PLGA-PEG-NH<sub>2</sub>/PCL- (c), and PLGA-PEG-<b>12</b>/PCL- (d) (<b>1</b>)-loaded NPs and corresponding particle size distribution. The scale bar is 200 nm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro release profiles of <b>1</b> from nontargeted (PLGA-A and PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) NPs, detected at pH 6.5 (a) and 7.4 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro cytotoxicity of nontargeted (PLGA-A, PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) NPs. MIA PaCa-2 cell treated with (<b>1</b>)-loaded NPs (<b>1</b>, 2.8 Î¼M) for 72 h. (*) significantly differ from each other.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SPR-based comparative binding analysis of ligand-functionalized NPs. Sensorgrams showing binding of targeted PLGA-PEG-<b>12</b> and nontargeted PLGA-PEG-NH<sub>2</sub> NPs to Plec-1 protein. The experiment was performed using a Biacore T-200 system. Plec-1 was directly immobilized in the sensor chip by amine coupling (at 11000 RU), and NPs were flowed over the protein-coated chip at 5 mg/mL in assay buffer, with single cycle kinetics. Lines represent the best fitting of the associationâdissociation processes for targeted NPs (green line) and nontargeted NPs (blue line). Standard HBS-N buffer with 1 mg/mL BSA (pink line) was used as control. Data for affinity evaluation were obtained and expressed as difference in RU. Data shown are representative of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/medium/jm-2015-015716_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Uptake assays for NPs. Panels show representative live cell fluorescence microscopy images of MIA PaCa-2 cells after exposure to nontargeted (PLGA-A, PLGA-PEG-NH<sub>2</sub>) and targeted (PLGA-<b>11</b> and PLGA-PEG-<b>12</b>) dye-loaded NPs. Left panels: cells incubated with dye-loaded NPs for 1 h. Middle panels: red fluorescence of the nuclei stained with DRAQ5 dye. Right panels: cellular uptake visualized by overlaying images (20Ã magnification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01571/20160603/images/large/jm-2015-015716_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01571&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58575" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58575" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ryan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span> </span><span class="NLM_article-title">Pancreatic adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1049</span><span class="refDoi">Â DOI: 10.1056/NEJMra1404198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMra1404198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25207767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Olt7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1039-1049&author=D.+P.+Ryanauthor=T.+S.+Hongauthor=N.+Bardeesy&title=Pancreatic+adenocarcinoma&doi=10.1056%2FNEJMra1404198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic adenocarcinoma</span></div><div class="casAuthors">Ryan, David P.; Hong, Theodore S.; Bardeesy, Nabeel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1049, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1-TPh2I8RbVg90H21EOLACvtfcHk0liw9nOgtFaYzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Olt7rK&md5=c916814b3ce1e14f3a93b9a0b05cd286</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1404198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1404198%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DD.%2BP.%26aulast%3DHong%26aufirst%3DT.%2BS.%26aulast%3DBardeesy%26aufirst%3DN.%26atitle%3DPancreatic%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1039%26epage%3D1049%26doi%3D10.1056%2FNEJMra1404198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics, <b>2016</b></span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">â</span> <span class="NLM_lpage">30</span><span class="refDoi">Â DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2ebFeialAYJ4c7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Malvezzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertuccio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Vecchia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, E.</span><span> </span><span class="NLM_article-title">European cancer mortality predictions for the year 2014</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1650</span><span class="NLM_x">â</span> <span class="NLM_lpage">1656</span><span class="refDoi">Â DOI: 10.1093/annonc/mdu138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1093%2Fannonc%2Fmdu138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24759568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC2cnmtFCmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1650-1656&author=M.+Malvezziauthor=P.+Bertuccioauthor=F.+Leviauthor=C.+La+Vecchiaauthor=E.+Negri&title=European+cancer+mortality+predictions+for+the+year+2014&doi=10.1093%2Fannonc%2Fmdu138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">European cancer mortality predictions for the year 2014</span></div><div class="casAuthors">Malvezzi M; Bertuccio P; Negri E; Levi F; La Vecchia C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1650-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  From most recent available data, we projected cancer mortality statistics for 2014, for the European Union (EU) and its six more populous countries.  Specific attention was given to pancreatic cancer, the only major neoplasm showing unfavorable trends in both sexes.  PATIENTS AND METHODS:  Population and death certification data from stomach, colorectum, pancreas, lung, breast, uterus, prostate, leukemias and total cancers were obtained from the World Health Organisation database and Eurostat.  Figures were derived for the EU, France, Germany, Italy, Poland, Spain and the UK.  Projected 2014 numbers of deaths by age group were obtained by linear regression on estimated numbers of deaths over the most recent time period identified by a joinpoint regression model.  RESULTS:  In the EU in 2014, 1,323,600 deaths from cancer are predicted (742,500 men and 581,100 women), corresponding to standardized death rates of 138.1/100,000 men and 84.7/100,000 women, falling by 7% and 5%, respectively, since 2009.  In men, predicted rates for the three major cancers (lung, colorectum and prostate cancer) are lower than in 2009, falling by 8%, 4% and 10%, respectively.  In women, breast and colorectal cancers had favorable trends (-9% and -7%), but female lung cancer rates are predicted to rise 8%.  Pancreatic cancer is the only neoplasm with a negative outlook in both sexes.  Only in the young (25-49 years), EU trends become more favorable in men, while women keep registering slight predicted rises.  CONCLUSIONS:  Cancer mortality predictions for 2014 confirm the overall favorable cancer mortality trend in the EU, translating to an overall 26% fall in men since its peak in 1988, and 20% in women, and the avoidance of over 250,000 deaths in 2014 compared with the peak rate.  Notable exceptions are female lung cancer and pancreatic cancer in both sexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS98DOyzhftHXwOGIfWJ7-GfW6udTcc2eYRIhxgLeZ5trntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnmtFCmsw%253D%253D&md5=088023e13e2ca45a7ee20668d8031f80</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu138%26sid%3Dliteratum%253Aachs%26aulast%3DMalvezzi%26aufirst%3DM.%26aulast%3DBertuccio%26aufirst%3DP.%26aulast%3DLevi%26aufirst%3DF.%26aulast%3DLa%2BVecchia%26aufirst%3DC.%26aulast%3DNegri%26aufirst%3DE.%26atitle%3DEuropean%2520cancer%2520mortality%2520predictions%2520for%2520the%2520year%25202014%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1650%26epage%3D1656%26doi%3D10.1093%2Fannonc%2Fmdu138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">New insights into pancreatic cancer biology</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">x135</span><span class="NLM_x">â</span> <span class="NLM_lpage">x138</span><span class="refDoi">Â DOI: 10.1093/annonc/mds313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1093%2Fannonc%2Fmds313" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=x135-x138&author=M.+Hidalgo&title=New+insights+into+pancreatic+cancer+biology&doi=10.1093%2Fannonc%2Fmds313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds313%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DNew%2520insights%2520into%2520pancreatic%2520cancer%2520biology%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3Dx135%26epage%3Dx138%26doi%3D10.1093%2Fannonc%2Fmds313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Pancreatic cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">â</span> <span class="NLM_lpage">1617</span><span class="refDoi">Â DOI: 10.1056/NEJMra0901557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMra0901557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20427809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsV2ns7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=1605-1617&author=M.+Hidalgo&title=Pancreatic+cancer&doi=10.1056%2FNEJMra0901557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic cancer</span></div><div class="casAuthors">Hidalgo, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1605-1617</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on a recent progress in understanding and management of pancreatic cancer.  Topics included are the biol. of pancreatic cancer, clin. presentation, diagnosis, staging, and management of early and advanced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSTq-bB-IhrVg90H21EOLACvtfcHk0li6Rx9KuEvLqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsV2ns7o%253D&md5=3663d7b19672fa1d11aef6640c0bb4e9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0901557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0901557%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DPancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D1605%26epage%3D1617%26doi%3D10.1056%2FNEJMra0901557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Conroy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desseigne, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ychou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimbaud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becouarn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raoul, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourgou-Bourgade, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Fouchardiere, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachet, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khemissa-Akouz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pere-Verge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assenat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauffert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montoto-Grillot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducreux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groupe Tumeurs Digestives of, U.; Intergroup, P.</span><span> </span><span class="NLM_article-title">FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1817</span><span class="NLM_x">â</span> <span class="NLM_lpage">1825</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1011923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMoa1011923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21561347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvF2jsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1817-1825&author=T.+Conroyauthor=F.+Desseigneauthor=M.+Ychouauthor=O.+Boucheauthor=R.+Guimbaudauthor=Y.+Becouarnauthor=A.+Adenisauthor=J.+L.+Raoulauthor=S.+Gourgou-Bourgadeauthor=C.+de+la+Fouchardiereauthor=J.+Bennounaauthor=J.+B.+Bachetauthor=F.+Khemissa-Akouzauthor=D.+Pere-Vergeauthor=C.+Delbaldoauthor=E.+Assenatauthor=B.+Chauffertauthor=P.+Michelauthor=C.+Montoto-Grillotauthor=M.+Ducreuxauthor=Groupe+Tumeurs+Digestives+of%2C+U.%3B+Intergroup%2C+P.&title=FOLFIRINOX+versus+gemcitabine+for+metastatic+pancreatic+cancer&doi=10.1056%2FNEJMoa1011923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">FOLFIRINOX versus gemcitabine or metastatic pancreatic cancer</span></div><div class="casAuthors">Conroy, Thierry; Desseigne, Francoise; Ychou, Marc; Bouche, Olivier; Guimbaud, Rosine; Becouarn, Yves; Adenis, Antoine; Raoul, Jean-Luc; Gourgou-Bourgade, Sophie; de la Fouchardiere, Christelle; Bennouna, Jaafar; Bachet, Jean-Baptiste; Khemissa-Akouz, Faiza; Pere-Verge, Denis; Delbaldo, Catherine; Assenat, Eric; Chauffert, Bruno; Michel, Pierre; Montoto-Grillot, Christine; Ducreux, Michel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1817-1825</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.  METHODS We randomly assigned 342 patients with an Eastern Cooperative Oncol. Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-h continuous infusion, every 2 wk) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 wk and then weekly for 3 of 4 wk.  Six months of chemotherapy were recommended in both groups in patients who had a response.  The primary end point was overall survival.  RESULTS The median overall survival was 11.1 mo in the FOLFIRINOX group as compared with 6.8 mo in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P < 0.001).  Median progression-free survival was 6.4 mo in the FOLFIRINOX group and 3.3 mo in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P < 0.001).  The objective response rate was 31.60% in the FOLFIRINOX group vs. 9.4% in the gemcitabine group (P < 0.001).  More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia.  At 6 mo, 31% of the patients in the FOLFIRINOX group had a definitive degrdn. of the quality of life vs. 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P < 0.001).  CONCLUSIONS As compared with gemcitabine, FOLFIRINOX was assocd. with a survival advantage and had increased toxicity.  FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGyDR85GUgOrVg90H21EOLACvtfcHk0lhNqtixEvnd1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvF2jsrw%253D&md5=a1a7135a6c97c4dc47233465ce0defd5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1011923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1011923%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DDesseigne%26aufirst%3DF.%26aulast%3DYchou%26aufirst%3DM.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DGuimbaud%26aufirst%3DR.%26aulast%3DBecouarn%26aufirst%3DY.%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DRaoul%26aufirst%3DJ.%2BL.%26aulast%3DGourgou-Bourgade%26aufirst%3DS.%26aulast%3Dde%2Bla%2BFouchardiere%26aufirst%3DC.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DBachet%26aufirst%3DJ.%2BB.%26aulast%3DKhemissa-Akouz%26aufirst%3DF.%26aulast%3DPere-Verge%26aufirst%3DD.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DAssenat%26aufirst%3DE.%26aulast%3DChauffert%26aufirst%3DB.%26aulast%3DMichel%26aufirst%3DP.%26aulast%3DMontoto-Grillot%26aufirst%3DC.%26aulast%3DDucreux%26aufirst%3DM.%26aulast%3D%26atitle%3DFOLFIRINOX%2520versus%2520gemcitabine%2520for%2520metastatic%2520pancreatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1817%26epage%3D1825%26doi%3D10.1056%2FNEJMoa1011923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Di Marco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cicilia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobili, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchiarelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasco, G.</span><span> </span><span class="NLM_article-title">Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review)</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1183</span><span class="NLM_x">â</span> <span class="NLM_lpage">1192</span><span class="refDoi">Â DOI: 10.3892/or_00000749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.3892%2For_00000749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20372829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVKhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1183-1192&author=M.+Di+Marcoauthor=R.+Di+Ciciliaauthor=M.+Macchiniauthor=E.+Nobiliauthor=S.+Vecchiarelliauthor=G.+Brandiauthor=G.+Biasco&title=Metastatic+pancreatic+cancer%3A+is+gemcitabine+still+the+best+standard+treatment%3F+%28Review%29&doi=10.3892%2For_00000749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (review)</span></div><div class="casAuthors">Di Marco, MariaCristina; Di Cicilia, Roberto; Macchini, Marina; Nobili, Elisabetta; Vecchiarelli, Silvia; Brandi, Giovanni; Biasco, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1183-1192</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">A review.  Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world.  Surgery remains the only treatment offering an advantage in terms of overall survival (5-yr survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis.  Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life.  Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved.  Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients.  This study examines the principal clin. trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPtsYDEHN5LVg90H21EOLACvtfcHk0lhNqtixEvnd1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVKhs7s%253D&md5=ae09fcaa5c1559646c184cb114ba7577</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3892%2For_00000749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For_00000749%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DM.%26aulast%3DDi%2BCicilia%26aufirst%3DR.%26aulast%3DMacchini%26aufirst%3DM.%26aulast%3DNobili%26aufirst%3DE.%26aulast%3DVecchiarelli%26aufirst%3DS.%26aulast%3DBrandi%26aufirst%3DG.%26aulast%3DBiasco%26aufirst%3DG.%26atitle%3DMetastatic%2520pancreatic%2520cancer%253A%2520is%2520gemcitabine%2520still%2520the%2520best%2520standard%2520treatment%253F%2520%2528Review%2529%26jtitle%3DOncol.%2520Rep.%26date%3D2010%26volume%3D23%26spage%3D1183%26epage%3D1192%26doi%3D10.3892%2For_00000749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Von Hoff, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arena, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiorean, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjulandin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laheru, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglesias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renschler, M. F.</span><span> </span><span class="NLM_article-title">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1691</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1304369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1056%2FNEJMoa1304369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24131140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCjsb7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1691-1703&author=D.+D.+Von+Hoffauthor=T.+Ervinauthor=F.+P.+Arenaauthor=E.+G.+Chioreanauthor=J.+Infanteauthor=M.+Mooreauthor=T.+Seayauthor=S.+A.+Tjulandinauthor=W.+W.+Maauthor=M.+N.+Salehauthor=M.+Harrisauthor=M.+Reniauthor=S.+Dowdenauthor=D.+Laheruauthor=N.+Baharyauthor=R.+K.+Ramanathanauthor=J.+Taberneroauthor=M.+Hidalgoauthor=D.+Goldsteinauthor=E.+Van+Cutsemauthor=X.+Weiauthor=J.+Iglesiasauthor=M.+F.+Renschler&title=Increased+survival+in+pancreatic+cancer+with+nab-paclitaxel+plus+gemcitabine&doi=10.1056%2FNEJMoa1304369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</span></div><div class="casAuthors">Von Hoff, Daniel D.; Ervin, Thomas; Arena, Francis P.; Chiorean, E. Gabriela; Infante, Jeffrey; Moore, Malcolm; Seay, Thomas; Tjulandin, Sergei A.; Ma, Wen Wee; Saleh, Mansoor N.; Harris, Marion; Reni, Michele; Dowden, Scot; Laheru, Daniel; Bahary, Nathan; Ramanathan, Ramesh K.; Tabernero, Josep; Hidalgo, Manuel; Goldstein, David; Van Cutsem, Eric; Wei, Xinyu; Iglesias, Jose; Renschler, Markus F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clin. activity was noted in patients with advanced pancreatic cancer.  We conducted a phase 3 study of the efficacy and safety of the combination vs. gemcitabine monotherapy in patients with metastatic pancreatic cancer.  METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 wk or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 wk (cycle 1) and then on days 1, 8, and 15 every 4 wk (cycle 2 and subsequent cycles).  Patients received the study treatment until disease progression.  The primary end point was overall survival; secondary end points were progression-free survival and overall response rate.  RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430).  The median overall survival was 8.5 mo in the nab-paclitaxel-gemcitabine group as compared with 6.7 mo in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001).  The survival rate was 35% in the nab-paclitaxel-gemcitabine group vs. 22% in the gemcitabine group at 1 yr, and 9% vs. 4% at 2 years.  The median progression-free survival was 5.5 mo in the nab-paclitaxel-gemcitabine group, as compared with 3.7 mo in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% vs. 7% in the two groups (P<0.001).  The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%).  Febrile neutropenia occurred in 3% vs. 1% of the patients in the two groups.  In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days.  CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCXpODbQZ6dLVg90H21EOLACvtfcHk0ljKr-TrpqcMHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCjsb7I&md5=b1169c7e9879c08061dd9e9389dc36fe</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1304369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1304369%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DArena%26aufirst%3DF.%2BP.%26aulast%3DChiorean%26aufirst%3DE.%2BG.%26aulast%3DInfante%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DM.%26aulast%3DSeay%26aufirst%3DT.%26aulast%3DTjulandin%26aufirst%3DS.%2BA.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DSaleh%26aufirst%3DM.%2BN.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DReni%26aufirst%3DM.%26aulast%3DDowden%26aufirst%3DS.%26aulast%3DLaheru%26aufirst%3DD.%26aulast%3DBahary%26aufirst%3DN.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DGoldstein%26aufirst%3DD.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DIglesias%26aufirst%3DJ.%26aulast%3DRenschler%26aufirst%3DM.%2BF.%26atitle%3DIncreased%2520survival%2520in%2520pancreatic%2520cancer%2520with%2520nab-paclitaxel%2520plus%2520gemcitabine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1304369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Srinivasarao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliford, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">219</span><span class="refDoi">Â DOI: 10.1038/nrd4519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+design+of+ligand-targeted+cancer+therapeutics+and+imaging+agents&doi=10.1038%2Fnrd4519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0ljKr-TrpqcMHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520design%2520of%2520ligand-targeted%2520cancer%2520therapeutics%2520and%2520imaging%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D203%26epage%3D219%26doi%3D10.1038%2Fnrd4519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">Active targeting schemes for nanoparticle systems in cancer therapeutics</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">â</span> <span class="NLM_lpage">1626</span><span class="refDoi">Â DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+targeting+schemes+for+nanoparticle+systems+in+cancer+therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0lgugDzt0exXvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520targeting%2520schemes%2520for%2520nanoparticle%2520systems%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennink, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, G.</span><span> </span><span class="NLM_article-title">Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">187</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2011.09.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.jconrel.2011.09.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21945285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2012&pages=175-187&author=T.+Lammersauthor=F.+Kiesslingauthor=W.+E.+Henninkauthor=G.+Storm&title=Drug+targeting+to+tumors%3A+principles%2C+pitfalls+and+%28pre-%29+clinical+progress&doi=10.1016%2Fj.jconrel.2011.09.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress</span></div><div class="casAuthors">Lammers, Twan; Kiessling, Fabian; Hennink, Wim E.; Storm, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many different systems and strategies were evaluated for drug targeting to tumors over the years.  Routinely used systems include liposomes, polymers, micelles, nanoparticles and antibodies, and examples of strategies are passive drug targeting, active drug targeting to cancer cells, active drug targeting to endothelial cells and triggered drug delivery.  Significant progress was made in this area of research both at the preclin. and at the clin. level, and a no. of (primarily passively tumor-targeted) nanomedicine formulations were approved for clin. use.  Significant progress was also made with regard to better understanding the (patho-) physiol. principles of drug targeting to tumors.  This has led to the identification of several important pitfalls in tumor-targeted drug delivery, including (I) overinterpretation of the EPR effect; (II) poor tumor and tissue penetration of nanomedicines; (III) misunderstanding of the potential usefulness of active drug targeting; (IV) irrational formulation design, based on materials which are too complex and not broadly applicable; (V) insufficient incorporation of nanomedicine formulations in clin. relevant combination regimens; (VI) negligence of the notion that the highest medical need relates to metastasis, and not to solid tumor treatment; (VII) insufficient integration of non-invasive imaging techniques and theranostics, which could be used to personalize nanomedicine-based therapeutic interventions; and (VIII) lack of (efficacy analyses in) proper animal models, which are physiol. more relevant and more predictive for the clin. situation.  These insights strongly suggest that besides making ever more nanomedicine formulations, future efforts should also address some of the conceptual drawbacks of drug targeting to tumors, and that strategies should be developed to overcome these shortcomings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVzCGIHDCrMbVg90H21EOLACvtfcHk0lgugDzt0exXvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtbY%253D&md5=b2f501f088ef8b19a6fbe7ee2290ab69</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.09.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.09.063%26sid%3Dliteratum%253Aachs%26aulast%3DLammers%26aufirst%3DT.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DHennink%26aufirst%3DW.%2BE.%26aulast%3DStorm%26aufirst%3DG.%26atitle%3DDrug%2520targeting%2520to%2520tumors%253A%2520principles%252C%2520pitfalls%2520and%2520%2528pre-%2529%2520clinical%2520progress%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D161%26spage%3D175%26epage%3D187%26doi%3D10.1016%2Fj.jconrel.2011.09.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrettini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taheri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1840</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">â</span> <span class="NLM_lpage">343</span><span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.bbagen.2013.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23954204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOls77E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=332-343&author=D.+Pathaniaauthor=M.+Sechiauthor=M.+Palombaauthor=V.+Sannaauthor=F.+Berrettiniauthor=A.+Siasauthor=L.+Taheriauthor=N.+Neamati&title=Design+and+discovery+of+novel+quinazolinedione-based+redox+modulators+as+therapies+for+pancreatic+cancer&doi=10.1016%2Fj.bbagen.2013.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer</span></div><div class="casAuthors">Pathania, Divya; Sechi, Mario; Palomba, Michele; Sanna, Vanna; Berrettini, Francesco; Sias, Angela; Taheri, Laleh; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">332-343</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Altered cellular bioenergetics and oxidative stress are emerging hallmarks of most cancers including pancreatic cancer.  Elevated levels of intrinsic reactive oxygen species (ROS) in tumors make them more susceptible to exogenously induced oxidative stress.  Excessive oxidative insults overwhelm their adaptive antioxidant capacity and trigger ROS-mediated cell death.  Recently, we have discovered a novel class of quinazolinediones that exert their cytotoxic effects by modulating ROS-mediated signaling.  Cytotoxic potential was detd. by colorimetric and colony formation assays.  An XF24 Extracellular Flux Analyzer, and colorimetric and fluorescent techniques were used to assess the bioenergetics and oxidative stress effects, resp.  Mechanism was detd. by Western blots.  Compd. 3a (6-[(2-acetylphenyl)amino]quinazoline-5,8-dione) was identified through a medium throughput screen of â¼ 1000 highly diverse inhouse compds. and chemotherapeutic agents for their ability to alter cellular bioenergetics.  Further structural optimizations led to the discovery of a more potent analog, 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) that displayed anti-proliferative activities in low micromolar range in both drug-sensitive and drug-resistant cancer cells.  Treatment with 3b causes Akt activation resulting in increased cellular oxygen consumption and oxidative stress in pancreatic cancer cells.  Moreover, oxidative stress induced by 3b promoted activation of stress kinases (p38/JNK) resulting in cancer cell death.  Treatment with antioxidants was able to reduce cell death confirming ROS-mediated cytotoxicity.  In conclusion, our novel quinazolinediones are promising lead compds. that selectively induce ROS-mediated cell death in cancer cells and warrant further preclin. studies.  Since 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) exerts Akt-dependent ROS-mediated cell death, it might provide potential therapeutic options for chemoresistant and Akt-overexpressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtv5xHFya9e7Vg90H21EOLACvtfcHk0lgugDzt0exXvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOls77E&md5=cbbcaca46c9dab2968538df71746ee0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DPalomba%26aufirst%3DM.%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DBerrettini%26aufirst%3DF.%26aulast%3DSias%26aufirst%3DA.%26aulast%3DTaheri%26aufirst%3DL.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DDesign%2520and%2520discovery%2520of%2520novel%2520quinazolinedione-based%2520redox%2520modulators%2520as%2520therapies%2520for%2520pancreatic%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26spage%3D332%26epage%3D343%26doi%3D10.1016%2Fj.bbagen.2013.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">â</span> <span class="NLM_lpage">63</span><span class="refDoi">Â DOI: 10.1111/bph.12855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1111%2Fbph.12855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=25047070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=50-63&author=D.+Pathaniaauthor=Y.+Kuangauthor=M.+Sechiauthor=N.+Neamati&title=Mechanisms+underlying+the+cytotoxicity+of+a+novel+quinazolinedione-based+redox+modulator%2C+QD232%2C+in+pancreatic+cancer+cells&doi=10.1111%2Fbph.12855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells</span></div><div class="casAuthors">Pathania, Divya; Kuang, Yuting; Sechi, Mario; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pancreatic cancer is characterized by alterations in several key signalling proteins, including increased expression and activity of the Src tyrosine kinase and focal adhesion kinase (FAK), which have been linked to its chemoresistance.  Sustained Src inhibition reactivates survival pathways regulated by the transcription factor STAT3, also leading to resistance.  Therefore, simultaneously targeting Src/FAK and STAT3 signalling could provide an important strategy for treating pancreatic cancer.  Recently, we described novel quinazolinediones that increased generation of reactive oxygen species (ROS) and were cytotoxic in pancreatic cancer cells.  Here, we have investigated effects of our lead compd., QD232, on Src/FAK and STAT3 signalling.  Exptl. Approach : The major signalling pathways affected by QD232 in pancreatic cancer cell lines were identified by Kinexus proteomic anal.  Changes in key signalling proteins were confirmed by Western blotting.  Cell migration was assessed by Boyden chamber and wound healing assays.  Direct inhibition of kinase activity in vitro was assayed with a panel of 92 oncogenic kinases.  Safety and efficacy of QD232 were detd. in a xenograft mouse model of pancreatic cancer.  Key Results : QD232 potently inhibited Src/FAK and STAT3 phosphorylation, decreasing pancreatic cancer cell viability and migration.  Furthermore, QD232 arrested cell cycle progression and induced apoptosis in these cells at low micromolar concns.  Effects of QD232 on Src/FAK and STAT3 phosphorylation were blocked by N-acetylcysteine or glutathione.  Conclusions and Implications : QD232 is a novel compd. with a unique, ROS-dependent mechanism, effective in drug-resistant cancer cell lines.  This compd. shows potential as therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT3-x-z_lL3rVg90H21EOLACvtfcHk0lh8VRI-_MYCfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLvK&md5=6471c264193699d9d78bd0f2c596008b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fbph.12855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12855%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DMechanisms%2520underlying%2520the%2520cytotoxicity%2520of%2520a%2520novel%2520quinazolinedione-based%2520redox%2520modulator%252C%2520QD232%252C%2520in%2520pancreatic%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D50%26epage%3D63%26doi%3D10.1111%2Fbph.12855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">â</span> <span class="NLM_lpage">674</span><span class="refDoi">Â DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lh8VRI-_MYCfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pathania, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neamati, N.</span><span> </span><span class="NLM_article-title">Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1250</span><span class="NLM_x">â</span> <span class="NLM_lpage">1275</span><span class="refDoi">Â DOI: 10.1016/j.addr.2009.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2009.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19716393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWmu7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1250-1275&author=D.+Pathaniaauthor=M.+Millardauthor=N.+Neamati&title=Opportunities+in+discovery+and+delivery+of+anticancer+drugs+targeting+mitochondria+and+cancer+cell+metabolism&doi=10.1016%2Fj.addr.2009.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism</span></div><div class="casAuthors">Pathania, Divya; Millard, Melissa; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1250-1275</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cancer cells are characterized by self-sufficiency in the absence of growth signals, their ability to evade apoptosis, resistance to anti-growth signals, sustained angiogenesis, uncontrolled proliferation, and invasion and metastasis.  Alterations in cellular bioenergetics are an emerging hallmark of cancer.  The mitochondrion is the major organelle implicated in the cellular bioenergetic and biosynthetic changes accompanying cancer.  These bioenergetic modifications contribute to the invasive, metastatic and adaptive properties typical in most tumors.  Moreover, mitochondrial DNA mutations complement the bioenergetic changes in cancer.  Several cancer management therapies have been proposed that target tumor cell metab. and mitochondria.  Glycolytic inhibitors serve as a classical example of cancer metab. targeting agents.  Several TCA cycle and OXPHOS inhibitors are being tested for their anticancer potential.  Moreover, agents targeting the PDC/PDK (pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase) interaction are being studied for reversal of Warburg effect.  Targeting of the apoptotic regulatory machinery of mitochondria is another potential anticancer field in need of exploration.  Addnl., oxidative phosphorylation uncouplers, potassium channel modulators, and mitochondrial redox are under investigation for their anticancer potential.  To this end there is an increased demand for agents that specifically hit their target.  Delocalized lipophilic cations have shown tremendous potential in delivering anticancer agents selectively to tumor cells.  This review provides an overview of the potential anticancer agents that act by targeting cancer cell metab. and mitochondria, and also brings us face to face with the emerging opportunities in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUD_gbQnpA7Vg90H21EOLACvtfcHk0li4e9GqxC8A2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWmu7nI&md5=b9d407cf595c188ada0e9f71cf17bd24</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2009.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2009.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DMillard%26aufirst%3DM.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DOpportunities%2520in%2520discovery%2520and%2520delivery%2520of%2520anticancer%2520drugs%2520targeting%2520mitochondria%2520and%2520cancer%2520cell%2520metabolism%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D1250%26epage%3D1275%26doi%3D10.1016%2Fj.addr.2009.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Storz, P.</span><span> </span><span class="NLM_article-title">Reactive oxygen species in tumor progression</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="NLM_x">â</span> <span class="NLM_lpage">1896</span><span class="refDoi">Â DOI: 10.2741/1667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2741%2F1667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=15769673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVygsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1881-1896&author=P.+Storz&title=Reactive+oxygen+species+in+tumor+progression&doi=10.2741%2F1667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive oxygen species in tumor progression</span></div><div class="casAuthors">Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1881-1896</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  The generation of reactive oxygen radicals in mammalian cells profoundly affects numerous crit. cellular functions, and the absence of efficient cellular detoxification mechanisms which remove these radicals can result in several human diseases.  Growing evidence suggests that reactive oxygen species (ROS) within cells act as second messengers in intracellular signaling cascades which induce and maintain the oncogenic phenotype of cancer cells.  ROS are tumorigenic by virtue of their ability to increase cell proliferation, survival, cellular migration, and also by inducing DNA damage leading to genetic lesions that initiate tumorigenicity and sustain subsequent tumor progression.  However, it is also known that ROS can induce cellular senescence and cell death and can therefore function as anti-tumorigenic agents.  Therefore, the mechanisms by which cells respond to reactive oxygen species depends on the mol. background of cell and tissues, the location of ROS prodn. and the concn. of individual ROS species.  Carcinoma cells produce ROS at elevated rates in vitro, and in vivo many tumors appear persistent to oxidative stress.  Thus, the finding that a diet rich in antioxidants or the elimination of ROS by antioxidant compds. prevents the development of certain cancers provided the setting for subsequent investigation of the tumorigenic actions of reactive oxygen species.  This review outlines the current knowledge on the various roles of ROS in tumor development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUvdFCyy2MXLVg90H21EOLACvtfcHk0li4e9GqxC8A2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVygsbw%253D&md5=0cdf71e6b16a45d706ed441c4f93b4ec</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2741%2F1667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F1667%26sid%3Dliteratum%253Aachs%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DReactive%2520oxygen%2520species%2520in%2520tumor%2520progression%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2005%26volume%3D10%26spage%3D1881%26epage%3D1896%26doi%3D10.2741%2F1667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shackelford, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paules, R. S.</span><span> </span><span class="NLM_article-title">Oxidative stress and cell cycle checkpoint function</span> <span class="citation_source-journal">Free Radical Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">â</span> <span class="NLM_lpage">1404</span><span class="refDoi">Â DOI: 10.1016/S0891-5849(00)00224-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0891-5849%2800%2900224-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10924858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlWgtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1387-1404&author=R.+E.+Shackelfordauthor=W.+K.+Kaufmannauthor=R.+S.+Paules&title=Oxidative+stress+and+cell+cycle+checkpoint+function&doi=10.1016%2FS0891-5849%2800%2900224-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and cell cycle checkpoint function</span></div><div class="casAuthors">Shackelford, R. E.; Kaufmann, W. K.; Paules, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1387-1404</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review is given with 275 refs. on biol. important reactive O species (ROS) and their sources, the cell cycle, checkpoints, and current knowledge about the effects of ROS on initiating checkpoint responses.  Oxidative stress and the damage that results from it were implicated in a wide no. of disease processes including atherosclerosis, autoimmune disorders, neuronal degeneration, and cancer.  ROS are ubiquitous and occur naturally in all aerobic species, coming from both exogenous and endogenous sources.  ROS are quite reactive and readily damage biol. mols., including DNA.  While the damaging effects of ROS on DNA were intensively studied, the effects of oxidative damage on cell cycle checkpoint function have not.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPLFMHhEUiLVg90H21EOLACvtfcHk0li4e9GqxC8A2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlWgtb0%253D&md5=9eed0a63dfd7eddc36f2fbf6510d44e6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0891-5849%2800%2900224-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0891-5849%252800%252900224-0%26sid%3Dliteratum%253Aachs%26aulast%3DShackelford%26aufirst%3DR.%2BE.%26aulast%3DKaufmann%26aufirst%3DW.%2BK.%26aulast%3DPaules%26aufirst%3DR.%2BS.%26atitle%3DOxidative%2520stress%2520and%2520cell%2520cycle%2520checkpoint%2520function%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2000%26volume%3D28%26spage%3D1387%26epage%3D1404%26doi%3D10.1016%2FS0891-5849%2800%2900224-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Trachootham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span> </span><span class="NLM_article-title">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">591</span><span class="refDoi">Â DOI: 10.1038/nrd2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19478820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=579-591&author=D.+Trachoothamauthor=J.+Alexandreauthor=P.+Huang&title=Targeting+cancer+cells+by+ROS-mediated+mechanisms%3A+a+radical+therapeutic+approach%3F&doi=10.1038%2Fnrd2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span></div><div class="casAuthors">Trachootham, Dunyaporn; Alexandre, Jerome; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-591</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increased generation of reactive oxygen species (ROS) and an altered redox status have long been obsd. in cancer cells, and recent studies suggest that this biochem. property of cancer cells can be exploited for therapeutic benefits.  Cancer cells in advanced stage tumors frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacol. ROS insults.  However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance.  Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications.  We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobgIa2fgBPBrVg90H21EOLACvtfcHk0liKTvH-EOsbbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D&md5=d50931b8de8bcab62d376becc768a71c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2803%26sid%3Dliteratum%253Aachs%26aulast%3DTrachootham%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DTargeting%2520cancer%2520cells%2520by%2520ROS-mediated%2520mechanisms%253A%2520a%2520radical%2520therapeutic%2520approach%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D579%26epage%3D591%26doi%3D10.1038%2Fnrd2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintus, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punzoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadino, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marceddu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzzau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Targeted biocompatible nanoparticles for the delivery of (â)-epigallocatechin 3-gallate to prostate cancer cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1321</span><span class="NLM_x">â</span> <span class="NLM_lpage">1332</span><span class="refDoi">Â DOI: 10.1021/jm1013715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1321-1332&author=V.+Sannaauthor=G.+P.+Pintusauthor=A.+M.+Roggioauthor=S.+Punzoniauthor=A.+M.+Posadinoauthor=A.+Arcaauthor=S.+Marcedduauthor=P.+Bandieraauthor=S.+Uzzauauthor=M.+Sechi&title=Targeted+biocompatible+nanoparticles+for+the+delivery+of+%28%E2%88%92%29-epigallocatechin+3-gallate+to+prostate+cancer+cells&doi=10.1021%2Fjm1013715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1013715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013715%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DPintus%26aufirst%3DG.%2BP.%26aulast%3DRoggio%26aufirst%3DA.%2BM.%26aulast%3DPunzoni%26aufirst%3DS.%26aulast%3DPosadino%26aufirst%3DA.%2BM.%26aulast%3DArca%26aufirst%3DA.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DBandiera%26aufirst%3DP.%26aulast%3DUzzau%26aufirst%3DS.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520biocompatible%2520nanoparticles%2520for%2520the%2520delivery%2520of%2520%2528%25E2%2588%2592%2529-epigallocatechin%25203-gallate%2520to%2520prostate%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1321%26epage%3D1332%26doi%3D10.1021%2Fjm1013715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Davis, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span> </span><span class="NLM_article-title">Nanoparticle therapeutics: an emerging treatment modality for cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span><span class="refDoi">Â DOI: 10.1038/nrd2614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrd2614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18758474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGgtL%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=771-782&author=M.+E.+Davisauthor=Z.+G.+Chenauthor=D.+M.+Shin&title=Nanoparticle+therapeutics%3A+an+emerging+treatment+modality+for+cancer&doi=10.1038%2Fnrd2614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle therapeutics: an emerging treatment modality for cancer</span></div><div class="casAuthors">Davis, Mark E.; Chen, Zhuo; Shin, Dong M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">771-782</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several nanoscaled systems for cancer therapy are approved or in clin. trials.  Here, Davis and colleagues discuss the key properties of nanotherapeutics for cancer, summarize clin. findings with first- and second-generation nanoparticles, and discuss the issues involved in translating exptl. nanotherapeutics to the clinic.  Nanoparticles - particles in the size range 1-100 nm - are emerging as a class of therapeutics for cancer.  Early clin. results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake.  Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities.  While large nos. of preclin. studies have been published, the emphasis here is placed on preclin. and clin. studies that are likely to affect clin. investigations and their implications for advancing the treatment of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPcHJcwgk8l7Vg90H21EOLACvtfcHk0liKTvH-EOsbbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGgtL%252FJ&md5=620da7abb91f82d2e0c5bd516e9d9e8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2614%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DShin%26aufirst%3DD.%2BM.%26atitle%3DNanoparticle%2520therapeutics%253A%2520an%2520emerging%2520treatment%2520modality%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D771%26epage%3D782%26doi%3D10.1038%2Fnrd2614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Peer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margalit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Nanocarriers as an emerging platform for cancer therapy</span> <span class="citation_source-journal">Nat. Nanotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">760</span><span class="refDoi">Â DOI: 10.1038/nnano.2007.387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnnano.2007.387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18654426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyktL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=751-760&author=D.+Peerauthor=J.+M.+Karpauthor=S.+Hongauthor=O.+C.+Farokhzadauthor=R.+Margalitauthor=R.+Langer&title=Nanocarriers+as+an+emerging+platform+for+cancer+therapy&doi=10.1038%2Fnnano.2007.387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers as an emerging platform for cancer therapy</span></div><div class="casAuthors">Peer, Dan; Karp, Jeffrey M.; Hong, Seungpyo; Farokhzad, Omid C.; Margalit, Rimona; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">751-760</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. has the potential to revolutionize cancer diagnosis and therapy.  Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients.  Several therapeutic nanocarriers were approved for clin. use.  However, to date, there are only a few clin. approved nanocarriers that incorporate mols. to selectively bind and target cancer cells.  This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic.  The authors detail the arsenal of nanocarriers and mols. available for selective tumor targeting, and emphasize the challenges in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSaHhszNVn2LVg90H21EOLACvtfcHk0liKTvH-EOsbbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyktL%252FI&md5=5f24033175e23e13d59e4a5b38753cad</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnnano.2007.387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnnano.2007.387%26sid%3Dliteratum%253Aachs%26aulast%3DPeer%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DMargalit%26aufirst%3DR.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DNanocarriers%2520as%2520an%2520emerging%2520platform%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2007%26volume%3D2%26spage%3D751%26epage%3D760%26doi%3D10.1038%2Fnnano.2007.387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Impact of nanotechnology on drug delivery</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">â</span> <span class="NLM_lpage">20</span><span class="refDoi">Â DOI: 10.1021/nn900002m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn900002m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFGisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=16-20&author=O.+C.+Farokhzadauthor=R.+Langer&title=Impact+of+nanotechnology+on+drug+delivery&doi=10.1021%2Fnn900002m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Nanotechnology on Drug Delivery</span></div><div class="casAuthors">Farokhzad, Omid C.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-20</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. is the engineering and manufg. of materials at the at. and mol. scale.  In its strictest definition from the National Nanotechnol. Initiative, nanotechnol. refers to structures roughly in the 1-100 nm size regime in at least one dimension.  Despite this size restriction, nanotechnol. commonly refers to structures that are up to several hundred nanometers in size and that are developed by top-down or bottom-up engineering of individual components.  Herein, we focus on the application of nanotechnol. to drug delivery and highlight several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYU9UEZANnYLVg90H21EOLACvtfcHk0lgMZDdEJCmYOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFGisQ%253D%253D&md5=092946aed00c4a9f740df6505b2e805c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fnn900002m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn900002m%26sid%3Dliteratum%253Aachs%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DImpact%2520of%2520nanotechnology%2520on%2520drug%2520delivery%26jtitle%3DACS%2520Nano%26date%3D2009%26volume%3D3%26spage%3D16%26epage%3D20%26doi%3D10.1021%2Fnn900002m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Nicolas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brambilla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couvreur, P.</span><span> </span><span class="NLM_article-title">Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">â</span> <span class="NLM_lpage">1235</span><span class="refDoi">Â DOI: 10.1039/C2CS35265F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1039%2FC2CS35265F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23238558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosV2gsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1147-1235&author=J.+Nicolasauthor=S.+Muraauthor=D.+Brambillaauthor=N.+Mackiewiczauthor=P.+Couvreur&title=Design%2C+functionalization+strategies+and+biomedical+applications+of+targeted+biodegradable%2Fbiocompatible+polymer-based+nanocarriers+for+drug+delivery&doi=10.1039%2FC2CS35265F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery</span></div><div class="casAuthors">Nicolas, Julien; Mura, Simona; Brambilla, Davide; Mackiewicz, Nicolas; Couvreur, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1147-1235</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Design and functionalization strategies for multifunctional nanocarriers (e.g., nanoparticles, micelles, polymersomes) based on biodegradable/biocompatible polymers intended to be employed for active targeting and drug delivery are reviewed.  This review will focus on the nature of the polymers involved in the prepn. of targeted nanocarriers, the synthesis methods to achieve the desired macromol. architecture, the selected coupling strategy, the choice of the homing mols. (vitamins, hormones, peptides, proteins, etc.), as well as the various strategies to display them at the surface of nanocarriers.  The resulting morphologies and the main colloidal features will be given as well as an overview of the biol. activities, with a special focus on the main in vivo achievements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb7as5d7CfKLVg90H21EOLACvtfcHk0lgMZDdEJCmYOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosV2gsQ%253D%253D&md5=70975cbcd347c244774cfc534cc00a4b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2FC2CS35265F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CS35265F%26sid%3Dliteratum%253Aachs%26aulast%3DNicolas%26aufirst%3DJ.%26aulast%3DMura%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DD.%26aulast%3DMackiewicz%26aufirst%3DN.%26aulast%3DCouvreur%26aufirst%3DP.%26atitle%3DDesign%252C%2520functionalization%2520strategies%2520and%2520biomedical%2520applications%2520of%2520targeted%2520biodegradable%252Fbiocompatible%2520polymer-based%2520nanocarriers%2520for%2520drug%2520delivery%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2013%26volume%3D42%26spage%3D1147%26epage%3D1235%26doi%3D10.1039%2FC2CS35265F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamaly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span><span class="refDoi">Â DOI: 10.1021/ar200054n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar200054n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvValtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=1123-1134&author=J.+Shiauthor=Z.+Xiaoauthor=N.+Kamalyauthor=O.+C.+Farokhzad&title=Self-assembled+targeted+nanoparticles%3A+evolution+of+technologies+and+bench+to+bedside+translation&doi=10.1021%2Far200054n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation</span></div><div class="casAuthors">Shi, Jinjun; Xiao, Zeyu; Kamaly, Nazila; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1123-1134</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoparticles (NPs) have become an important tool in many industries including healthcare.  The use of NPs for drug delivery and imaging has introduced exciting opportunities for the improvement of disease diagnosis and treatment.  Over the past two decades, several first-generation therapeutic NP products have entered the market.  Despite the lack of controlled release and mol. targeting properties in these products, they improved the therapeutic benefit of clin. validated drugs by enhancing drug tolerability and/or efficacy.  NP-based imaging agents have also improved the sensitivity and specificity of different diagnostic modalities.  The introduction of controlled-release properties and targeting ligands toward the development of next-generation NPs should enable the development of safer and more effective therapeutic NPs and facilitate their application in theranostic nanomedicine.  Targeted and controlled-release NPs can drastically alter the pharmacol. characteristics of their payload, including their pharmacokinetic and, in some cases, their pharmacodynamic properties.  As a result, these NPs can improve drug properties beyond what can be achieved through classic medicinal chem.  Despite their enormous potential, the translation of targeted NPs into clin. development has faced considerable challenges.  One significant problem has been the difficulty in developing targeted NPs with optimal biophysicochem. properties while using robust processes that facilitate scale-up and manufg.  Recently, efforts have focused on developing NPs through self-assembly or high-throughput processes to facilitate the development and screening of NPs with these distinct properties and the subsequent scale-up of their manuf.  We have also undertaken parallel efforts to integrate addnl. functionality within therapeutic and imaging NPs, including the ability to carry more than one payload, to respond to environmental triggers, and to provide real-time feedback.  In addn., novel targeting approaches are being developed to enhance the tissue-, cell-, or subcellular-specific delivery of NPs for a myriad of important diseases.  These include the selection of internalizing ligands for enhanced receptor-mediated NP uptake and the development of extracellular targeting ligands for vascular tissue accumulation of NPs.  In this Account, we primarily review the evolution of marketed NP technologies.  We also recount our efforts in the design and optimization of NPs for medical applications, which formed the foundation for the clin. translation of the first-in-man targeted and controlled-release NPs (BIND-014) for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD3GVCH7nem7Vg90H21EOLACvtfcHk0lgMZDdEJCmYOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvValtb0%253D&md5=247786da97b882db196826de1ede004c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Far200054n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far200054n%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DSelf-assembled%2520targeted%2520nanoparticles%253A%2520evolution%2520of%2520technologies%2520and%2520bench%2520to%2520bedside%2520translation%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2011%26volume%3D44%26spage%3D1123%26epage%3D1134%26doi%3D10.1021%2Far200054n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pala, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Targeted therapy using nanotechnology: focus on cancer</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">467</span><span class="NLM_x">â</span> <span class="NLM_lpage">483</span><span class="refDoi">Â DOI: 10.2147/IJN.S36654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2147%2FIJN.S36654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=24531078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12lsb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=V.+Sannaauthor=N.+Palaauthor=M.+Sechi&title=Targeted+therapy+using+nanotechnology%3A+focus+on+cancer&doi=10.2147%2FIJN.S36654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy using nanotechnology: focus on cancer</span></div><div class="casAuthors">Sanna, Vanna; Pala, Nicolino; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-483, 17</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in nanotechnol. and biotechnol. have contributed to the development of engineered nanoscale materials as innovative prototypes to be used for biomedical applications and optimized therapy.  Due to their unique features, including a large surface area, structural properties, and a long circulation time in blood compared with small mols., a plethora of nanomaterials has been developed, with the potential to revolutionize the diagnosis and treatment of several diseases, in particular by improving the sensitivity and recognition ability of imaging contrast agents and by selectively directing bioactive agents to biol. targets.  Focusing on cancer, promising nanoprototypes have been designed to overcome the lack of specificity of conventional chemotherapeutic agents, as well as for early detection of precancerous and malignant lesions.  However, several obstacles, including difficulty in achieving the optimal combination of physicochem. parameters for tumor targeting, evading particle clearance mechanisms, and controlling drug release, prevent the translation of nanomedicines into therapy.  In spite of this, recent efforts have been focused on developing functionalized nanoparticles for delivery of therapeutic agents to specific mol. targets overexpressed on different cancer cells.  In particular, the combination of targeted and controlled-release polymer nanotechnologies has resulted in a new programmable nanotherapeutic formulation of docetaxel, namely BIND-014, which recently entered Phase II clin. testing for patients with solid tumors.  BIND-014 has been developed to overcome the limitations facing delivery of nanoparticles to many neoplasms, and represents a validated example of targeted nanosystems with the optimal biophysicochem. properties needed for successful tumor eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqINXgpClbCz7Vg90H21EOLACvtfcHk0lgMZDdEJCmYOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12lsb%252FK&md5=89e099f88b74db9de2c4ff0f951306c1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2147%2FIJN.S36654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S36654%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DPala%26aufirst%3DN.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520therapy%2520using%2520nanotechnology%253A%2520focus%2520on%2520cancer%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.2147%2FIJN.S36654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">544</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span><span class="refDoi">Â DOI: 10.1007/978-1-59745-483-4_37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-1-59745-483-4_37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19488725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2009&pages=589-598&author=F.+Guauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation%2Fpreparation+of+functionalized+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1007%2F978-1-59745-483-4_37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Gu, Frank; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">Micro and Nano Technologies in Bioanalysis</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues.  Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles.  Here we describe the prepn. of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine RNA aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells.  We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo.  This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfC9f0Yuf8k7Vg90H21EOLACvtfcHk0lhENNWW2TdpPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D&md5=3dcd84c203b87965a94afd69c590004e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-483-4_37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-483-4_37%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%252Fpreparation%2520of%2520functionalized%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D544%26spage%3D589%26epage%3D598%26doi%3D10.1007%2F978-1-59745-483-4_37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Alexis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Nanoparticle technologies for cancer therapy</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">197</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.1007/978-3-642-00477-3_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-3-642-00477-3_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20217526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1Chsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2010&pages=55-86&author=F.+Alexisauthor=E.+M.+Pridgenauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Nanoparticle+technologies+for+cancer+therapy&doi=10.1007%2F978-3-642-00477-3_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle technologies for cancer therapy</span></div><div class="casAuthors">Alexis, Frank; Pridgen, Eric M.; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">Drug Delivery</span>),
    <span class="NLM_cas:pages">55-86</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Nanoparticles as drug delivery systems enable unique approaches for cancer treatment.  Over the last two decades, a large no. of nanoparticle delivery systems have been developed for cancer therapy, including org. and inorg. materials.  Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater no. of nanoparticle platforms are currently in the preclin. stages of development.  More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease.  In this chapter, we will review the available preclin. and clin. nanoparticle technol. platforms and their impact for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJARaLb7HsCrVg90H21EOLACvtfcHk0lhENNWW2TdpPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1Chsrs%253D&md5=42d99169ff1e1d31f5edd2f023fe71c1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00477-3_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00477-3_2%26sid%3Dliteratum%253Aachs%26aulast%3DAlexis%26aufirst%3DF.%26aulast%3DPridgen%26aufirst%3DE.%2BM.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DNanoparticle%2520technologies%2520for%2520cancer%2520therapy%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D197%26spage%3D55%26epage%3D86%26doi%3D10.1007%2F978-3-642-00477-3_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kamaly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valencia, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic-Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Targeted polymeric therapeutic nanoparticles: design, development and clinical translation</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2971</span><span class="NLM_x">â</span> <span class="NLM_lpage">3010</span><span class="refDoi">Â DOI: 10.1039/c2cs15344k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1039%2Fc2cs15344k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=22388185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Cks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=2971-3010&author=N.+Kamalyauthor=Z.+Xiaoauthor=P.+M.+Valenciaauthor=A.+F.+Radovic-Morenoauthor=O.+C.+Farokhzad&title=Targeted+polymeric+therapeutic+nanoparticles%3A+design%2C+development+and+clinical+translation&doi=10.1039%2Fc2cs15344k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polymeric therapeutic nanoparticles: design, development and clinical translation</span></div><div class="casAuthors">Kamaly, Nazila; Xiao, Zeyu; Valencia, Pedro M.; Radovic-Moreno, Aleksandar F.; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2971-3010</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Polymeric materials have been used in a range of pharmaceutical and biotechnol. products for more than 40 years.  These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopedic implants, macroscale and microscale drug delivery systems such as microparticles and wafers used as controlled drug release depots, to multifunctional nanoparticles (NPs) capable of targeting, and controlled release of therapeutic and diagnostic agents.  These newer generations of targeted and controlled release polymeric NPs are now engineered to navigate the complex in vivo environment, and incorporate functionalities for achieving target specificity, control of drug concn. and exposure kinetics at the tissue, cell, and subcellular levels.  Indeed this optimization of drug pharmacol. as aided by careful design of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to drug enhancements that are traditionally achieved by medicinal chem.  In this regard, polymeric NPs have the potential to result in a highly differentiated new class of therapeutics, distinct from the original active drugs used in their compn., and distinct from first generation NPs that largely facilitated drug formulation.  A greater flexibility in the design of drug mols. themselves may also be facilitated following their incorporation into NPs, as drug properties (soly., metab., plasma binding, biodistribution, target tissue accumulation) will no longer be constrained to the same extent by drug chem. compn., but also become in-part the function of the physicochem. properties of the NP.  The combination of optimally designed drugs with optimally engineered polymeric NPs opens up the possibility of improved clin. outcomes that may not be achievable with the administration of drugs in their conventional form.  In this crit. review, we aim to provide insights into the design and development of targeted polymeric NPs and to highlight the challenges assocd. with the engineering of this novel class of therapeutics, including considerations of NP design optimization, development and biophysicochem. properties.  Addnl., we highlight some recent examples from the literature, which demonstrate current trends and novel concepts in both the design and utility of targeted polymeric NPs (444 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh4tt5gwv2KbVg90H21EOLACvtfcHk0lhENNWW2TdpPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Cks7w%253D&md5=15ea25b2595c963c1f584e198c3594b5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1039%2Fc2cs15344k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2cs15344k%26sid%3Dliteratum%253Aachs%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DValencia%26aufirst%3DP.%2BM.%26aulast%3DRadovic-Moreno%26aufirst%3DA.%2BF.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DTargeted%2520polymeric%2520therapeutic%2520nanoparticles%253A%2520design%252C%2520development%2520and%2520clinical%2520translation%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D2971%26epage%3D3010%26doi%3D10.1039%2Fc2cs15344k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Siu, D.</span><span> </span><span class="NLM_article-title">Cancer therapy using tumor-associated antigens to reduce side effects</span> <span class="citation_source-journal">Clin. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">â</span> <span class="NLM_lpage">198</span><span class="refDoi">Â DOI: 10.1007/s10238-009-0047-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2Fs10238-009-0047-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19408102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotl2ks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=181-198&author=D.+Siu&title=Cancer+therapy+using+tumor-associated+antigens+to+reduce+side+effects&doi=10.1007%2Fs10238-009-0047-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy using tumor-associated antigens to reduce side effects</span></div><div class="casAuthors">Siu, David</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-198</span>CODEN:
                <span class="NLM_cas:coden">CEMLBA</span>;
        ISSN:<span class="NLM_cas:issn">1591-8890</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia Srl</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. antigens recently have become very popular in cancer therapy.  They can be targeted to reduce side effects of traditional cancer therapy.  In this review, ten promising tumor-assocd. antigens are being discussed in detail.  The characteristics of each one are being reviewed in detail.  Monoclonal antibodies attached to traditional anticancer agents can target a specific type of cancer cells thereby reducing the amt. of traditional anticancer agents reaching normal tissues.  This sort of cancer targeting can be a very attractive anticancer therapy because it substantially reduces the amt. of side effects normally caused by traditional anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5LcT0jKKm0LVg90H21EOLACvtfcHk0lhbBHgUx-fx3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotl2ks78%253D&md5=104533c423cb5c4c7f5f23a4cfb049a4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10238-009-0047-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10238-009-0047-z%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DD.%26atitle%3DCancer%2520therapy%2520using%2520tumor-associated%2520antigens%2520to%2520reduce%2520side%2520effects%26jtitle%3DClin.%2520Exp.%2520Med.%26date%3D2009%26volume%3D9%26spage%3D181%26epage%3D198%26doi%3D10.1007%2Fs10238-009-0047-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Steinbock, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiche, G.</span><span> </span><span class="NLM_article-title">Plectin: a cytolinker by design</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.1515/BC.1999.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1515%2FBC.1999.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=1999&pages=151-158&author=F.+A.+Steinbockauthor=G.+Wiche&title=Plectin%3A+a+cytolinker+by+design&doi=10.1515%2FBC.1999.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1515%2FBC.1999.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.1999.023%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbock%26aufirst%3DF.%2BA.%26aulast%3DWiche%26aufirst%3DG.%26atitle%3DPlectin%253A%2520a%2520cytolinker%2520by%2520design%26jtitle%3DBiol.%2520Chem.%26date%3D1999%26volume%3D380%26spage%3D151%26epage%3D158%26doi%3D10.1515%2FBC.1999.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bausch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-del, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warshaw, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thayer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. A.</span><span> </span><span class="NLM_article-title">Plectin-1 as a novel biomarker for pancreatic cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">â</span> <span class="NLM_lpage">309</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-0999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1158%2F1078-0432.CCR-10-0999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21098698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyqsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=302-309&author=D.+Bauschauthor=S.+Thomasauthor=M.+Mino-Kenudsonauthor=C.+C.+Fernandez-delauthor=T.+W.+Bauerauthor=M.+Williamsauthor=A.+L.+Warshawauthor=S.+P.+Thayerauthor=K.+A.+Kelly&title=Plectin-1+as+a+novel+biomarker+for+pancreatic+cancer&doi=10.1158%2F1078-0432.CCR-10-0999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Plectin-1 as a Novel Biomarker for Pancreatic Cancer</span></div><div class="casAuthors">Bausch, Dirk; Thomas, Stephanie; Mino-Kenudson, Mari; Fernandez-del, Castillo Carlos; Bauer, Todd W.; Williams, Mark; Warshaw, Andrew L.; Thayer, Sarah P.; Kelly, Kimberly A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-309</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We are in great need of specific biomarkers to detect pancreatic ductal adenocarcinoma (PDAC) at an early stage, ideally before invasion.  Plectin-1 (Plec1) was recently identified as one such biomarker.  However, its suitability as a specific biomarker for human pancreatic cancer, and its usability as an imaging target, remain to be assessed.  Specimens of human PDAC, chronic pancreatitis, and normal pancreata were evaluated by immunohistochem. and Western blot anal.  To validate Plec1 as an imaging target, Plec1-targeting peptides (tPTP) were used as a contrast agent for single photon emission computed tomog. in an orthotopic and liver metastasis murine model of PDAC.  Plec1 expression was noted to be pos. in all PDACs but neg. in benign tissues.  Plec1 expression increases during pancreatic carcinogenesis.  It was found to be misexpressed in only 0% to 3.85% of early PDAC precursor lesions (PanIN I/II) but in 60% of PanIN III lesions.  Plec1 expression was further noted to be retained in all metastatic foci assayed and clearly highlighted these metastatic deposits in lymph nodes, liver, and peritoneum.  In vivo imaging using tPTP specifically highlighted the primary and metastatic tumors.  Biodistribution studies performed after imaging show that the primary pancreatic tumors and liver metastases retained 1.9- to 2.9-fold of tPTP over normal pancreas and 1.7-fold over normal liver.  Plec1 is the first biomarker to identify primary and metastatic PDAC by imaging and may also detect preinvasive PanIN III lesions.  Strategies designed to image Plec1 could therefore improve detection and staging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv2vNc3hj3WLVg90H21EOLACvtfcHk0lhbBHgUx-fx3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyqsg%253D%253D&md5=e9af1df96c81b82792d2f7a2e46ea030</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0999%26sid%3Dliteratum%253Aachs%26aulast%3DBausch%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DFernandez-del%26aufirst%3DC.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BW.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWarshaw%26aufirst%3DA.%2BL.%26aulast%3DThayer%26aufirst%3DS.%2BP.%26aulast%3DKelly%26aufirst%3DK.%2BA.%26atitle%3DPlectin-1%2520as%2520a%2520novel%2520biomarker%2520for%2520pancreatic%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D302%26epage%3D309%26doi%3D10.1158%2F1078-0432.CCR-10-0999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kelly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anbazhagan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurumurthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alencar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e85</span><span class="refDoi">Â DOI: 10.1371/journal.pmed.0050085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1371%2Fjournal.pmed.0050085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18416599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BD1c3osFaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=e85&author=K.+A.+Kellyauthor=N.+Bardeesyauthor=R.+Anbazhaganauthor=S.+Gurumurthyauthor=J.+Bergerauthor=H.+Alencarauthor=R.+A.+Depinhoauthor=U.+Mahmoodauthor=R.+Weissleder&title=Targeted+nanoparticles+for+imaging+incipient+pancreatic+ductal+adenocarcinoma&doi=10.1371%2Fjournal.pmed.0050085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Kelly Kimberly A; Bardeesy Nabeel; Anbazhagan Rajesh; Gurumurthy Sushma; Berger Justin; Alencar Herlen; Depinho Ronald A; Mahmood Umar; Weissleder Ralph</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies.  The development of molecular markers and imaging probes for incipient PDAC would enable earlier detection and guide the development of interventive therapies.  Here we sought to identify novel molecular markers and to test their potential as targeted imaging agents.  METHODS AND FINDINGS:  Here, a phage display approach was used in a mouse model of PDAC to screen for peptides that specifically bind to cell surface antigens on PDAC cells.  These screens yielded a motif that distinguishes PDAC cells from normal pancreatic duct cells in vitro, which, upon proteomics analysis, identified plectin-1 as a novel biomarker of PDAC.  To assess their utility for in vivo imaging, the plectin-1 targeted peptides (PTP) were conjugated to magnetofluorescent nanoparticles.  In conjunction with intravital confocal microscopy and MRI, these nanoparticles enabled detection of small PDAC and precursor lesions in engineered mouse models.  CONCLUSIONS:  Our approach exploited a well-defined model of PDAC, enabling rapid identification and validation of PTP.  The developed specific imaging probe, along with the discovery of plectin-1 as a novel biomarker, may have clinical utility in the diagnosis and management of PDAC in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMjW_qppa_E6_dlEzl_fBafW6udTcc2eYaLs2ff-2udrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3osFaksg%253D%253D&md5=fa17efd85b718f7207674f1434f6b99f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0050085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0050085%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DK.%2BA.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DAnbazhagan%26aufirst%3DR.%26aulast%3DGurumurthy%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DAlencar%26aufirst%3DH.%26aulast%3DDepinho%26aufirst%3DR.%2BA.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DTargeted%2520nanoparticles%2520for%2520imaging%2520incipient%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DPLoS%2520Med.%26date%3D2008%26volume%3D5%26spage%3De85%26doi%3D10.1371%2Fjournal.pmed.0050085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtatland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, L.</span><span> </span><span class="NLM_article-title">Cell-specific targeting of nanoparticles by multivalent attachment of small molecules</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">â</span> <span class="NLM_lpage">1423</span><span class="refDoi">Â DOI: 10.1038/nbt1159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnbt1159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=16244656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyis7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1418-1423&author=R.+Weisslederauthor=K.+Kellyauthor=E.+Y.+Sunauthor=T.+Shtatlandauthor=L.+Josephson&title=Cell-specific+targeting+of+nanoparticles+by+multivalent+attachment+of+small+molecules&doi=10.1038%2Fnbt1159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific targeting of nanoparticles by multivalent attachment of small molecules</span></div><div class="casAuthors">Weissleder, Ralph; Kelly, Kimberly; Sun, Eric Yi; Shtatland, Timur; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1418-1423</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nanomaterials with precise biol. functions have considerable potential for use in biomedical applications.  Here the authors investigate whether multivalent attachment of small mols. can increase specific binding affinity and reveal new biol. properties of such nanomaterials.  The authors describe the parallel synthesis of a library comprising 146 nanoparticles decorated with different synthetic small mols.  Using fluorescent magnetic nanoparticles, the authors rapidly screened the library against different cell lines and discovered a series of nanoparticles with high specificity for endothelial cells, activated human macrophages or pancreatic cancer cells.  Hits from the last-mentioned screen were shown to target pancreatic cancer in vivo.  The method and described materials could facilitate development of functional nanomaterials for applications such as differentiating cell lines, detecting distinct cellular states and targeting specific cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgZjQM3_dzhrVg90H21EOLACvtfcHk0ljt58In73RrLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyis7jM&md5=6aa04aee374b7cb17eaf499b7cfaa475</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnbt1159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1159%26sid%3Dliteratum%253Aachs%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DE.%2BY.%26aulast%3DShtatland%26aufirst%3DT.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DCell-specific%2520targeting%2520of%2520nanoparticles%2520by%2520multivalent%2520attachment%2520of%2520small%2520molecules%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1418%26epage%3D1423%26doi%3D10.1038%2Fnbt1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Polymers for the sustained release of proteins and other macromolecules</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">â</span> <span class="NLM_lpage">800</span><span class="refDoi">Â DOI: 10.1038/263797a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2F263797a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=995197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADyaE2sXnvVKntQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1976&pages=797-800&author=R.+Langerauthor=J.+Folkman&title=Polymers+for+the+sustained+release+of+proteins+and+other+macromolecules&doi=10.1038%2F263797a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polymers for the sustained release of proteins and other macromolecules</span></div><div class="casAuthors">Langer, Robert; Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5580</span>),
    <span class="NLM_cas:pages">797-800</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An increase in the ratio of polymer:water (â¤10% polymer concn.) in the casting soln. of poly(vinyl alc.) decreased the rate at which soybean trypsin inhibitor (I) [9078-38-0] (mol. wt. 21,000) was released from the casting soln. in Ringer's soln. at 37Â°.  Similar effects were obsd. with the polymers Hydron-S [25249-16-5] and ethylene-vinyl acetate copolymer (II) [24937-78-8].  In these slow-release systems, a large percentage of protein was released during the first hour of incubation, and the rate of release was retarded in polymer 'sandwiches'.  Proteins and macromols. released from the polymers were >80% biol.-active, as shown with I, alk. phosphatase [9001-78-9], tumor angiogenesis factor, and lysozyme [9001-63-2].  Hydron and II caused no inflammation when implanted into the cornea of rabbits; poly(vinyl alc.) [9002-89-5] however produced inflammation which could be greatly reduced, but not eliminated, by exhaustive washing with alc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVUsmFV61sHLVg90H21EOLACvtfcHk0ljt58In73RrLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXnvVKntQ%253D%253D&md5=b3738fc0a8377e8255499eb8a8a47840</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2F263797a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F263797a0%26sid%3Dliteratum%253Aachs%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DPolymers%2520for%2520the%2520sustained%2520release%2520of%2520proteins%2520and%2520other%2520macromolecules%26jtitle%3DNature%26date%3D1976%26volume%3D263%26spage%3D797%26epage%3D800%26doi%3D10.1038%2F263797a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Gref, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamitake, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peracchia, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trubetskoy, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torchilin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Biodegradable long-circulating polymeric nanospheres</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1600</span><span class="NLM_x">â</span> <span class="NLM_lpage">1603</span><span class="refDoi">Â DOI: 10.1126/science.8128245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1126%2Fscience.8128245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=8128245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADyaK2cXit1KktLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1600-1603&author=R.+Grefauthor=Y.+Minamitakeauthor=M.+T.+Peracchiaauthor=V.+Trubetskoyauthor=V.+Torchilinauthor=R.+Langer&title=Biodegradable+long-circulating+polymeric+nanospheres&doi=10.1126%2Fscience.8128245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable long-circulating polymer nanospheres</span></div><div class="casAuthors">Gref, Ruxandra; Minamitake, Yoshiharu; Peracchia, Maria Teresa; Trubetskoy, Vladimir; Torchilin, Vladimir; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5153</span>),
    <span class="NLM_cas:pages">1600-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging.  Conventional carriers, however, cannot generally be used because they are eliminated by the reticuloendothelial system within seconds or minutes after i.v. injection.  To address these limitations, monodisperse biodegradable nanospheres were developed from amphiphilic copolymers composed of two biocompatible blocks.  The nanospheres exhibited dramatically increased blood circulation times and reduced liver accumulation in mice.  Furthermore, they entrapped up to 45 percent by wt. of the drug in the dense core in a one-step procedure and could be freeze-dried and easily redispersed without additives in aq. solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAaowcQZQFbVg90H21EOLACvtfcHk0ljt58In73RrLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXit1KktLc%253D&md5=298696ca173279294f37833ed1c9d74e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.8128245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8128245%26sid%3Dliteratum%253Aachs%26aulast%3DGref%26aufirst%3DR.%26aulast%3DMinamitake%26aufirst%3DY.%26aulast%3DPeracchia%26aufirst%3DM.%2BT.%26aulast%3DTrubetskoy%26aufirst%3DV.%26aulast%3DTorchilin%26aufirst%3DV.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DBiodegradable%2520long-circulating%2520polymeric%2520nanospheres%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1600%26epage%3D1603%26doi%3D10.1126%2Fscience.8128245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherifi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richie, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">6315</span><span class="NLM_x">â</span> <span class="NLM_lpage">6320</span><span class="refDoi">Â DOI: 10.1073/pnas.0601755103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1073%2Fpnas.0601755103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=16606824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=6315-6320&author=O.+C.+Farokhzadauthor=J.+Chengauthor=B.+A.+Teplyauthor=I.+Sherifiauthor=S.+Jonauthor=P.+W.+Kantoffauthor=J.+P.+Richieauthor=R.+Langer&title=Targeted+nanoparticle-aptamer+bioconjugates+for+cancer+chemotherapy+in+vivo&doi=10.1073%2Fpnas.0601755103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo</span></div><div class="casAuthors">Farokhzad, Omid C.; Cheng, Jianjun; Teply, Benjamin A.; Sherifi, Ines; Jon, Sangyong; Kantoff, Philip W.; Richie, Jerome P.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6315-6320</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technol.  Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2'-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells.  These Dtxl-encapsulated nanoparticle aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the surface of LNCaP prostate epithelial cells and get taken up by these cells resulting in significantly enhanced in vitro cellular toxicity as compared with nontargeted nanoparticles that lack the PSMA aptamer (Dtxl-NP) (P < 0.0004).  The Dtxl-NP-Apt bioconjugates also exhibit remarkable efficacy and reduced toxicity as measured by mean body wt. loss (BWL) in vivo [body wt. loss of 7.7Â±4% vs. 18Â±5% for Dtxl-NP-Apt vs. Dtxl-NP at nadir, resp. (mean Â± SD); n = 7].  After a single intratumoral injection of Dxtl-NP-Apt bioconjugates, complete tumor redn. was obsd. in five of seven LNCaP xenograft nude mice (initial tumor vol. of â300 mm3), and 100% of these animals survived our 109-day study.  In contrast, two of seven mice in the Dtxl-NP group had complete tumor redn. with 109-day survivability of only 57%.  Dtxl alone had a survivability of only 14%.  Saline and nanoparticles without drug were similarly nonefficacious.  This report demonstrates the potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwutpDjrmArVg90H21EOLACvtfcHk0lh39vjNpFjtLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamsbk%253D&md5=9661fe3f15194c6bf0e2df010c028796</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0601755103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0601755103%26sid%3Dliteratum%253Aachs%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DSherifi%26aufirst%3DI.%26aulast%3DJon%26aufirst%3DS.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DRichie%26aufirst%3DJ.%2BP.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DTargeted%2520nanoparticle-aptamer%2520bioconjugates%2520for%2520cancer%2520chemotherapy%2520in%2520vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D6315%26epage%3D6320%26doi%3D10.1073%2Fpnas.0601755103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic- Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2586</span><span class="NLM_x">â</span> <span class="NLM_lpage">2591</span><span class="refDoi">Â DOI: 10.1073/pnas.0711714105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1073%2Fpnas.0711714105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Ojtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2586-2591&author=F.+Guauthor=L.+Zhangauthor=B.+A.+Teplyauthor=N.+Mannauthor=A.+Wangauthor=A.+F.+Radovic-+Morenoauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Precise+engineering+of+targeted+nanoparticles+by+using+self-assembled+biointegrated+block+copolymers&doi=10.1073%2Fpnas.0711714105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers</span></div><div class="casAuthors">Gu, Frank; Zhang, Liangfang; Teply, Benjamin A.; Mann, Nina; Wang, Andrew; Radovic-Moren, Aleksandar F.; Langer, Robert; Farkokhzad, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2586-2591</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">There has been progressively heightened interest in the development of targeted nanoparticles (NPs) for differential delivery and controlled release of drugs.  Despite nearly three decades of research, approaches to reproducibly formulate targeted NPs with the optimal biophysicochem. properties have remained elusive.  A central challenge has been defining the optimal interplay of parameters that confer mol. targeting, immune evasion, and drug release to overcome the physiol. barriers in vivo.  Here, we report a strategy for narrowly changing the biophysicochem. properties of NPs in a reproducible manner, thereby enabling systematic screening of optimally formulated drug-encapsulated targeted NPs.  NPs were formulated by the self-assembly of an amphiphilic triblock copolymer composed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer (PCa) cells, enabling, resp., controlled drug release, "stealth" properties for immune evasion, and cell-specific targeting.  Fine-tuning of NP size and drug release kinetics was further accomplished by controlling the copolymer compn.  By using distinct ratios of PLGA-b-PEG-b-Apt triblock copolymer with PLGA-b-PEG diblock copolymer lacking the A10 Apt, we developed a series of targeted NPs with increasing Apt densities that inversely affected the amt. of PEG exposure on NP surface and identified the narrow range of Apt d. when the NPs were maximally targeted and maximally stealth, resulting in most efficient PCa cell uptake in vitro and in vivo.  This approach may contribute to further development of targeted NPs as highly selective and effective therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbYtEUpGFDqbVg90H21EOLACvtfcHk0lh39vjNpFjtLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Ojtb8%253D&md5=f761176b38055c0dfaf3da272490ed78</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711714105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711714105%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DMann%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DRadovic-%2BMoreno%26aufirst%3DA.%2BF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DPrecise%2520engineering%2520of%2520targeted%2520nanoparticles%2520by%2520using%2520self-assembled%2520biointegrated%2520block%2520copolymers%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2586%26epage%3D2591%26doi%3D10.1073%2Fpnas.0711714105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">544</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span><span class="refDoi">Â DOI: 10.1007/978-1-59745-483-4_37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1007%2F978-1-59745-483-4_37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=19488725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2009&pages=589-598&author=F.+Guauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation%2Fpreparation+of+functionalized+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1007%2F978-1-59745-483-4_37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Gu, Frank; Langer, Robert; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">Micro and Nano Technologies in Bioanalysis</span>),
    <span class="NLM_cas:pages">589-598</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues.  Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles.  Here we describe the prepn. of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine RNA aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells.  We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo.  This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfC9f0Yuf8k7Vg90H21EOLACvtfcHk0lh39vjNpFjtLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVSgtw%253D%253D&md5=3dcd84c203b87965a94afd69c590004e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-483-4_37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-483-4_37%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%252Fpreparation%2520of%2520functionalized%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D544%26spage%3D589%26epage%3D598%26doi%3D10.1007%2F978-1-59745-483-4_37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Otsuka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span> </span><span class="NLM_article-title">PEGylated nanoparticles for biological and pharmaceutical applications</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">â</span> <span class="NLM_lpage">419</span><span class="refDoi">Â DOI: 10.1016/S0169-409X(02)00226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0169-409X%2802%2900226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=12628324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Cgurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=403-419&author=H.+Otsukaauthor=Y.+Nagasakiauthor=K.+Kataoka&title=PEGylated+nanoparticles+for+biological+and+pharmaceutical+applications&doi=10.1016%2FS0169-409X%2802%2900226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylated nanoparticles for biological and pharmaceutical applications</span></div><div class="casAuthors">Otsuka, Hidenori; Nagasaki, Yukio; Kataoka, Kazunori</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-419</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The utility of polymeric micelles formed through the multimol. assembly of block copolymer was comprehensively described as novel core-shell typed colloidal carriers for drug and gene targeting.  Particularly, novel approaches for the formation of functionalized poly(ethylene glycol) (PEG) layers as hydrophilic outer shell were focused to attain receptor-mediated drug and gene delivery through PEG-conjugated ligands with a minimal non-specific interaction with other proteins.  Surface organization of block copolymer micelles with crosslinking core was also described from a standpoint of the prepn. of a new functional surface-coating with a unique macromol. architecture.  The micelle-attached surface and the thin hydrogel layer made by layered micelles exhibited nonfouling properties and worked as the reservoir for hydrophobic reagents.  Furthermore, the potential utility of multimol. assembly derived from heterobifunctional PEGs and block copolymers were explored to systematically modify the properties of metal and semiconductor nanostructures by controlling their structure and their surface properties, making them extremely attractive for use in biol. and biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqW3GfbUZRpLVg90H21EOLACvtfcHk0liNKqOB9Ki2kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Cgurg%253D&md5=dfcf439976d122febdd6691ac8218ba3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900226-0%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuka%26aufirst%3DH.%26aulast%3DNagasaki%26aufirst%3DY.%26aulast%3DKataoka%26aufirst%3DK.%26atitle%3DPEGylated%2520nanoparticles%2520for%2520biological%2520and%2520pharmaceutical%2520applications%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D403%26epage%3D419%26doi%3D10.1016%2FS0169-409X%2802%2900226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Avgoustakis, K.</span><span> </span><span class="NLM_article-title">PEGylated poly(lactide) and poly(lactide-coglycolide) nanoparticles: Preparation, properties and possible applications in drug delivery</span> <span class="citation_source-journal">Curr. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">333</span><span class="refDoi">Â DOI: 10.2174/1567201043334605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2174%2F1567201043334605" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=321-333&author=K.+Avgoustakis&title=PEGylated+poly%28lactide%29+and+poly%28lactide-coglycolide%29+nanoparticles%3A+Preparation%2C+properties+and+possible+applications+in+drug+delivery&doi=10.2174%2F1567201043334605"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2174%2F1567201043334605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567201043334605%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustakis%26aufirst%3DK.%26atitle%3DPEGylated%2520poly%2528lactide%2529%2520and%2520poly%2528lactide-coglycolide%2529%2520nanoparticles%253A%2520Preparation%252C%2520properties%2520and%2520possible%2520applications%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2004%26volume%3D1%26spage%3D321%26epage%3D333%26doi%3D10.2174%2F1567201043334605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunaryo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowder, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadapakkam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casciato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">PEGylation strategies for active targeting of PLA/PLGA nanoparticles</span> <span class="citation_source-journal">J. Biomed. Mater. Res., Part A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">â</span> <span class="NLM_lpage">276</span><span class="refDoi">Â DOI: 10.1002/jbm.a.32247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1002%2Fjbm.a.32247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=18980197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVekurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2009&pages=263-276&author=T.+Betancourtauthor=J.+D.+Byrneauthor=N.+Sunaryoauthor=S.+W.+Crowderauthor=M.+Kadapakkamauthor=S.+Patelauthor=S.+Casciatoauthor=L.+Brannon-Peppas&title=PEGylation+strategies+for+active+targeting+of+PLA%2FPLGA+nanoparticles&doi=10.1002%2Fjbm.a.32247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation strategies for active targeting of PLA/PLGA nanoparticles</span></div><div class="casAuthors">Betancourt, Tania; Byrne, James D.; Sunaryo, Nicole; Crowder, Spencer W.; Kadapakkam, Meena; Patel, Shefali; Casciato, Shelly; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Materials Research, Part A</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">91A</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-276</span>CODEN:
                <span class="NLM_cas:coden">JBMRCH</span>;
        ISSN:<span class="NLM_cas:issn">1549-3296</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This work evaluates various techniques for the incorporation of poly(ethylene glycol) (PEG) onto biodegradable nanoparticles (NPs) of poly(lactic-co-glycolic acid) (PLGA) or poly(lactic acid) (PLA) with the purpose of providing a functional site for surface conjugation of targeting agents and for improving surface properties.  The techniques compared were based on NP prepn. with blends of PLGA and poloxemer or with block copolymers of PLGA/PLA with PEG.  Blending of PLGA with poloxamer 407 resulted in the incorporation of the latter to up to a 43 wt % content.  Direct conjugation of heterofunctional NH2-PEG-COOH to the surface of premade NPs was not highly effective.  Prepn. of copolymers of PLGA with PEG was detd. to be more effective and versatile by polymn. of lactide and glycolide dimers onto the hydroxyl group of heterofunctional OH-PEG-COOH than by conjugation of the premade polymers with carbodiimide chem.  NPs prepd. with these copolymers confirmed the surface localization of PEG and proved to be useful for conjugation of mouse Ig as a model targeting agent. Â© 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ59mcOfs9ZrVg90H21EOLACvtfcHk0liNKqOB9Ki2kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVekurzK&md5=ff7538d6803b6b2f1f54657e1afbe5f5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjbm.a.32247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm.a.32247%26sid%3Dliteratum%253Aachs%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DSunaryo%26aufirst%3DN.%26aulast%3DCrowder%26aufirst%3DS.%2BW.%26aulast%3DKadapakkam%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DCasciato%26aufirst%3DS.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DPEGylation%2520strategies%2520for%2520active%2520targeting%2520of%2520PLA%252FPLGA%2520nanoparticles%26jtitle%3DJ.%2520Biomed.%2520Mater.%2520Res.%252C%2520Part%2520A%26date%3D2009%26volume%3D91%26spage%3D263%26epage%3D276%26doi%3D10.1002%2Fjbm.a.32247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teply, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherifi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy-Nissenbaum, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovic-Moreno, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">â</span> <span class="NLM_lpage">876</span><span class="refDoi">Â DOI: 10.1016/j.biomaterials.2006.09.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.biomaterials.2006.09.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=17055572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BD28nlsVehtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=869-876&author=J.+Chengauthor=B.+A.+Teplyauthor=I.+Sherifiauthor=J.+Sungauthor=G.+Lutherauthor=F.+X.+Guauthor=E.+Levy-Nissenbaumauthor=A.+F.+Radovic-Morenoauthor=R.+Langerauthor=O.+C.+Farokhzad&title=Formulation+of+functionalized+PLGA-PEG+nanoparticles+for+in+vivo+targeted+drug+delivery&doi=10.1016%2Fj.biomaterials.2006.09.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery</span></div><div class="casAuthors">Cheng Jianjun; Teply Benjamin A; Sherifi Ines; Sung Josephine; Luther Gaurav; Gu Frank X; Levy-Nissenbaum Etgar; Radovic-Moreno Aleksandar F; Langer Robert; Farokhzad Omid C</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">869-76</span>
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    </div><div class="casAbstract">Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner.  Herein we have developed NPs from carboxy-terminated poly(d,L-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent.  We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied).  NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer.  The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24h; NP-Apt 0.83%+/-0.21% vs.  NP 0.22%+/-0.07% of injected dose per gram of tissue; mean+/-SD, n=4, p=0.002).  The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUML4ghXv7uresJRIHUP1ofW6udTcc2eYb3SS4N4bjdLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nlsVehtg%253D%253D&md5=ed5628a94eadd79fd28e3541e1e739b6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2006.09.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2006.09.047%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DTeply%26aufirst%3DB.%2BA.%26aulast%3DSherifi%26aufirst%3DI.%26aulast%3DSung%26aufirst%3DJ.%26aulast%3DLuther%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DF.%2BX.%26aulast%3DLevy-Nissenbaum%26aufirst%3DE.%26aulast%3DRadovic-Moreno%26aufirst%3DA.%2BF.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFormulation%2520of%2520functionalized%2520PLGA-PEG%2520nanoparticles%2520for%2520in%2520vivo%2520targeted%2520drug%2520delivery%26jtitle%3DBiomaterials%26date%3D2007%26volume%3D28%26spage%3D869%26epage%3D876%26doi%3D10.1016%2Fj.biomaterials.2006.09.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Alexis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span> </span><span class="NLM_article-title">Factors affecting the clearance and biodistribution of polymeric nanoparticles</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">â</span> <span class="NLM_lpage">515</span><span class="refDoi">Â DOI: 10.1021/mp800051m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp800051m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wlurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=505-515&author=F.+Alexisauthor=E.+Pridgenauthor=L.+K.+Molnarauthor=O.+C.+Farokhzad&title=Factors+affecting+the+clearance+and+biodistribution+of+polymeric+nanoparticles&doi=10.1021%2Fmp800051m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles</span></div><div class="casAuthors">Alexis, Frank; Pridgen, Eric; Molnar, Linda K.; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-515</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nanoparticle (NP) drug delivery systems (5-250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biol. barriers and releasing a therapeutic load in the optimal dosage range.  Rapid clearance of circulating nanoparticles during systemic delivery is a crit. issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life.  In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation.  These factors include interactions with biol. barriers and tunable nanoparticle parameters, such as compn., size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization.  All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs4ijsyOkpfrVg90H21EOLACvtfcHk0lhMMpQ3EcVe_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wlurs%253D&md5=21f004c979978944d7a56d05fe4b319d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fmp800051m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp800051m%26sid%3Dliteratum%253Aachs%26aulast%3DAlexis%26aufirst%3DF.%26aulast%3DPridgen%26aufirst%3DE.%26aulast%3DMolnar%26aufirst%3DL.%2BK.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DFactors%2520affecting%2520the%2520clearance%2520and%2520biodistribution%2520of%2520polymeric%2520nanoparticles%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D505%26epage%3D515%26doi%3D10.1021%2Fmp800051m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, K.</span><span> </span><span class="NLM_article-title">Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">284</span><span class="refDoi">Â DOI: 10.1016/S0168-3659(99)00248-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2FS0168-3659%2899%2900248-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10699287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtl2qsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=271-284&author=H.+Maedaauthor=J.+Wuauthor=T.+Sawaauthor=Y.+Matsumuraauthor=K.+Hori&title=Tumor+vascular+permeability+and+the+EPR+effect+in+macromolecular+therapeutics%3A+a+review&doi=10.1016%2FS0168-3659%2899%2900248-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review</span></div><div class="casAuthors">Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">271-284</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 55 refs.  Most solid tumors have unique pathophysiol. characteristics that are not obsd. in normal tissues or organs, such as extensive angiogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic drainage/recovery system, and greatly increased prodn. of a no. of permeability mediators.  The phenomenon now known as the enhanced permeability and retention (EPR) effect for lipid and macromol. agents has been obsd. to be universal in solid tumors.  Primarily, enhanced vascular permeability will sustain an adequate supply of nutrients and oxygen for rapid tumor growth.  The EPR effect also provides a great opportunity for more selective targeting of lipid- or polymer-conjugated anticancer drugs, such as SMANCS and PK-1, to the tumor.  In the present review, the basic characteristics of the EPR effect, particularly the factors involved, are described, as well as its modulation for improving delivery of macromol. drugs to the tumor.  Tumor-specific vascular physiol. is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGxDuzaxisLrVg90H21EOLACvtfcHk0lhMMpQ3EcVe_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtl2qsLo%253D&md5=b26ddf9ebdfd3073209f882a4378cf8d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2899%2900248-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252899%252900248-5%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSawa%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DK.%26atitle%3DTumor%2520vascular%2520permeability%2520and%2520the%2520EPR%2520effect%2520in%2520macromolecular%2520therapeutics%253A%2520a%2520review%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2000%26volume%3D65%26spage%3D271%26epage%3D284%26doi%3D10.1016%2FS0168-3659%2899%2900248-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianopoulos, T.</span><span> </span><span class="NLM_article-title">Delivering nanomedicine to solid tumors</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">664</span><span class="refDoi">Â DOI: 10.1038/nrclinonc.2010.139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1038%2Fnrclinonc.2010.139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20838415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCrsb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=653-664&author=R.+K.+Jainauthor=T.+Stylianopoulos&title=Delivering+nanomedicine+to+solid+tumors&doi=10.1038%2Fnrclinonc.2010.139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Delivering nanomedicine to solid tumors</span></div><div class="casAuthors">Jain, Rakesh K.; Stylianopoulos, Triantafyllos</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nanotechnol. offers great promise for the detection, prevention and treatment of cancer.  Current limitations of this technol. include the heterogeneous distribution of nanoparticles to tumors, caused in part by the physiol. barriers presented by the abnormal tumor vasculature and interstitial matrix.  This Review discusses these barriers and summarizes strategies that have been developed to overcome them.  It addnl. examines design considerations for the optimization of delivery of nanoparticles to tumors.  Recent advances in nanotechnol. have offered new hope for cancer detection, prevention, and treatment.  While the enhanced permeability and retention effect has served as a key rationale for using nanoparticles to treat solid tumors, it does not enable uniform delivery of these particles to all regions of tumors in sufficient quantities.  This heterogeneous distribution of therapeutics is a result of physiol. barriers presented by the abnormal tumor vasculature and interstitial matrix.  These barriers are likely to be responsible for the modest survival benefit offered by many FDA-approved nanotherapeutics and must be overcome for the promise of nanomedicine in patients to be realized.  Here, we review these barriers to the delivery of cancer therapeutics and summarize strategies that have been developed to overcome these barriers.  Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzsCeKPsAxSLVg90H21EOLACvtfcHk0lhMMpQ3EcVe_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCrsb7P&md5=aa5d26883f983a0fd6d4cabdbe5457c6</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2010.139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2010.139%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DStylianopoulos%26aufirst%3DT.%26atitle%3DDelivering%2520nanomedicine%2520to%2520solid%2520tumors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26spage%3D653%26epage%3D664%26doi%3D10.1038%2Fnrclinonc.2010.139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Danquah, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahato, R. I.</span><span> </span><span class="NLM_article-title">Extravasation of polymeric nanomedicines across tumor vasculature</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">â</span> <span class="NLM_lpage">639</span><span class="refDoi">Â DOI: 10.1016/j.addr.2010.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.addr.2010.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21144874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnmt1Chsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=623-639&author=M.+K.+Danquahauthor=X.+A.+Zhangauthor=R.+I.+Mahato&title=Extravasation+of+polymeric+nanomedicines+across+tumor+vasculature&doi=10.1016%2Fj.addr.2010.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Extravasation of polymeric nanomedicines across tumor vasculature</span></div><div class="casAuthors">Danquah Michael K; Zhang Xin A; Mahato Ram I</div><div class="citationInfo"><span class="NLM_cas:title">Advanced drug delivery reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">623-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor microvasculature is fraught with numerous physiological barriers which hinder the efficacy of anticancer agents.  These barriers include chaotic blood supply, poor tumor vasculature permeability, limited transport across the interstitium due to high interstitial pressure and absence of lymphatic network.  Abnormal microvasculature also leads to hypoxia and acidosis which limits effectiveness of chemotherapy.  These barriers restrict drug or drug carrier extravasation which hampers tumor regression.  Targeting key features of the tumor microenvironment such as tumor microvessels, interstitial hypertension and tumor pH is a promising approach to improving the efficacy of anticancer drugs.  This review highlights the current knowledge on the distinct tumor microenvironment generated barriers which limit extravasation of drugs and focuses on modalities for overcoming these barriers using multi-functional polymeric carriers.  Special attention is given to utilizing polymeric nanomedicines to facilitate extravasation of anticancer drugs for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9p3ytq5U5bMkU0YCbOU3EfW6udTcc2eZD74C_roK3FLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnmt1Chsw%253D%253D&md5=47f91381cc890d1cd3b23524146a99f9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DDanquah%26aufirst%3DM.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BA.%26aulast%3DMahato%26aufirst%3DR.%2BI.%26atitle%3DExtravasation%2520of%2520polymeric%2520nanomedicines%2520across%2520tumor%2520vasculature%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D623%26epage%3D639%26doi%3D10.1016%2Fj.addr.2010.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Knop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenboom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, U. S.</span><span> </span><span class="NLM_article-title">Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6288</span><span class="NLM_x">â</span> <span class="NLM_lpage">6308</span><span class="refDoi">Â DOI: 10.1002/anie.200902672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1002%2Fanie.200902672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=20648499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6288-6308&author=K.+Knopauthor=R.+Hoogenboomauthor=D.+Fischerauthor=U.+S.+Schubert&title=Poly%28ethylene+glycol%29+in+drug+delivery%3A+pros+and+cons+as+well+as+potential+alternatives&doi=10.1002%2Fanie.200902672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives</span></div><div class="casAuthors">Knop, Katrin; Hoogenboom, Richard; Fischer, Dagmar; Schubert, Ulrich S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6288-6308</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Poly(ethylene glycol) (PEG) is the most used polymer and also the gold std. for stealth polymers in the emerging field of polymer-based drug delivery.  The properties that account for the overwhelming use of PEG in biomedical applications are outlined in this Review.  The first approved PEGylated products have already been on the market for 20 years.  A vast amt. of clin. experience has since been gained with this polymer-not only benefits, but possible side effects and complications have also been found.  The areas that might need consideration and more intensive and careful examn. can be divided into the following categories: hypersensitivity, unexpected changes in pharmacokinetic behavior, toxic side products, and an antagonism arising from the easy degrdn. of the polymer under mech. stress as a result of its ether structure and its non-biodegradability, as well as the resulting possible accumulation in the body.  These possible side effects will be discussed in this Review and alternative polymers will be evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbYINW5v_3rVg90H21EOLACvtfcHk0lifXZQzV5E2eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOqtLbN&md5=02ff87df9c11cf218d3799ecd259d2a0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.200902672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200902672%26sid%3Dliteratum%253Aachs%26aulast%3DKnop%26aufirst%3DK.%26aulast%3DHoogenboom%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DD.%26aulast%3DSchubert%26aufirst%3DU.%2BS.%26atitle%3DPoly%2528ethylene%2520glycol%2529%2520in%2520drug%2520delivery%253A%2520pros%2520and%2520cons%2520as%2520well%2520as%2520potential%2520alternatives%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D6288%26epage%3D6308%26doi%3D10.1002%2Fanie.200902672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Jokerst, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobovkina, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zare, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambhi, S. S.</span><span> </span><span class="NLM_article-title">Nanoparticle PEGylation for imaging and therapy</span> <span class="citation_source-journal">Nanomedicine (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">â</span> <span class="NLM_lpage">728</span><span class="refDoi">Â DOI: 10.2217/nnm.11.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.2217%2Fnnm.11.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21718180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsVajtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=715-728&author=J.+V.+Jokerstauthor=T.+Lobovkinaauthor=R.+N.+Zareauthor=S.+S.+Gambhi&title=Nanoparticle+PEGylation+for+imaging+and+therapy&doi=10.2217%2Fnnm.11.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle PEGylation for imaging and therapy</span></div><div class="casAuthors">Jokerst, Jesse V.; Lobovkina, Tatsiana; Zare, Richard N.; Gambhir, Sanjiv S.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">715-728</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanoparticles are an essential component in the emerging field of nanomedical imaging and therapy.  When deployed in vivo, these materials are typically protected from the immune system by polyethylene glycol (PEG).  A wide variety of strategies to coat and characterize nanoparticles with PEG has established important trends on PEG size, shape, d., loading level, mol. wt., charge and purifn.  Strategies to incorporate targeting ligands are also prevalent.  This article presents a background to investigators new to stealth nanoparticles, and suggests some key considerations needed prior to designing a nanoparticle PEGylation protocol and characterizing the performance features of the product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEyisd8_v8G7Vg90H21EOLACvtfcHk0liJu5PK8uLjIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsVajtro%253D&md5=960e4aed2f95aae187beeb7d6e5eb882</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2217%2Fnnm.11.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.11.19%26sid%3Dliteratum%253Aachs%26aulast%3DJokerst%26aufirst%3DJ.%2BV.%26aulast%3DLobovkina%26aufirst%3DT.%26aulast%3DZare%26aufirst%3DR.%2BN.%26aulast%3DGambhi%26aufirst%3DS.%2BS.%26atitle%3DNanoparticle%2520PEGylation%2520for%2520imaging%2520and%2520therapy%26jtitle%3DNanomedicine%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D6%26spage%3D715%26epage%3D728%26doi%3D10.2217%2Fnnm.11.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Dash, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkimalla, V. B.</span><span> </span><span class="NLM_article-title">Polymeric modification and its implication in drug delivery: poly-Îµ-caprolactone (PCL) as a model polymer</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2365</span><span class="NLM_x">â</span> <span class="NLM_lpage">2379</span><span class="refDoi">Â DOI: 10.1021/mp3001952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp3001952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKqurbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2365-2379&author=T.+K.+Dashauthor=V.+B.+Konkimalla&title=Polymeric+modification+and+its+implication+in+drug+delivery%3A+poly-%CE%B5-caprolactone+%28PCL%29+as+a+model+polymer&doi=10.1021%2Fmp3001952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric Modification and Its Implication in Drug Delivery: Poly-Îµ-caprolactone (PCL) as a Model Polymer</span></div><div class="casAuthors">Dash, Tapan K.; Konkimalla, V. Badireenath</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2365-2379</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Biodegradable polymers provided the opportunity to explore beyond conventional drug delivery and turned out to be the focus of current drug delivery.  In spite of availability of diverse class of polymers, several of these polymers lack important physicochem. and biol. properties, limiting their widespread application in pharmaceutical drug delivery.  However, most polymers in the form of blends, copolymers and functionally modified polymers have exhibited their applicability to overcome specific limitations and to produce novel and/or functionalized formulations for drug delivery as well as tissue engineering.  This review aims to provide the need of polymeric modification, approaches adopted to modify and their scope.  Special emphasis has been given to synthetic polyester PCL, as it is widely demonstrated in its modified form to overcome its problem of hydrophobicity and much slower degrdn. over the past decade.  Past studies show a significantly higher utility of modified form of PCL in comparison to its native form.  From the statistical anal. of these modifications and the formulations prepd., we present a basic understanding of the impact of selective modifications on the formulation design.  In conclusion, we remark that a thorough understanding of the polymer and its modification has a huge potential to be the future trend for drug delivery and tissue engineering applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQlbrULkIU97Vg90H21EOLACvtfcHk0liJu5PK8uLjIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKqurbN&md5=14a0dc7e32ffe00d9b30a1bf93c27e2e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fmp3001952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp3001952%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DT.%2BK.%26aulast%3DKonkimalla%26aufirst%3DV.%2BB.%26atitle%3DPolymeric%2520modification%2520and%2520its%2520implication%2520in%2520drug%2520delivery%253A%2520poly-%25CE%25B5-caprolactone%2520%2528PCL%2529%2520as%2520a%2520model%2520polymer%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2365%26epage%3D2379%26doi%3D10.1021%2Fmp3001952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddiqui, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhtar, H.</span><span> </span><span class="NLM_article-title">Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactic-<i>co</i>-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3871</span><span class="NLM_x">â</span> <span class="NLM_lpage">3881</span><span class="refDoi">Â DOI: 10.1021/mp400342f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400342f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWru7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=3871-3881&author=V.+Sannaauthor=I.+A.+Siddiquiauthor=M.+Sechiauthor=H.+Mukhtar&title=Resveratrol-loaded+nanoparticles+based+on+poly%28epsilon-caprolactone%29+and+poly%28d%2Cl-lactic-co-glycolic+acid%29-poly%28ethylene+glycol%29+blend+for+prostate+cancer+treatment&doi=10.1021%2Fmp400342f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol-Loaded Nanoparticles Based on Poly(epsilon-caprolactone) and Poly(D,L-lactic-co-glycolic acid)-Poly(ethylene glycol) Blend for Prostate Cancer Treatment</span></div><div class="casAuthors">Sanna, Vanna; Siddiqui, Imtiaz Ahmad; Sechi, Mario; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3871-3881</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoencapsulation of antiproliferative and chemopreventive phytoalexin trans-resveratrol (RSV) is likely to provide protection against degrdn., enhancement of bioavailability, improvement in intracellular penetration and control delivery.  In this study, polymeric nanoparticles (NPs) encapsulating RSV (nano-RSV) as novel prototypes for prostate cancer (PCa) treatment were designed, characterized and evaluated using human PCa cells.  Nanosystems, composed of a biocompatible blend of poly-(Îµ-caprolactone) (PCL) and poly-(D,L-lactic-co-glycolic acid)-poly-(ethylene glycol) conjugate (PLGA-PEG-COOH), were prepd. by a nanopptn. method, and characterized in terms of morphol., particle size and zeta potential, encapsulation efficiency, thermal analyses, and in vitro release studies.  Cellular uptake of NPs was then evaluated in PCa cell lines DU-145, PC-3, and LNCaP using confocal fluorescence microscopy, and antiproliferative efficacy was assessed using MTT assay.  With encapsulation efficiencies ranging from 74% to 98%, RSV was successfully loaded in PCL:PLGA-PEG-COOH NPs, which showed an av. diam. of 150 nm.  NPs were able to control the RSV release at pH 6.5 and 7.4, mimicking the acidic tumoral microenvironment and physiol. conditions, resp., with only 55% of RSV released within 7 h.  In gastrointestinal simulated fluids, NPs released about 55% of RSV in the first 2 h in acidic medium, and their total RSV content within the subsequent 5 h at pH 7.4.  Confocal fluorescence microscopy observations revealed that NPs were efficiently taken up by PCa cell lines.  Furthermore, nano-RSV significantly improved the cytotoxicity compared to that of free RSV toward all three cell lines, at all tested concns. (from 10 Î¼M to 40 Î¼M), proving a consistent sensitivity toward both the androgen-independent DU-145 and hormone-sensitive LNCaP cells.  Our findings support the potential use of developed nanoprototypes for the controlled delivery of bioactive RSV for PCa chemoprevention/chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8l3WqXmfGjbVg90H21EOLACvtfcHk0lgVbFI8bsAmvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWru7jJ&md5=0f4de236624b2c98fab90da0fedc4033</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fmp400342f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400342f%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DSiddiqui%26aufirst%3DI.%2BA.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DResveratrol-loaded%2520nanoparticles%2520based%2520on%2520poly%2528epsilon-caprolactone%2529%2520and%2520poly%2528d%252Cl-lactic-co-glycolic%2520acid%2529-poly%2528ethylene%2520glycol%2529%2520blend%2520for%2520prostate%2520cancer%2520treatment%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D3871%26epage%3D3881%26doi%3D10.1021%2Fmp400342f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Sanna, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadino, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marceddu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzzau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sechi, M.</span><span> </span><span class="NLM_article-title">Novel docetaxel-loaded nanoparticles based on poly(lactide-<i>co</i>-caprolactone) and poly(lactide-<i>co</i>-glycolide-<i>co</i>-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies</span> <span class="citation_source-journal">Nanoscale Res. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">260</span><span class="refDoi">Â DOI: 10.1186/1556-276X-6-260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1186%2F1556-276X-6-260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=21711774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2msbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=260&issue=1&author=V.+Sannaauthor=A.+M.+Roggioauthor=A.+M.+Posadinoauthor=A.+Cossuauthor=S.+Marcedduauthor=A.+Marianiauthor=V.+Alzariauthor=S.+Uzzauauthor=G.+Pintusauthor=M.+Sechi&title=Novel+docetaxel-loaded+nanoparticles+based+on+poly%28lactide-co-caprolactone%29+and+poly%28lactide-co-glycolide-co-caprolactone%29+for+prostate+cancer+treatment%3A+formulation%2C+characterization+and+cytotoxicity+studies&doi=10.1186%2F1556-276X-6-260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies</span></div><div class="casAuthors">Sanna, Vanna; Roggio, Anna Maria; Posadino, Anna Maria; Cossu, Annalisa; Marceddu, Salvatore; Mariani, Alberto; Alzari, Valeria; Uzzau, Sergio; Pintus, Gianfranco; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale Research Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">260, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NRLAAD</span>;
        ISSN:<span class="NLM_cas:issn">1556-276X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Docetaxel (Dtx) chemotherapy is the optional treatment in patients with hormone-refractory metastatic prostate cancer, and Dtx-loaded polymeric nanoparticles (NPs) have the potential to induce durable clin. responses.  However, alternative formulations are needed to overcome the serious side effects, also due to the adjuvant used, and to improve the clin. efficacy of the drug.  In the present study, two novel biodegradable block-copolymers, poly(lactide-co-caprolactone) (PLA-PCL) and poly (lactide-co-caprolactone-co-glycolide) (PLGA-PCL), were explored for the formulation of Dtx-loaded NPs and compared with PLA- and PLGA-NPs.  The nanosystems were prepd. by an original nanopptn. method, using Pluronic F-127 as surfactant agent, and were characterized in terms of morphol., size distribution, encapsulation efficiency, cryst. structure, and in vitro release.  To evaluate the potential anticancer efficacy of a nanoparticulate system, in vitro cytotoxicity studies on human prostate cancer cell line (PC3) were carried out.  NPs were found to be of spherical shape with an av. diam. in the range of 100 to 200 nm and a unimodal particle size distribution.  Dtx was incorporated into the PLGA-PCL NPs with higher (p < 0.05) encapsulation efficiency than that of other polymers.  Differential scanning calorimetry suggested that Dtx was molecularly dispersed in the polymeric matrixes.  In vitro drug release study showed that release profiles of Dtx varied on the bases of characteristics of polymers used for formulation.  PLA-PCL and PLGA-PCL drug loaded NPs shared an overlapping release profiles, and are able to release about 90% of drug within 6 h, when compared with PLA- and PLGA-NPs.  Moreover, cytotoxicity studies demonstrated advantages of the Dtx-loaded PLGA-PCL NPs over pure Dtx in both time- and concn.-dependent manner.  In particular, an increase of 20% of PC3 growth inhibition was detd. by PLGA-PCL NPs with respect to free drug after 72 h incubation and at all tested Dtx concn.  In summary, PLGA-PCL copolymer may be considered as an attractive and promising polymeric material for the formulation of Dtx NPs as delivery system for prostate cancer treatment, and can also be pursued as a validated system in a more large context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHj03YXUg277Vg90H21EOLACvtfcHk0lgVbFI8bsAmvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2msbbM&md5=0dfef9f67391b71dc54a729f384101e9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1186%2F1556-276X-6-260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1556-276X-6-260%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DRoggio%26aufirst%3DA.%2BM.%26aulast%3DPosadino%26aufirst%3DA.%2BM.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DMariani%26aufirst%3DA.%26aulast%3DAlzari%26aufirst%3DV.%26aulast%3DUzzau%26aufirst%3DS.%26aulast%3DPintus%26aufirst%3DG.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DNovel%2520docetaxel-loaded%2520nanoparticles%2520based%2520on%2520poly%2528lactide-co-caprolactone%2529%2520and%2520poly%2528lactide-co-glycolide-co-caprolactone%2529%2520for%2520prostate%2520cancer%2520treatment%253A%2520formulation%252C%2520characterization%2520and%2520cytotoxicity%2520studies%26jtitle%3DNanoscale%2520Res.%2520Lett.%26date%3D2011%26volume%3D6%26issue%3D1%26spage%3D260%26doi%3D10.1186%2F1556-276X-6-260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Patching, S. G.</span><span> </span><span class="NLM_article-title">Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1838</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">55</span><span class="refDoi">Â DOI: 10.1016/j.bbamem.2013.04.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=10.1016%2Fj.bbamem.2013.04.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=23665295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslWrtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1838&publication_year=2014&pages=43-55&author=S.+G.+Patching&title=Surface+plasmon+resonance+spectroscopy+for+characterisation+of+membrane+protein-ligand+interactions+and+its+potential+for+drug+discovery&doi=10.1016%2Fj.bbamem.2013.04.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery</span></div><div class="casAuthors">Patching, Simon G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1838</span>
        (<span class="NLM_cas:issue">1PA</span>),
    <span class="NLM_cas:pages">43-55</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Surface plasmon resonance (SPR) spectroscopy is a rapidly developing technique for the study of ligand binding interactions with membrane proteins, which are the major mol. targets for validated drugs and for current and foreseeable drug discovery.  SPR is label-free and capable of measuring real-time quant. binding affinities and kinetics for membrane proteins interacting with ligand mols. using relatively small quantities of materials and has potential to be medium-throughput.  The conventional SPR technique requires one binding component to be immobilized on a sensor chip while the other binding component in soln. is flowed over the sensor surface; a binding interaction is detected using an optical method that measures small changes in refractive index at the sensor surface.  This review first describes the basic SPR expt. and the challenges that have to be considered for performing SPR expts. that measure membrane protein-ligand binding interactions, most importantly having the membrane protein in a lipid or detergent environment that retains its native structure and activity.  It then describes a wide-range of membrane protein systems for which ligand binding interactions have been characterised using SPR, including the major drug targets G protein-coupled receptors, and how challenges have been overcome for achieving this.  Finally it describes some recent advances in SPR-based technol. and future potential of the technique to screen ligand binding in the discovery of drugs.  This article is part of a Special Issue entitled: Structural and biophys. characterization of membrane protein-ligand binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKHXrfkR3d3rVg90H21EOLACvtfcHk0lhaQ2T3MPeOHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslWrtr8%253D&md5=5b1def21c34b67529fd472e796861252</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2013.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2013.04.028%26sid%3Dliteratum%253Aachs%26aulast%3DPatching%26aufirst%3DS.%2BG.%26atitle%3DSurface%2520plasmon%2520resonance%2520spectroscopy%2520for%2520characterisation%2520of%2520membrane%2520protein-ligand%2520interactions%2520and%2520its%2520potential%2520for%2520drug%2520discovery%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2014%26volume%3D1838%26spage%3D43%26epage%3D55%26doi%3D10.1016%2Fj.bbamem.2013.04.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01571">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60466"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01571">10.1021/acs.jmedchem.5b01571</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">MS and NMR spectra, elemental analyses, for compounds <b>1</b>, <b>2</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>10</b>, <b>11</b>. NMR spectra for polymers PLGA-<b>11</b>, PLGA-PEG-NH<sub>2</sub>, and PLGA-PEG-<b>12</b>. <sup>1</sup>H NMR spectrum for peptide <b>12</b>. Synthesis and characterization of <b>12</b>. Characterization details of 6C-loaded NPs. GPC-SEC data (molecular weights, polydispersity, and refractive indexes) for PLGA-PEG-NH<sub>2</sub> and PLGA-PEG-<b>12</b> polymers (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Additional compound data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_001.pdf">jm5b01571_si_001.pdf (2.66 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01571/suppl_file/jm5b01571_si_002.csv">jm5b01571_si_002.csv (0.31 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-11%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01571%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01571" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0de0d9f88d1b7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
